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Abstract	
Despite	the	association	of	neuronal	cell	loss	with	a	wide	range	of	neurodegenerative	disorders,	the	
mechanisms	 leading	 to	 this	 cell	death	 remain	poorly	understood.	 In	 this	 thesis	 I	have	 investigated	
these	mechanisms	and	tested	whether	they	represent	viable	targets	for	therapeutic	intervention.	The	
adult	mouse	retinal	explant	is	a	popular	model	of	axotomy-induced	neuronal	degeneration	but	has	
been	limited	by	the	lack	of	morphometric	data.	Since	dendritic	pruning	is	well-evidenced	to	precede	
cell	 loss	 in	neurodegenerative	diseases,	 including	glaucoma	and	Alzheimer’s	disease,	 I	 investigated	
whether	the	quantification	of	dendritic	morphology	of	retinal	ganglion	cells	in	the	retinal	explant	could	
be	used	 as	 a	more	 sensitive	measure	of	 neuronal	 health	 after	 axotomy.	 I	 report	 here	 that	 retinal	
ganglion	cell	dendrite	loss	precedes	cell	loss	by	at	least	7	days	and	that	this	retraction	is	substantially	
retarded	 following	 treatment	 with	 brain-derived	 neurotrophic	 factor	 applied	 at	 the	 time	 of	
explantation.	Perhaps	most	importantly,	I	demonstrate	for	the	first	time	in	this	model	that	delayed	
application	of	brain-derived	neurotrophic	factor	significantly	protects	against	dendritic	retraction	of	
retinal	 ganglion	 cells.	 The	 work	 outlined	 in	 this	 thesis	 thus	 supports	 the	 targeting	 of	 dendritic	
outgrowth	and/or	synaptic	connectivity	for	the	treatment	of	neurodegenerative	disorders.	
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Chapter	1:	Introduction	
1.1	The	retina	
Retinal	 ganglion	 cells	 (RGCs)	 are	 neurons	 in	 the	 inner	 retina	 that	 collect	 information	 from	
photoreceptors.	 This	 information	 is	 transmitted	 via	 RGC	 axons,	 which	 leave	 the	 back	 of	 the	 eye	
through	the	optic	nerve	head	and	terminate	in	the	lateral	geniculate	nucleus	or	the	superior	colliculus	
in	humans.	There	are	two	parallel	pathways	in	retinal	processing,	the	ON	and	the	OFF	pathways.	In	
the	ON	pathway	bipolar	cells	and	RGCs	are	depolarised	by	light,	but	in	the	OFF	pathway	bipolar	cells	
and	 RGCs	 are	 hyperpolarised	 by	 light.	 Following	 light	 transduction,	 photoreceptors	 synapse	 to	
horizontal	 cells	 and	 bipolar	 cells.	 Cone-driven	 bipolar	 cells	 synapse	 directly	 to	 RGCs	 of	 the	 same	
ON/OFF	pathway	(i.e.	ON	bipolar	à	ON	RGC;	OFF	bipolar	à	OFF	RGC),	whereas	rod-driven	bipolar	
cells	transmit	signals	to	ON	and	OFF	RGCs	via	AII	amacrine	cells	(Figure	1.1)	(Famiglietti	and	Kolb	1976;	
Nelson	et	al.	1978).	Whilst	the	majority	of	RGCs	carry	out	a	visual	processing	role,	a	small	percentage,	
termed	 intrinsically	 photosensitive	 RGCs,	 contain	melanopsin	 and	 are	 important	 for	 the	 circadian	
rhythm	and	controlling	the	pupillary	light	reflex	(Schmidt	et	al.	2011;	Pickard	and	Sollars	2012).	
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Figure 1.1. Neural processing in the mammalian retina. Under scotopic conditions photoreceptors are 
depolarised and release glutamate, which hyperpolarised cone-driven ON bipolar cells and rod-driven 
bipolar cells via metabotropic glutamate receptors (Shiells and Falk 1990). Glutamate depolarises OFF 
bipolar cells via ionotropic glutamate receptors. Under photopic conditions glutamate release from 
photoreceptors is suppressed, resulting in depolarisation of ON bipolar cells and rod-driven bipolar cells, 
and hyperpolarisation of OFF bipolar cells (Stryer 1986). Cone-driven ON bipolar cells synapse to ON 
RGCs, and cone-driven OFF bipolar cells synapse to OFF RGCs. Bistratified RGCs receive signals 
from ON and OFF bipolar cells (Kolb 1970; Famiglietti and Kolb 1976; Nelson et al. 1978). Rod-driven 
bipolar cells synapse to AII amacrine cells, which in turn depolarise cone-driven ON bipolar cells via 
gap junctions, and hyperpolarise cone-driven OFF bipolar cells and OFF RGCs via glycine (Tagawa et 
al. 1999; Bloomfield and Dacheux 2001; Xu and Tian 2008). G (ganglion cell); A (amacrine cell); AII (AII 
amacrine cell); H (horizontal cell); B (bipolar cell); white cells in ONL (cones); black cells in ONL (rods); 
GCL (ganglion cell layer); IPL (inner plexiform layer); INL (inner nuclear layer); OPL (outer plexiform 
layer); ONL (outer nuclear layer); OS (outer segments). The IPL is divided into 5 strata (S1-S5); OFF 
cells (blue) stratify in S1-S2 (sublamina a); ON cells (red) stratify in S3-S5 (sublamina b); bistratified 
cells (purple) stratify in sublaminas a and b.	
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1.2	Classes	of	retinal	ganglion	cells	
RGCs	are	a	very	heterogeneous	population	of	neurons	in	terms	of	morphology,	as	demonstrated	in	
Figure	1.2.	Not	only	does	the	dendritic	field	size	of	RGCs	increases	with	distance	from	the	optic	nerve	
head	(Doi	et	al.	1995),	but	other	morphological	parameters,	such	as	soma	area,	branching	complexity	
and	dendritic	field	asymmetry,	vary	greatly	between	neighbouring	cells.	The	variance	in	the	mouse	is	
particularly	well	demonstrated	by	the	number	of	different	morphological	classes	of	RGCs	identified:	
14	types	by	Sun	et	al.	(2002)	and	Coombs	et	al.	(2006).	In	addition	to	classification	by	cell	shape,	RGCs	
have	recently	begun	to	be	classified	by	function,	of	which	there	has	been	found	to	be	at	least	30	types	
(Baden	et	al.	2016),	and	this	number	is	likely	to	increase	as	neuronal	recording	methods	are	optimised.	
Transgenic	mouse	lines	offer	a	method	of	labelling	specific	classes	of	RGCs,	such	as	Isl2+	RGCs	(Triplett	
et	al.	2014)	or	ON-OFF	direction-selective	RGCs	(Kay	et	al.	2011).	For	a	summary	of	available	transgenic	
mouse	lines	that	label	specific	classes	of	RGCs,	the	reader	should	refer	to	Sanes	&	Masland	(2015).	
Chapter	1:	Introduction	 19	
	
	
Figure 1.2. Example types of mouse RGCs classified by soma diameter, dendritic field diameter and 
stratification depth, demonstrating the morphological variety of these neurons. Figure adapted from Sun 
et al. (2002). 
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1.3	Normal	retinal	neurogenesis	and	dendritogenesis	
1.3.1	Retinal	neurogenesis	
The	developing	retina	contains	a	population	of	stem	cells	capable	of	differentiating	into	all	cell	types	
in	the	retina.	In	the	retinae	of	fish	and	amphibians	a	retinal	stem	cell	population	also	exists	in	the	adult	
in	the	ciliary	margin	zone	(Fischer	et	al.	2013).	While	many	groups	have	attempted	to	find	this	stem	
cell	niche	in	higher	vertebrates	for	the	application	of	stem	cell	replacement	therapies,	several	reports	
suggest	that	the	ciliary	margin	zone	is	reduced	in	more	highly	evolved	vertebrates	and	is	completely	
absent	 in	 the	mouse	 (Li	 et	 al.	 2013).	 Nevertheless,	 there	 is	 evidence	 that	 a	 population	 of	 retinal	
stem/progenitor	cells	does	exist	in	the	retinae	of	mice	(Kubota	et	al.	2002)	and	humans	(Mayer	et	al.	
2005;	Johnsen	et	al.	2012),	which	may	act	to	repair	the	tissue	following	ocular	injury.	
The	10	layers	of	the	vertebrate	retina	consist	of	7	types	of	neuronal	and	glial	cells,	which	all	originate	
from	retinal	progenitor	cells	(RPCs).	Differentiation	of	the	different	cell	types	occurs	in	waves	and	it	is	
imperative,	therefore,	that	there	is	tight	regulation	of	both	extrinsic	and	intrinsic	cues	to	ensure	the	
correct	sequence	of	differentiation	(Zhang	and	Yang	2001).	Ca2+	waves	are	important	for	controlling	
the	expression	of	specific	genes	by	binding	to	calcium	response	elements	and	for	proliferation	of	NPCs	
(Tao	et	al.	1998;	West	et	al.	2001;	Stroh	et	al.	2011).		
In	 general,	 neurons	 in	 the	 retina	 are	 formed	 from	 RPCs	 in	 descending	 size	 order,	 with	 the	
differentiation	of	RGCs	as	the	first	cell	type	(Jeffery	1997).	In	addition,	the	position	relative	to	the	optic	
nerve	seems	to	be	important;	RGCs	with	axons	deepest	in	the	optic	tract	are	formed	first	(alpha	cells	
in	rat,	beta	cells	 in	cat)	 (Reese	and	Colello	1992).	Low	sonic	hedgehog	(Shh)	concentrations	 induce	
expression	 of	 several	 genes,	 including	atonal,	 and	mitogen-activated	 kinase	 (MAPK)	waves,	which	
stimulate	 naïve	 RPCs	 to	 become	 competent	 for	 differentiation.	 RGCs	 themselves	 secrete	 Shh.	
Increased	concentration	of	Shh	inhibits	further	RGC	differentiation	and	stimulates	the	next	wave	of	
neuronal	differentiation	(amacrines)	(Zhang	and	Yang	2001).	
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1.3.2	Dendrite	and	axon	guidance	
The	processes	of	dendrite	and	axon	development	are	mediated	through	a	collection	of	extracellular	
guidance	molecules	or	receptors	and	 intracellular	signal	molecules.	A	 list	of	 the	most	 important	of	
these	molecules	can	be	found	in	Table	1.1.
Table 1.1. Summary of molecules and proteins involved in the signalling cascades upstream of dendritic 
and axonal changes during development. 
	
Once	 cells	 have	 fully	 differentiated	 into	 RGCs,	 the	 process	 of	 dendrite	 outgrowth	 and	 branching	
occurs.	After	dendrite	growth	initiation,	one	dendrite	is	selected	to	become	the	axon	and	the	process	
of	axon	guidance	to	the	midbrain	and	the	thalamus	via	the	optic	nerve	begins.	Simultaneously,	the	
remaining	primary	dendrites	continue	to	grow	and	branch	in	response	to	a	number	of	positive	and	
negative	guidance	cues	(Erskine	and	Herrera	2007).	Neurite	outgrowth	is	mediated	by	intrinsic	factors,	
such	as	intracellular	cyclic	nucleotide	concentration	(Marrs	et	al.	2006),	and	extrinsic	factors,	including	
ephrins	(Xu	and	Henkemeyer	2012)	and	neurotrophins	(Bosco	and	Linden	1999;	Lom	and	Cohen-Cory	
1999).	
Extracellular	guidance	molecules	 Transmembrane	proteins	 Intracellular	signal	molecules	
Semaphorins	(secreted)	 Integrins	 Cyclic	AMP/GMP	
Extracellular	matrix	components	 NMDA	receptor	 Calcium	
	 Cadherins	 Rho	GTPases	
	 Neuropilins	 LIM	domain	kinase	1	
	 Plexins	 Focal	adhesion	kinase	
	 	 CAMKII	
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Regulation	 of	 cytoskeleton	 dynamics	 is	 controlled	 by	 cyclic	 nucleotides	 and	 proteins	 affecting	 the	
equilibrium	between	actin	polymerisation	and	actin	depolymerisation.	Rho	GTPases	and	Ca2+	currents	
play	a	role	 in	regulation	of	actin	dynamics,	therefore	regulation	of	these	affects	dendrite	and	axon	
growth	(Shi	and	Ethell	2006).	One	protein	downstream	of	Rho	GTPases	is	LIM	domain	kinase	1,	which	
phosphorylates	cofilin,	causing	actin	polymerisation.	LIM	domain	kinase	1	activity	is	important	for	RGC	
axon	outgrowth	and	is	expressed	in	Xenopus	RGCs	at	the	time	of	axon	extension	(Hocking	et	al.	2009).	
Actin	 remodelling	 is	 important	 to	 enable	 synaptic	 plasticity,	 which	 is	 essential	 in	 the	 cortex	 for	
information	processing	(Meng	et	al.	2004).	
Integrin-extracellular	matrix	(ECM)	interactions	are	also	important	in	synaptogenesis	and	modulation	
of	dendrites	and	axons.	This	is	thought	to	be	achieved	through	integrin	interaction	with	N-methyl-D-
aspartate	(NMDA)	receptors	in	hippocampal	neurons.	In	these	neurons	dendrite	length	and	branching	
is	modulated	by	activation	of	CaMKII	by	increases	in	Ca2+	concentration	within	dendritic	spines	(Shi	
and	Ethell	2006).	Cadherin-integrin	 interaction	may	play	an	 integral	 role	 in	dendrite	development.	
Experiments	in	Drosophila	and	Xenopus	suggest	that	type	I	cadherins	and	β1	integrins	are	required	
for	dendrite	extension,	and	N-cadherin	inhibits	dendritic	branching	(Marrs	et	al.	2006).	
Semaphorins	 are	 a	 class	 of	 guidance	 cues	 that	 bind	 to	 their	 receptors	 neuropilins	 and	 plexins	
(Nakamura	et	al.	2000).	The	class	3	semaphorin	Sema3A	stimulates	dendrite	growth	and	branching	
(Fenstermaker	 et	 al.	 2004)	 by	 increasing	 focal	 adhesion	 kinase	 phosphorylation	 at	 sites	 Y397	 and	
Y576/577,	however	this	is	dependent	on	simultaneous	β1	integrin	activation.	Sema3A	signalling	also	
increases	cGMP	production	in	neurons	(axons	and	dendrites)	(Polleux	et	al.	2000;	Schlomann	et	al.	
2009).	Sema3A	causes	integrin	inhibition	in	axons	and	as	a	result	has	a	repulsive	effect	on	axon	growth	
and	causes	growth	cone	collapse	(Luo	et	al.	1993;	Nakamura	et	al.	2000;	He	et	al.	2002;	Judas	et	al.	
2003).	These	opposing	effects	of	Sema3A	in	dendrites	and	axons	is	indicative	of	bidirectional	signalling	
between	semaphorins	and	integrins	(Schlomann	et	al.	2009),	and	the	differences	may	be	due	to	cGMP	
signalling	downstream	of	the	receptors	(Nakamura	et	al.	2000).	
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1.3.3	Synaptic	formation	and	remodelling	
Throughout	development	of	 the	central	nervous	system	(CNS)	dendritic	 spines	and	axons	undergo	
stages	of	growth	and	retraction.	Dendritic	spine	stability	is	essential	for	synaptogenesis	since	both	pre-	
and	post-synaptic	partners	need	to	be	present	for	 long	enough	for	a	synapse	to	form	(Bourne	and	
Harris	2008).	Changes	to	dendrites	and	synapses	occur	in	parallel	during	CNS	development	and	in	the	
adult	to	facilitate	plasticity	 in	the	brain	(Calverley	and	Jones	1990;	Titus	et	al.	2007).	Dendritic	and	
synaptic	 remodelling	 has	 been	 observed	 in	 neurons	 in	 the	 hippocampus	 (Fischer	 et	 al.	 1998;	
Dunaevsky	et	al.	1999),	frontal	and	prefrontal	cortex	(Huttenlocher	1979;	Elston	et	al.	2009;	Petanjek	
et	al.	2011),	cat	visual	cortex	(Cragg	1975),	and	rabbit	auditory	cortex	(Rihn	and	Claiborne	1990).	In	
the	 developing	 retina	 glutamate	 signalling	 is	 important	 for	 the	 regulation	 of	 the	 final	 dendritic	
structure	and	synaptic	contacts	of	RGCs	(Bodnarenko	&	Chalupa	1993).	Glutamate	released	by	bipolar	
cells	 in	a	spontaneous	fashion	before	eye	opening	(Wong	1999)	and	as	a	result	of	 light	stimulation	
after	 eye	 opening	 causes	 increased	 calcium	 signalling	 following	 activation	 of	 the	 RGC	 glutamate	
receptors	(Xu	&	Tian	2007).	The	resultant	increased	stability	of	dendrites	and	synapses	may	be	due	to	
increased	 brain-derived	 neurotrophic	 factor	 (BDNF)	 signalling	 (Landi	 et	 al.	 2007),	 which	 regulates	
dendritic	and	synaptic	structure	and	function	in	an	activity-dependent	manner	(see	1.6	Neurotrophin	
signalling).	
In	addition	to	development	it	has	been	postulated	that	dendritic	and	synaptic	changes	are	important	
in	memory	and	learning	(De	Roo	et	al.	2008;	Woronowicz	et	al.	2010).	In	particular,	the	size	of	dendritic	
spines	 is	 an	 important	 factor	 in	 calcium	 signalling	 in	 Purkinje	 cells	 during	 memory	 formation	
(Matsuzaki	2007).	Dendritic	remodelling	in	the	hippocampus	and	amygdala	is	also	involved	in	stress	
response	(Watanabe	et	al.	1992;	Magarinos	and	McEwen	1995;	Vyas	et	al.	2002).	
Importantly,	although	the	retina	is	often	considered	an	extension	of	the	CNS	(London	et	al.	2013)	there	
is	limited	plasticity	in	adult	RGCs.	At	the	end	of	the	critical	period,	an	inhibitory	mesh-like	structure,	
termed	 the	 perineuronal	 net	 (PNN)	 (see	 1.7.1),	 is	 laid	 down	 in	 the	 visual	 cortex	 to	 stabilise	 the	
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synapses	formed	during	development	(Guimaraes	et	al.	1990;	Pizzorusso	et	al.	2002).	The	PNN	can	be	
considered	a	specialised	form	of	extracellular	matrix	and	is	predominantly	comprised	of	chondroitin	
sulphate	proteoglycans	(CSPGs),	which	are	highly	negatively	charged.	PNN	components	are	secreted	
by	 neurons	 and	 glial	 cells	 and	 the	 net-like	 structure	 is	 laid	 down	 around	 the	 soma	 and	 proximal	
dendrites	of	neurons.	It	is	interesting	to	note	that	the	secretion	of	PNN	components	is	regulated	by	
neuronal	 activity;	 inhibition	 of	 sodium	 channels	 inhibits	 the	 formation	 of	 the	 PNN	 (Reimers	 et	 al.	
2007).	The	PNN	has	been	evidenced	to	play	important	roles	in	neuronal	protection,	by	acting	as	an	ion	
buffering	system,	as	well	as	the	modulation	of	synaptic	activity,	by	restricting	the	lateral	diffusion	of	
AMPA	 receptors	 (Frischknecht	 et	 al.	 2009).	 Stabilisation	of	 synapses	 in	 this	way	 restricts	 neuronal	
plasticity,	which	has	been	demonstrated	in	several	areas	of	the	CNS,	including	the	mouse	barrel	cortex	
(Nowicka	et	al.	2009)	and	amygdala	(Gogolla	et	al.	2009).	In	addition,	ON	RGC-bipolar	synapses	may	
be	stabilised	by	light-induced	inhibition	of	AMPA	receptor	cycling	(Xia	et	al.	2007).	The	timing	of	the	
critical	period	 in	 the	visual	 cortex	may	be	modulated	by	 brain-derived	neurotrophic	 factor	 (BDNF)	
(Huang	et	al.	1999).	
1.3.4	Dendritic	arbor	tiling	of	the	retina	
During	the	process	of	dendrite	outgrowth,	contact	inhibition	occurs	between	dendrites	of	the	same	
cell/cell	type,	creating	a	mosaic	of	dendritic	arbors	across	the	retina.	The	dendritic	fields	(DFs)	of	RGCs	
partially	overlap	with	the	DFs	of	amacrine	and	bipolar	cells.	This	allows	both	excitatory	and	inhibitory	
input	to	control	the	receptive	fields	(RFs),	and	therefore	the	basics	of	spatial	detection	(Barlow	and	
Levick	 1965;	 Torre	 and	 Poggio	 1978).	 RGC	 RFs	 and	 DFs	 are	 approximately	 equal	 in	 size,	 although	
directionally	 selective	 RGCs	 show	 a	 slight	 shift	 in	 RF	 (<30%)	 relative	 to	 the	 DF,	 towards	 the	 null	
direction,	allowing	spatial	information	to	be	provided	(Yang	and	Masland	1994).	Further	information	
is	provided	by	virtue	of	the	fact	that	within	RGC	RFs	areas	of	high	activity	exist.	Both	of	these	features	
of	RFs	may	be	controlled	by	the	specific	morphology	of	each	dendritic	tree	(Amthor	et	al.	1984;	Brown	
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et	 al.	 2000).	 In	 addition	 to	 spatial	 information,	 dendritic	 tiling	 of	 the	 retina	 permits	 maximum	
sensitivity	to	light,	and	means	that	there	is	little	redundancy	in	the	system	(Han	et	al.	2012).	
1.3.5	Cell	surface	antigens	
Cells	 membranes	 contain	 a	 wide	 array	 of	 proteins.	 Cell	 sub-types	 can	 be	 defined	 by	 the	 specific	
collection	of	cell	surface	antigens	they	display.	This	is	often	useful	to	define	as	it	allows,	for	example,	
the	monitoring	of	the	health	of	a	sub-type	of	neuron	that	may	be	of	interest	under	a	given	disease	
state,	which	may	allow	predictions	in	terms	of	disease	mechanisms	or	therapeutic	targets.	Examples	
of	some	retinal	cell-specific	antigens	are	outlined	in	this	section.	
Thy-1	is	a	membrane	glycoprotein	that	binds	ECM	components,	such	as	laminin	(Liesi	et	al.	1990).	Thy-
1	is	present	on	the	cell	membrane	of	many	cell	types,	including	lymphocytes	(Aoki	et	al.	1969;	Owen	
and	Raff	1970)	and	RGCs	(Barnstable	and	Drager	1984).	Whilst	Thy-1	is	one	of	the	most	widely	used	
RGC	markers,	it	is	by	no	means	ideal;	30%	of	Thy-1	expression	in	the	retina	is	on	the	membranes	of	
cells	which	are	not	RGCs	(Perry	et	al.	1984),	and	Thy-1	does	not	allow	targeting	of	sub-types	of	RGCs.	
Further,	it	has	been	found	that	following	optic	nerve	damage,	Thy-1	may	be	downregulated	(Nash	and	
Osborne	1999;	Schlamp	et	al.	2001;	Huang	et	al.	2006)	or	upregulated	(Lee	et	al.	1998;	Astafurov	et	
al.	2014).	Thy-1	is	upregulated	in	other	cells	in	the	retina,	including	Müller	cells	(Dabin	and	Barnstable	
1995).	This	may	mark	an	important	ECM	remodelling	step	in	the	damaged	retina.	Since	amacrine	cells	
express	Thy-1	receptors	(Dreyer	et	al.	1995),	changes	in	Thy-1	expression	may	permit	amacrine-Müller	
cell	interactions.	
Brn3	is	a	transcription	factor	that	has	roles	in	axon	guidance	and	cell	survival	(Gan	et	al.	1999;	Wang	
et	al.	2000;	Badea	et	al.	2009).	In	the	mouse	approximately	70%	of	RGCs	express	Brn3b	(Erkman	et	al.	
1996;	Gan	et	al.	1996),	and	in	the	rat	70%	of	RGCs	express	at	least	2	of	Brn3a,	Brn3b	and	Brn3c	(Nadal-
Nicolas	et	al.	2012).	Brn3b	is	commonly	used	as	an	RGC-specific	marker,	for	example	in	the	study	using	
yellow	 fluorescent	 protein-tagged	 channel	 rhodopsin	 molecules	 expressed	 downstream	 of	 Thy-1	
(Zhang	et	al.	2012).	However,	as	with	Thy-1,	Brn3	does	not	allow	sub-type	targeting.	
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There	are	several	bipolar	cell	markers,	including	Bhlhb4	(Bramblett	et	al.	2004),	Irx5	(Cheng	et	al.	2005)	
and	 Gli5	 (Blackshaw	 et	 al.	 2004).	 Recently	 Grm6,	 the	 promoter	 for	 the	 gene	 encoding	 mGluR6	
(required	for	ON-bipolar	cell	response	to	glutamate	released	from	photoreceptor	cells	(Nawy	and	Jahr	
1990;	Shiells	and	Falk	1990,	1992;	Nomura	et	al.	1994;	Nawy	1999)),	has	been	found	to	stimulate	the	
expression	of	genes	that	result	in	the	translation	of	proteins	found	in	ON-bipolar	cells	(Dhingra	et	al.	
2008).	This	presents	exciting	prospects	of	sophisticated	visual	circuitry	control.	
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1.4	Aberrant	dendritic	morphology	in	ageing	and	disease	
Retinal	 degeneration	 is	 one	 of	 the	 leading	 causes	 of	 blindness	 in	 the	world	 today	 (Quigley	 1996;	
Congdon	et	al.	2004;	Quigley	and	Broman	2006).	Age-related	macular	degeneration	(AMD)	commonly	
involves	the	deposition	of	drusen	and	degeneration	of	retinal	pigment	epithelium	(RPE),	 leading	to	
photoreceptor	 damage	 (Green	 et	 al.	 1985;	 Coleman	 et	 al.	 2008).	 AMD	 is	 often	 associated	 with	
increased	oxidative	damage	and	the	presence	of	splice	variants	of	Complement	factor	H.	These	splice	
variants,	for	example	the	Y402H	mutation,	increase	the	activity	of	the	complement	pathway	and	are	
linked	to	increased	likelihood	of	AMD	development	(Rutar	et	al.	2012).	
Glaucoma	is	an	umbrella	term	for	a	group	of	diseases	associated	with	optic	nerve	damage	and	RGC	
degeneration	 (Quigley	et	al.	1995).	Glaucoma	 is	often	associated	with,	although	 is	not	defined	by,	
increased	intraocular	pressure	(IOP)	(Quigley	et	al.	1987;	Quigley	et	al.	1988).	Eyes	with	an	IOP	of	>21	
mmHg	are	classified	as	glaucomatous	(Weber	et	al.	2008).	Current	treatments	focus	on	reducing	IOP	
(Peeters	et	al.	2010),	however	future	therapies	should	aim	to	preserve	cell	function	in	the	GCL	and	
prevent	further	degeneration	since	it	is	the	RGC	loss	which	ultimately	leads	to	vision	loss	(Howell	et	
al.	2007).	
Retinitis	pigmentosa	 is	associated	with	degeneration	of	 the	photoreceptor	 layer	 (Dryja	et	al.	1990;	
Hartong	 et	 al.	 2006).	 RGCs	 are	 still	 present	 following	 photoreceptor	 death.	 However,	 it	 has	 been	
shown	that	transneuronal	degeneration	occurs	through	the	neuronal	pathway,	ultimately	resulting	in	
loss	 of	 RGCs	 (although	 this	 has	 been	 disputed	 in	 one	mouse	model),	 with	 evidence	 of	 abnormal	
electrical	 activity	 (Stone	 et	 al.	 1992;	 Strettoi	 et	 al.	 2002;	Mazzoni	 et	 al.	 2008;	 Stasheff	 2008).	 It	 is	
postulated,	 therefore,	 that	although	 introduction	of	photosensitive	 cells	or	 stimulation	of	 resident	
cells,	for	example	by	introduction	of	photosensitive	bacterial	proteins	via	gene	therapy	(Tomita	et	al.	
2009;	 Busskamp	 and	 Roska	 2011;	 Deisseroth	 2011),	 can	 still	 result	 in	 RGC	 action	 potential	 firing	
(Margolis	et	al.	2008;	Jensen	and	Rizzo	2009),	neuroprotective	agents	must	be	given	in	combination	
to	prevent	secondary	degeneration.	
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1.4.1	Dendritic	changes	
During	normal	development	of	 the	nervous	 system,	neuronal	degradation	and	dendrite	 retraction	
occurs.	Dendritic	pruning	is	an	important	process	in	ensuring	correct	neuronal	networks	are	created.	
Mice	lacking	caspase-3	have	an	abnormally	large	number	of	dendritic	spines,	implicating	caspase-3	in	
the	modulation	of	dendritic	remodelling	(Erturk	et	al.	2014).	Indeed,	numerous	studies	have	provided	
evidence	for	the	role	of	caspases	in	dendritic	pruning	in	class	IV	dendritic	arborisation	sensory	neurons	
in	 Drosophila	 melanogaster	 undergoing	 morphogenesis	 (Kuo	 et	 al.	 2006;	 Williams	 et	 al.	 2006).	
Interestingly,	the	location	of	caspases	determines	the	downstream	effects;	local	caspase	activation	in	
dendrites	 causes	 dendritic	 pruning,	 whereas	 inhibition	 of	 the	 ubiquitin-proteasome	 machinery	
permits	global	caspase	activation	and	results	 in	cell	death	 	 (Rumpf	et	al.	2011;	Erturk	et	al.	2014).	
Other	 regulatory	 factors,	 such	 as	 reactive	 oxygen	 species	 or	 duration	 of	 caspase	 activation,	 may	
modulate	 the	downstream	effects,	 i.e.	 cell	death	or	dendritic	 remodelling	 (Snigdha	et	al.	2012).	 In	
addition,	it	has	been	demonstrated	in	mice	and	Drosophila	that	a	parallel	NAD+-dependent	pathway	
may	 regulate	 axonal	 pruning	of	 neurons	 during	 development	 (Schoenmann	et	 al.	 2010).	Although	
specific	details	are	yet	to	be	determined,	it	is	likely	that	the	process	of	dendritic	retraction	involves	
destabilisation	 of	 the	 cytoskeleton,	 fragmentation	 and	 finally	 removal	 of	 debris	 by	 glial	
cells/macrophages	(Hyman	&	Yuan	2012).	
Downstream	signalling	of	the	excitatory	neurotransmitter	glutamate	has	been	shown	to	increase	the	
rate	of	dendritic	pruning	(Andres	et	al.	2008).	Since	retinal	degeneration	is	associated	with	reactive	
gliosis,	 which	 involves	 excessive	 glutamate	 signalling	 and	 activation	 of	 inflammatory	 pathways,	 it	
would	 be	 logical	 to	 predict	 that	 retinal	 degeneration	 could	 be	 associated	 with	 dendritic	 pruning.	
Further,	 it	 has	 been	 postulated	 that	 the	 degree	 of	 pruning	 could	 be	 indicative	 of	 the	 level	 of	
degeneration	within	the	retina	since	it	seems	likely	that	the	reduction	of	dendritic	branching	occurs	
before	the	onset	of	RGC	death	(Morquette	and	Di	Polo	2008).	
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Morphological	remodelling	has	been	demonstrated	in	a	range	of	disease/injury	models	affecting	the	
CNS.	Firstly,	Alzheimers	disease	models	show	dendritic	pruning	of	pyramidal	neurons	and	reduced	
complexity	of		glial	cells	in	the	hippocampus	and	entorhinal	cortex	(Beauquis	et	al.	2013;	Williams	et	
al.	2013b),	as	well	as	atrophy	of	astrocyte	processes	in	amyloid	cores	(Nagele	et	al.	2004).	Secondly,	
neuroblastoma	dendritic	 atrophy	 is	 one	of	 the	morphological	 changes	demonstrated	 in	models	 of	
prion	diseases,	including	Creutzfeldt-Jakob	disease	(Ishikura	et	al.	2005).	Thirdly,	structural	changes	in	
dendrites	and	synapses	of	motor	neurons	have	been	noted	in	models	of	spinal	cord	injury	(Bannerman	
et	al.	2005;	Macias	2008).	Finally,	there	is	evidence	for	neuronal	remodelling	in	retinal	degeneration	
(Jones	and	Marc	2005).	In	particular,	dendritic	pruning	in	RGCs	has	been	suggested	to	occur	prior	to	
cell	death	in	glaucoma	(Weber	et	al.	1998).	Rett	syndrome	is	associated	with	alterations	in	the	MECP2	
gene	in	patients	(Amir	et	al.	1999)	and	knockout	or	mutation	of	mecp2	produces	a	mouse	model	of	
the	disorder	(Chen	et	al.	2001;	Guy	et	al.	2001).	MECP2	is	a	protein	involved	in	the	maintenance	of	the	
structural	integrity	of	neuronal	circuits	(Dani	and	Nelson	2009;	Na	et	al.	2013),	as	well	as	the	protection	
of	neurons	from	oxidative	stress	(De	Felice	et	al.	2014).	
Reduction	in	DF	size	and	dendritic	pruning	has	been	shown	to	occur	in	cat,	rat,	and	primate	models	of	
glaucoma	before	the	cell	is	committed	to	the	fate	of	apoptosis	(Morgan	2002;	Shou	et	al.	2003;	Kisiswa	
et	al.	2010a;	Morgan	2012).	Dendritic	pruning	could	therefore	provide	an	invaluable	early	read-out	of	
cell	health	and	illuminate	the	therapeutic	window	in	which	to	prevent	the	onset	of	apoptosis	in	order	
to	maintain	some	vision	in	patients.	
1.4.2	Oxidative	damage	
In	ageing	cells,	mitochondrial	electron	transport	becomes	less	efficient,	resulting	in	an	accumulation	
of	 reactive	 oxygen	 species	 (ROS)	 (Harman	 1981;	 Liang	 and	Godley	 2003).	 ROS	 increase	 apoptosis,	
stimulate	vascular	endothelial	growth	factor-mediated	angiogenesis	through	upregulation	of	hypoxia	
inducible	factor,	and	causes	degeneration	of	membrane	lipids,	especially	those	in	outer	segments	of	
photoreceptors	(Cano	et	al.	1986).	Oxidative	damage	is	also	stimulated	by	white	light	and	results	in	
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activation	of	the	complement	pathway,	including	upregulation	of	complement	3	(Maller	et	al.	2007;	
Yates	et	al.	2007).	 Increased	activity	of	 the	complement	pathway	aids	 in	breaking	down	apoptotic	
cells,	however	dysregulated	activity	may	contribute	to	tissue	degeneration.	
High	 ROS	 levels	 activate	 secretion	 of	 matrix	 metalloproteases	 (MMPs),	 which	 break	 down	 ECM	
proteins,	 causing	 remodelling.	 Remodelling	 affects	 cell	 survival,	 for	 example	 gliosis-mediated	
upregulation	of	MMP-9	reduces	RGC	survival	and	migration	(Santos	et	al.	2012).	Similarly,	in	retinal	
degeneration	the	structure	of	the	outer	limiting	membrane	(OLM)	is	changed	to	localise	damage	by	
restricting	cell	migration.	Cell	replacement	therapies	rely	on	the	ability	of	inserted	cells	to	migrate	to	
their	 target.	 For	 these	 therapies	 it	 has	been	 found	 that	 integration	efficiency	 can	be	 increased	by	
manipulating	 ECM	 remodelling,	 for	 example	 by	 the	 addition	 of	 MMP-2,	 and	 compromising	 the	
integrity	of	the	OLM	(Zhang	et	al.	2007;	Barber	et	al.	2012).	
1.4.3	Neuroprotection	
RGC	death	 is	 the	 final	step	 in	most	cases	of	 retinal	degeneration,	and	since	they	are	the	cells	 that	
transmit	the	retinal	output	to	the	brain,	 if	this	step	can	be	prevented	some	visual	function	may	be	
preserved.	One	mechanism	contributing	to	RGC	apoptosis	in	glaucoma	is	postulated	to	be	blockage	of	
axonal	 retrograde	 transport	of	 growth	 factors	 to	 the	 soma	 (Quigley	1995),	which	may	 lead	 to	 cell	
stress.	Since	autophagy	 is	upregulated	by	oxidative	stress	and	excitotoxicity,	and	under	high	stress	
conditions	 may	 stimulate	 cell	 death,	 this	 may	 be	 implicated	 in	 glaucoma.	 On	 the	 other	 hand,	
downregulation	of	autophagy	 in	 the	Atg4B-/-	mouse	model	 is	 combined	with	 reduced	RGC	survival	
(Caprioli	et	al.	1996;	Zhu	et	al.	2005;	White	et	al.	2009;	Rodriguez-Muela	et	al.	2012),	therefore	further	
study	of	the	mechanisms	linking	cell	stress	and	neuronal	death	are	required.	
It	has	been	proposed	that	a	more	achievable	method	to	manage	retinal	degenerative	diseases	may	be	
to	provide	neuroprotection	to	the	existing	healthy	cells	(Morquette	and	Di	Polo	2008;	Bull	et	al.	2011;	
Johnson	et	al.	2011).	This	protection	could	come	from	the	addition	of	growth	factors,	such	as	ciliary	
neurotrophic	factor	(CNTF)	or	BDNF,	inhibition	of	glutamate	receptor	activation,	or	addition	of	factors	
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to	inhibit	apoptosis	(Morquette	and	Di	Polo	2008).	The	evidence	for	this	approach	in	the	literature	is	
mixed.	CNTF	reduces	photoreceptor	death	in	patients	with	retinal	degeneration	(Tibbetts	et	al.	2012),	
but	in	a	clinical	trial	with	sustained	release	of	CNTF	there	was	no	effect	on	visual	acuity	or	visual	field	
sensitivity	 (Talcott	 et	 al.	 2011).	 Neuroprotection,	 in	 theory,	 should	 retard	 disease	 progression	 by	
maintaining	 the	 connections	 between	 healthy	 cells	 and	 reducing	 gliosis,	 thereby	 preserving	 visual	
acuity.	It	should	be	noted	that	this	method	can	only	prevent	further	deterioration	of	vision,	whereas	
successful	transplantation	of	neurons	has	the	potential	to	improve	vision,	therefore	ideally	the	two	
approaches	would	be	combined.	On	the	other	hand,	application	of	an	agent	capable	of	stimulating	
regrowth	 of	 neurons	 could	 re-wire	 the	 damaged	 neuronal	 network	 and	 restore	 visual	 function	
(Morgan	2012).		
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1.5	Neurotrophin	signalling	
Growth	factors	are	small	proteins	that	act	to	regulate	cell	processes	in	every	tissue	in	the	body	via	
intracellular	signalling	pathways	or	by	binding	to	plasma	membrane	receptors.	Neurotrophic	factors	
are	generally,	although	not	exclusively,	expressed	in	the	nervous	system	(Levi-Montalcini	et	al.	1996).	
Neurotrophic	factors	consist	of	3	main	groups	of	growth	factors:	glial	cell-line	derived	neurotrophic	
factor	family	ligands,	e.g.	glial	cell-line	derived	neurotrophic	factor;	neuropoietic	cytokines,	e.g.	CNTF;	
and	neurotrophins.	The	term	‘neurotrophin’	specifically	refers	to	the	4	proteins	nerve	growth	factor	
(NGF),	BDNF,	neurotrophin-3	 (NT-3)	and	NT-4,	which	share	55%	sequence	 identity	 for	amino	acids	
(Suter	et	al.	1992)	and	most	have	low	affinity	for	the	p75	neurotrophin	receptor	(NTR).	Neurotrophins	
exert	 their	primary	downstream	effects	via	binding	to	tropomyosin	receptor	kinase	(Trk)	receptors	
(Table	 1.2).	Neurotrophins	 have	 essential	 roles	 during	 development	 and	 adult	 homeostasis	 of	 the	
nervous	 system,	particularly	with	 respect	 to	cell	 survival,	differentiation,	 synaptogenesis	and	 long-
term	potentiation.	
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Table 1.2. Summary of neurotrophins and their respective affinities for neurotrophin receptors 
(Dechant et al. 1997; Chao 2003). The relative affinities are important when considering interplay 
between Trk and p75NTR signalling (see text for explanation). 
Neurotrophin	 High	affinity	receptor	 Low	affinity	receptor(s)	
NGF	 TrkA	 P75NTR	
BDNF	 TrkB	 P75NTR	
NT-3	 TrkC;	p75NTR	 TrkA;	TrkB	
NT-4	 TrkB	 P75NTR	
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1.5.1	BDNF	gene	expression	and	regulation	
BDNF	was	first	isolated	from	porcine	brain	in	1982	(Barde	et	al.	1982).	The	bdnf	gene	is	encoded	on	
chromosome	 11p13.	 In	 the	murine	 retina	 expression	 of	mRNA	 and	 protein	 of	 both	 BDNF	 and	 its	
candidate	receptor,	TrkB,	is	predominantly	seen	in	RGCs	(Gao	et	al.	1997;	Bennett	et	al.	1999),	as	well	
as	displaced	amacrine	cells	(Cellerino	&	Kohler	1997;	Vecino	et	al.	2002).	Although	mRNA	expression	
of	the	low	affinity	receptor,	p75NTR,	is	seen	in	RGCs	(Suzuki	et	al.	1998),	at	the	protein	level	it	has	only	
been	observed	in	Muller	cells,	with	no	detectable	levels	in	RGCs	in	the	adult	murine	retina	(Hu	et	al.	
1999).	
In	the	rodent,	bdnf	contains	one	3’	protein-coding	exon	(exon	IX)	and	nine	5’	non-coding	exons	(Aid	
et	al.	2007),	each	containing	separate	promoter	sites,	which,	in	combination	with	multiple	splice	sites	
and	polyadenylation	sites,	can	result	in	the	formation	of	18	different	mRNA	transcripts,	all	of	which	
are	ultimately	translated	into	the	same	protein	(Greenberg	2010).	It	has	been	postulated	that	BDNF	
gene	expression	has	so	many	points	of	regulation	because	BDNF	signalling	is	so	important	in	neuronal	
structure,	function	and	survival,	therefore	it	is	imperative	that	BDNF	levels	are	able	to	be	modulated	
downstream	of	multiple	 cell	 signalling	 cascades.	 For	 example,	 transcripts	 that	 include	 exon	 IV	 are	
associated	with	 dendritic	 localisation,	whereas	 exon	 III	 transcripts	 are	 associated	with	 localisation	
within	the	soma	(Pattabiraman	et	al.	2005).	Post-transcriptional	modifications	offer	another	level	of	
control.	Bdnf	transcripts	are	polyadenlyated	at	2	sites,	resulting	in	a	3’	untranslated	region	(UTR).	The	
length	of	the	UTR	appears	to	be	important	for	localisation	of	the	transcript;	in	the	hippocampus	short	
UTRs	restrict	the	transcript	to	the	soma,	whereas	long	UTRs	promote	transport	to	dendrites	(An	et	al.	
2008).	
Expression	of	bdnf	is	sensitive	to	cell	signalling	and	neuronal	activity	due	to	the	presence	of	3	calcium	
response	elements	(CaRE1-3)	upstream	of	the	promoter	(Tao	et	al.	1998;	Zheng	et	al.	2012).	Increased	
intracellular	 calcium	 levels	 results	 in	 increased	 recruitment	 of	 nuclear	 binding	 proteins	 binding	 to	
CaREs	via	calcium-dependent	kinases	and	phosphatases	(Schuh	et	al.	2004),	resulting	in	an	increase	in	
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the	rate	of	transcription	of	exon	IV	(Figure	1.3).	Intracellular	calcium	concentration	can	be	increased	
through	membrane	recruitment	of	phospholipase	Cγ	(PLCγ),	which	results	in	efflux	of	calcium	from	
calcium	 stores	 via	 binding	of	 inositol	 1,4,5-trisphosphate	 to	 inositol	 1,4,5-trisphosphate	 receptors.	
Calcium	 influx	 into	 the	 cytosol	 is	 also	 increased	 through	 voltage-gated	 calcium	 channels	 following	
membrane	depolarisation.	
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Figure 1.3 Calcium response elements regulate transcription of bdnf exon IV in response to calcium. 
CaRE1 is bound by calcium responsive factor (CaRF) in response to calcium levels via signalling 
cascades including protein kinase A and PI3K. CaRE2 is bound by upstream stimulatory factor 1/2 
(USF1/2), a basic helix-loop-helix member. CaRE3 is bound by cAMP response element binding protein 
(CREB) in response to calcium levels via voltage-gated calcium channels and NMDA receptors. The 
positions of each CaRE is shown relative to the initiation site. Figure modified from Zheng et al. 2012. 
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Epigenetic	regulation	of	bdnf	is	another	level	of	control	that	is	linked	to	altered	expression	of	bdnf	in	
relation	to	neuronal	activity	and	disease.	Exon	IV	contains	a	CpG	island	–	these	are	reported	to	be	
important	sites	for	the	epigenetic	regulation	of	genes.	This	CpG	island	is	demethylated	by	activation-
induced	cytidine	deaminase	(Ratnu	et	al.	2014)	following	upregulation	of	the	CaMK	pathway	through	
either	TrkB	activation	or	membrane	depolarisation.	Neuronal	activity	is	also	associated	with	decreased	
binding	of	MeCP2	(binds	methylated	DNA)	and	increased	binding	of	CREB,	both	of	which	have	specific	
binding	sites	on	exon	IV.	These	binding	profiles	are	associated	with	increased	transcription	levels	of	
bdnf	 (Martinowich	 et	 al.	 2003;	 Boulle	 et	 al.	 2012;	 Karpova	 2014).	 Downregulation	 of	 BDNF	 in	
Schizophrenia	 and	 bipolar	 disorder	 is	 correlated	 with	 overexpression	 of	 DNA	 methyltransferase1	
(DNMT1),	which	binds	to	the	bdnf	promoter	on	exon	IX	 in	glutamatergic	neurons	of	the	prefrontal	
cortex,	and	seems	to	be	independent	of	a	methylation	mechanism	(Dong	et	al.	2014).	
1.5.2	P75NTR	receptor	signalling	
P75NTR	is	a	member	of	the	tumour	necrosis	factor	receptor	family	and	as	such	is	capable	of	activating	
downstream	signalling	pathways,	predominantly	c-JUN	N-terminal	kinase	(JNK),	NF-kappaB	and	RhoA	
(Carter	et	al.	1996;	Yamashita	et	al.	1999;	Friedman	2000;	Harrington	et	al.	2002).	These	pathways	are	
associated	with	apoptosis	induction,	long-term	depression,	neurite	retraction	and	synapse	loss	(Bamji	
et	al.	1998;	Frade	and	Barde	1999;	Woo	et	al.	2005;	Zagrebelsky	et	al.	2005;	Yang	et	al.	2009).	P75NTR	
forms	 a	 dimer,	 linked	 through	 a	 disulphide	 bond	 at	 cys257,	 which	 is	 essential	 for	 neurotrophin-
mediated	p75NTR	signalling	(Vilar	et	al.	2009).	It	has	been	proposed	that	neurotrophin	binding	to	the	
extracellular	domain	causes	separation	of	the	death	domains	inside	the	cell,	thus	permitting	binding	
of	adapter	proteins	to	the	death	domains	(Vilar	et	al.	2009).	These	adapter	proteins	are	associated	
with	cell	death	and	modulation	of	neurite	retraction	(Friedman	2000).	
Downstream	signalling	of	p75NTR	is	not	activated	in	the	absence	of	neurotrophin	binding.	Apoptosis	
may	be	mediated	 through	NGF	binding	 to	 p75NTR,	which	 facilitates	 binding	of	 the	 adapter	 protein	
p75NTR-associated	death	executor	 to	 the	death	domain	of	p75NTR	 (Mukai	et	al.	2000).	Knock-out	of	
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either	p75NTR	or	NGF	results	in	an	approximately	50%	reduction	in	cell	death	in	retinae	and	spinal	cord	
of	E15.5	mice	(Frade	and	Barde	1999).	During	development,	NGF-p75NTR	signalling	promotes	cell	death	
in	cells	that	do	not	express	TrkA	(Dechant	and	Barde	1997).	These	studies	provide	strong	evidence	for	
the	role	of	p75NTR	signalling	in	apoptosis.		
It	should	be	noted	that	p75NTR	signalling	also	has	positive	roles.	During	development	p75NTR	is	strongly	
expressed	by	neurons,	particularly	in	neurons	with	long-spanning	axons,	such	as	spinal	motor	neurons,	
and	neurons	with	dense	dendritic	arbors,	such	as	RGCs.	In	the	absence	of	neurotrophin,	RhoA,	a	small	
GTPase,	binds	 to	amino	acids	331-416	 in	 the	death	domain	of	p75NTR	 (Roux	and	Barker	2002)	and	
inhibits	neurite	outgrowth.	However,	following	neurotrophin	binding	to	p75NTR	RhoA	is	not	activated	
(Yamashita	et	al.	1999),	which	may	explain	the	expression	pattern	of	p75NTR	in	developing	neurons.	In	
the	adult	p75NTR	is	reduced	in	these	neurons	(Yan	and	Johnson	1988).	Following	axonal	injury	p75NTR	
expression	 is	 upregulated	 in	 a	 range	 of	 neuronal	 populations	 (Ibanez	 and	 Simi	 2012)	 and	 is	
subsequently	restored	to	normal	levels	following	axonal	re-growth	(Ernfors	et	al.	1989).	
1.5.3	Trk	receptor	signalling	
Neurotrophins	elicit	their	primary	effect	by	binding	to	one	of	the	3	structurally	related	receptors	TrkA,	
TrkB	and	TrkC.	BDNF	and	NT-4	bind	to	TrkB	with	picomolar	affinity,	while	NT-3	binds	with	nanomolar	
affinity.	BDNF	and	NT-4	form	a	salt	bridge	with	TrkB,	but	NGF	does	not	form	a	salt	bridge	with	TrkA,	
which	may	explain	the	relative	binding	affinities	(Banfield	et	al.	2001;	Naylor	et	al.	2002).	Upon	ligand	
binding,	the	Trk	receptors	dimerise	and	are	autophosphorylated	at	up	to	3	Tyr	residues;	Tyr670,	Tyr	
674	and	Tyr675	in	TrkA	(Middlemas	et	al.	1994).	Tyr	phosphorylation	recruits	scaffold	proteins,	such	
as	PLC	and	phosphatidylinositol	3-kinase	(PI3K)	and	MAPK	to	the	membrane	(Minichiello	et	al.	2002;	
Schratt	et	al.	2004).	Resultant	downstream	signalling	leads	to	cell	survival,	neurite	outgrowth,	synapse	
formation	and	strengthening,	and	long-term	potentiation	(Korte	et	al.	1995;	Xu	et	al.	2000;	Yacoubian	
and	Lo	2000).	Following	receptor	dimerisation,	TrkB	is	internalised	by	clathrin-mediated	endocytosis,	
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which	is	a	key	step	in	continuation	of	the	signal.	TrkB	and	p75NTR	signalling	pathways	are	summarised	
in	Figure	1.4.	
Neurotrophin	signalling	can	have	opposing	downstream	effects.	 	While	this	may	seem	nonsensical,	
one	key	 factor	 that	ultimately	determines	 the	 final	outcome	 (cell	 death	or	 survival)	 is	 the	 relative	
affinities	for	each	receptor.	As	outlined	in	Table	1.1,	with	the	exception	of	NT-3,	mature	neurotrophins	
have	higher	affinity	for	the	‘positive’	Trk	receptors	than	for	the	‘negative’	p75NTR.		For	the	unprocessed,	
pro-neurotrophins	the	reverse	affinity	pattern	exists	(Rodriguez-Tebar	et	al.	1990;	Lee	et	al.	2001).	
This	means	that	processes	like	apoptosis	can	be	subtly	modulated	on	a	temporal	scale	by	the	ratio	of	
pro-neurotrophins	 and	 mature	 neurotrophins,	 which	 may	 be	 modulated	 through	 neurotrophin	
processing	 or	 secretion,	 as	 well	 as	 the	 relative	 expression/membrane	 recruitment	 of	 each	
neurotrophin	receptor.
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Figure 1.4 Summary of signalling cascades downstream of p75NTR and TrkB receptors via ligand 
binding. Pro-BDNF binds p75NTR and mature BDNF (mBDNF) binds TrkB. Pro-BDNF binding to p75NTR 
recruits sortilin and results in downstream JNK signalling, leading to cell death. Mature BDNF can bind 
to p75NTR and may inhibit downstream TrkB signalling through JNK and RhoA (not shown), or may 
strengthen BDNF binding to TrkB, increase MAPK and Akt signalling, and promote cell survival through 
NF-kB. Mature BDNF binds TrkB and stimulates downstream signalling of PLCγ, Akt and MAPK, 
leading to cell survival, neurite outgrowth, as well as increased BDNF transcription through upregulation 
of CREB (Longo and Massa 2013).	
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The	Trk	receptor	family	is	another	group	of	proteins	that	p75NTR	can	interact	with.	Interaction	of	Trk	
receptors	 with	 p75	 may	 increase	 the	 affinity	 of	 the	 Trk	 receptor	 for	 the	 ligand,	 and	 therefore	
strengthen	downstream	signalling	(Benedetti	et	al.	1993;	Bibel	et	al.	1999).	Indeed,	sensory	deficits	
are	observed	in	animals	with	a	mutated	NGF,	which	is	able	to	bind	TrkA	but	not	p75	(Horton	et	al.	
1997;	Ryden	et	al.	1997),	or	with	a	mutated	p75	(Lee	et	al.	1992;	Lee	et	al.	1994).	TrkA	and	TrkC	are	
localised	in	lipid	rafts,	along	with	the	enzyme	γ-secretase.	In	the	absence	of	ligand	(NGF/NT-3)	TrkA/C	
associates	with	 p75	NTR	within	 the	 lipid	 raft,	 allowing	 γ-secretase	 to	 cleave	 the	 intracellular	 death	
domain	 of	 p75	 NTR	 and	 activate	 apoptosis	 signalling	 via	 stimulation	 of	 cytochrome	 c	 release	 from	
mitochondria.	In	the	presence	of	ligand	TrkA/C	dimerise,	permitting	recruitment	of	scaffold	proteins:	
Shc	recruitment	to	Tyr490	stimulates	the	Ras	pathway;	PLCγ	recruitment	to	Tyr785	stimulates	the	PKC	
pathway;	 and	 PI3K	 recruitment	 to	 Tyr751	 stimulates	 the	Akt	 pathway.	 Ras	 and	 PKC	 pathways	 are	
associated	with	neurite	outgrowth	and	differentiation,	while	the	Akt	pathway	suppresses	apoptosis	
and	promotes	cell	survival.	In	this	way,	TrkA	and	TrkC	are	‘dependence’	receptors,	that	is	they	depend	
on	the	presence	of	their	ligand	in	order	for	them	not	to	induce	programmed	cell	death		(Dekkers	et	al.	
2013).		
TrkB,	which	contains	a	structurally	different	transmembrane	domain	to	TrkA/C,	is	localised	in	the	lipid	
bilayer.	 In	 the	 absence	 of	 BDNF/NT-4,	 TrkB	 associates	 with	 p75NTR,	 however,	 since	 γ-secretase	 is	
absent	in	the	lipid	bilayer,	the	death	domain	of	p75NTR	is	not	cleaved	and	therefore	apoptosis	is	not	
induced.	Studies	have	demonstrated	that	knocking	out	BDNF/NT-4	and	not	TrkB	does	not	result	 in	
wide-spread	cell	death,	as	seen	in	similar	studies	with	TrkA/C	(Nikoletopoulou	et	al.	2010).	In	this	way,	
TrkB	is	not	a	dependence	receptor.	Dekkers	et	al.	created	a	mosaic	TrkB	receptor	that	contained	the	
transmembrane	 domain	 of	 TrkA,	 thereby	 confining	 it	 to	 lipid	 rafts,	 and	 demonstrated	 that	 in	 the	
absence	of	BDNF	this	mosaic	receptor	causes	cell	death	(Dekkers	et	al.	2013).	This	elegant	experiment	
supports	the	theory	that	membrane	localisation	is	key	to	the	downstream	effects	of	these	receptors.	
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1.5.4	BDNF	post-translational	processing	and	sorting	
In	 common	with	 other	 secreted	 peptides,	 all	 neurotrophins	 are	 translated	 as	 a	 precursor,	 or	 pro-
neurotrophin.	 As	 outlined	 above,	 pro-neurotrophins	 and	mature	 neurotrophin	 signalling	 cascades	
have	 largely	 opposing	 effects,	 therefore	 the	 relative	 amounts	 of	 precursor	 versus	 processed	
neurotrophin	is	 likely	to	be	a	determining	factor	of	whether	the	end	result	 is	pro-apoptotic	or	pro-
survival.	 Since	 the	 ratio	 can	 be	 rapidly	 modulated	 by	 pro-neurotrophin	 processing,	 this	 enables	
neurotrophin	secretion	to	be	rapidly	switched	on	and	off	–	an	essential	property	of	molecules	that	
must	 respond	 to	changes	 in	neuronal	activity.	 In	general,	precursor	proteins	are	 inactive,	but	pro-
neurotrophins	are	able	to	stimulate	intracellular	signalling	pathways.	Pro-neurotrophins	have	a	higher	
affinity	for	p75NTR	than	Trk	receptors,	therefore	pro-neurotrophin	signalling	stimulates	apoptosis	and	
neurite	retraction	(Lee	et	al.	2001).	
Mature	 neurotrophins	 are	 generated	 by	 proteolytic	 cleavage	 of	 the	 signal	 peptide	 on	 pro-
neurotrophins,	 followed	by	dimerization	 (Heymach	and	Shooter	1995;	 Lee	et	al.	2001).	Pro-NGF	 is	
processed	 intracellularly,	processed	through	the	constitutive	pathway,	and	secreted	as	 the	mature	
NGF.	Pro-BDNF	may	be	cleaved	intracellularly	or	extracellularly.	Intracellularly,	pro-BDNF	is	cleaved	
by	furin	in	the	endoplasmic	reticulum,	or	by	proconvertases	in	secretory	vesicles	(Matsumoto	et	al.	
2008).	 In	non-neuronal	cells,	 such	as	astrocytes,	BDNF	 is	 sorted	 through	 the	constitutive	pathway.	
Neuronal	cells	use	both	 the	constitutive	pathway	and	the	regulated	pathway	 in	 the	golgi,	which	 is	
mediated	through	the	binding	of	sortilin	to	the	signal	peptide	of	pro-BDNF,	or	by	the	binding	of	CPE	
to	 a	motif	 on	 the	mature	 BDNF	 section	 of	 the	 protein.	 The	 constitutive	 pathway	 corresponds	 to	
constitutive	BDNF	release	and	the	regulated	pathway	corresponds	to	activity-dependent	secretion.	
The	precursor	and	mature	 forms	of	BDNF	are	 released	via	 secretory	vesicles	 into	 the	extracellular	
milieu,	where	pro-BDNF	can	be	processed	by	plasmin	(a	serine	protease;	Figure	1.5)	or	by	MMP-3	and	
MMP-7	(Lee	et	al.	2001;	Pang	et	al.	2004;	Dwivedi	2012).	Plasmin	is	 inhibited	by	the	blood-derived	
protein	 α-2-macroglobulin,	 which	 may	 reduce	 BDNF	 processing	 as	 well	 as	 directly	 blocking	 TrkB	
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phosphorylation	 in	 dopaminergic	 neurons	 (Hu	 and	 Koo	 1998).	 Processing	 may	 be	 particularly	
important	 in	 the	 hippocampus,	 where	 BDNF	 is	 secreted	 as	 the	 precursor	 protein	 in	 response	 to	
neuronal	activity	(Pang	et	al.	2004).	
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Figure 1.5 Extracellular BDNF processing. Extracellular pro-BDNF is cleaved at Arg-125-Val by 
plasmin, the activity of which is dependent on tPA (Lee et al. 2001; Gray and Ellis 2008). 
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1.5.5	BDNF-TrkB	signalling	and	neuronal	activity	
BDNF-TrkB	signalling	and	neuronal	activity	are	closely	linked.	BDNF	is	released	pre-synaptically	and	
binds	as	a	dimer	to	TrkB	receptors	located	on	the	post-synaptic	membrane.	BDNF	signalling	results	in	
formation	and	 stabilisation	of	 synapses	 through	 transcriptional	 changes	associated	with	 long-term	
potentiation	(LTP)	and	dendritic	spine	growth,	in	part	through	regulation	of	the	translation	of	Homer2,	
a	scaffold	protein	implicated	in	dendritic	spine	function	(Schratt	et	al.	2004),	and	upregulation	of	the	
cytoskeletal	 protein	 Arc	 (Yin	 et	 al.	 2002).	 BDNF	 also	 increases	 neurotransmitter	 release	 from	
presynaptic	terminals,	which,	along	with	stabilisation	of	synapses,	results	in	an	increase	in	neuronal	
activity.	In	turn,	neuronal	firing	causes	upregulation	of	bdnf	expression	via	increased	calcium	influx.	
Neuronal	 activity	 results	 in	 an	 increase	 in	 intracellular	 cAMP.	 In	 the	hippocampus	 cAMP	 regulates	
BDNF	 downstream	 effects	 by	 modulating	 BDNF	 phosphorylation	 of	 TrkB	 as	 well	 as	 modulating	
membrane	 recruitment	of	 TrkB,	possibly	 through	 strengthening	 the	 connection	between	TrkB	and	
Post-synaptic	 density	 95	 (PSD-95)	 (Ji	 et	 al.	 2005).	 PSD-95	 is	 recruited	 to	 dendrites	 through	 BDNF	
signalling	via	the	PI3K-Akt	pathway	(Yoshii	and	Constantine-Paton	2007),	which,	 in	turn,	stimulates	
the	 production	 of	 more	 TrkB-PSD-95	 complexes	 through	 activation	 of	 PI3K	 and	 PLCγ	 (Yoshii	 and	
Constantine-Paton	2010).	Neuronal	activity	causes	increased	release	of	tissue	plasminogen	activator	
(tPA),	resulting	in	increased	cleavage	of	pro-BDNF.	In	this	way,	BDNF	processing	and	signalling	acts	as	
a	positive	feedback	loop.	This	is	important	to	consider	when	targeting	BDNF	signalling,	as	a	change	in	
any	part	of	the	loop	will	feed	forward	to	the	rest	of	the	loop.		
1.5.6	Retinal	levels	of	neurotrophins	and	their	receptors	
In	the	retina,	protein	expression	of	TrkA,	TrkB	and	TrkC	is	low	but	widespread,	with	TrkB	expression	
strongest	in	RGCs,	amacrine	cells	and	Muller	cells	(Cui	et	al.	2002;	Harada	et	al.	2011).	In	the	rat,	axonal	
injury	results	in	a	5-fold	increase	in	TrkB	protein	expression	in	RGCs	(Cui	et	al.	2002).	However,	changes	
to	Trk	receptor	levels	likely	varies	with	the	type	of	injury.	In	the	rat	TrkB	is	upregulated	following	optic	
nerve	 injury	 (Cui	 et	 al.	 2002),	 whereas	 in	 glaucomatous	 retinas	 the	 mRNA	 level	 of	 TrkB	 remains	
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constant	(Figure	1.6)	(Rudzinski	et	al.	2004).	Although	it	is	interesting	to	map	the	transcription	profiles	
of	neurotrophins	and	their	receptors	post-injury,	levels	of	mRNA	do	not	necessarily	equate	to	levels	
of	 protein.	 Consequently,	 conclusions	 cannot	 be	 drawn	 regarding	 the	 relative	 levels	 of	 pro-
neurotrophins	 and	mature	peptides,	 nor	 the	 localisation	of	 the	 receptors	within	 the	 retina.	When	
investigating	profiles	of	Trk	receptors	it	is	also	important	to	consider	their	phosphorylation	state	since	
protein	expression	alone	is	not	sufficient	to	promote	Trk	signalling.	Under	glaucomatous	stress	TrkB	
may	be	deactivated	(dephosphorylated)	through	increased	interaction	with	the	phophatase	Shp-2	via	
hyperphosphorylation	of	caveolin	(Gupta	et	al.	2012).	
	
 
Chapter	1:	Introduction	 47	
 
Figure 1.6. Levels of neurotrophins and their receptors in the rat retina. mRNA levels of (A) 
neurotrophin receptors and (B) their ligands from whole retinas following injury to induce high IOP. 
Modified from (Rudzinski et al. 2004). 
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1.6	Neurotrophin	signalling	in	disease	
Given	their	 role	 in	neuronal	development	and	maintenance,	 it	 is	perhaps	not	surprising	 that	 there	
have	been	numerous	reports	of	links	between	levels	of	neurotrophins	and/or	their	receptors	in	injury	
or	disease	in	the	CNS.	A	PubMed	search	of	“BDNF”+”disease”	generates	a	result	of	474	publications	
in	2015	alone.	This	section	will	explore	some	of	these	associations.	
1.6.1	Alterations	in	neurotrophin	signalling	implicated	in	disease	
P75NTR	 is	 upregulated	 following	 injury	 (Ernfors	 et	 al.	 1989;	 Beattie	 et	 al.	 2002)	 and	 in	 disease,	
particularly	where	neuroinflammation	 is	a	component	of	 the	disorder,	such	as	Alzheimer’s	disease	
(Mufson	and	Kordower	1992)	and	multiple	sclerosis	(Dowling	et	al.	1999).	Levels	of	proneurotrophins	
have	 also	 been	 found	 to	 be	 increased	 in	 diseases	 affecting	 the	 CNS.	 Pro-NGF	 is	 upregulated	 in	
Alzheimer’s	disease	 (Fahnestock	et	al.	2001),	and	CNS	 injury	 (Beattie	et	al.	2002;	Harrington	et	al.	
2004).	There	is	evidence	that	in	depression	pro-BDNF	and	p75NTR	are	upregulated,	whilst	mature	BDNF	
and	TrkB	are	downregulated	(Zhou	et	al.	2013).	
Reduced	 expression	 and	 protein	 levels	 of	 TrkB	 and	 its	 ligands	 have	 been	 reported	 in	 a	 range	 of	
neurological	 disorders.	 Rett	 syndrome	 patients	 and	 the	Mecp2-null	 mouse	 model,	 have	 reduced	
expression	of	BDNF	(Wang	et	al.	2006;	Abuhatzira	et	al.	2007).	Schizophrenia	and	bipolar	disorder	are	
associated	with	decreased	mRNA	expression	levels	of	bdnf	and	trkb	(Weickert	et	al.	2003;	Ray	et	al.	
2014).	 In	 Huntington’s	 disease	 BDNF	 signalling	may	 be	 impaired	 (Baydyuk	 and	 Xu	 2014).	 There	 is	
evidence	 that	mutations	 in	 the	 gene	 encoding	 NT-4	may	 be	 a	 risk	 factor	 for	 primary	 open-angle	
glaucoma	 (Pasutto	 et	 al.	 2009).	 In	 the	 hippocampus	 and	 temporal	 cortex	 of	 Alzheimer’s	 disease	
patients,	the	levels	of	BDNF	mRNA	and	protein	are	reduced	(Phillips	et	al.	1991;	Connor	et	al.	1997;	
Fahnestock	et	al.	2002).	The	Val66Met	polymorphism	on	codon	66	of	the	bdnf	gene	is	associated	with	
an	increased	risk	of	Alzheimer’s	disease	and	depression.	It	has	also	been	reported	that	the	levels	of	
the	catalytic	 form	of	TrkB	are	decreased	 in	 the	 temporal	and	 frontal	 cortex	 in	Alzheimer’s	disease	
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(Allen	 et	 al.	 1999),	 which	 is	 likely	 to	 have	 important	 implications	 for	 TrkB-targeted	 treatment	
strategies.	
1.6.2	BDNF	processing	in	disease	
In	many	CNS	disorders	BDNF	levels	are	not	notably	decreased	relative	to	healthy	controls.	In	the	rat	
prefrontal	 cortex	 and	 hippocampus	 the	 normal	 ratio	 of	 pro-BDNF:BDNF	 is	 1:1	 (Tang	 et	 al.	 2014).	
Because	the	signalling	pathways	of	the	2	forms	of	BDNF	have	opposing	effects,	it	may	be	that	the	ratio	
of	 these	 2	 proteins,	 rather	 than	 absolute	 concentrations,	 ultimately	 determines	 the	 downstream	
effect,	for	example	whether	the	cell	will	be	signalled	to	survive	or	to	undergo	apoptosis.	Since	this	
ratio	 is	controlled	by	how	much	pro-BDNF	is	cleaved	to	form	BDNF,	there	 is	mounting	evidence	to	
suggest	that	the	level	of	BDNF	processing	may	be	a	major	contributing	factor	to	the	pathological	state	
of	numerous	neurological	disorders.	Indeed,	levels	of	the	tissue	inhibitor	of	MMPs	have	been	reported	
to	be	increased	in	Huntington’s	disease	and	Parkinson’s	disease	(Lorenzl	et	al.	2003).	Finally,	knockout	
of	 tPA	 accelerates	 the	 onset	 and	 increases	 the	 severity	 of	 disease	 in	 a	mouse	model	 of	multiple	
sclerosis	(East	et	al.	2005).	
As	previously	stated,	the	Val66Met	mutation	in	the	bdnf	gene	is	associated	with	neurological	disease.	
The	reduced	activity-dependent	secretion	of	BDNF	associated	with	this	mutation	is	presumably	the	
result	of	steric	hindrance	caused	by	the	bulky	sidechain	of	methionine	at	the	site	that	interacts	with	
the	binding	pocket	of	sortilin	(Egan	et	al.	2003;	Chen	et	al.	2004).	Truncation	or	siRNA	inhibition	of	
sortilin	similarly	cause	missorting	of	BDNF	to	the	constitutive	pathway,	resulting	in	reduced	activity-
dependent	release,	but	no	change	to	constitutive	release	(Chen	et	al.	2005).	This	demonstrates	the	
importance	 of	 sortilin	 in	 BDNF	 processing.	 Paradoxically,	 although	 a	 decline	 in	 activity-dependent	
BDNF	 processing	 is	 hypothesised	 to	 cause	 reduced	 plasticity,	 the	 presence	 of	 the	 Val66Met	
polymorphism	may	enable	cognitive	processing	to	override	the	decelerated	plastic	motor	response.	
This	may	explain	how	the	mutation	may	be	beneficial	in	initial	visual	adaptation	(Barton	et	al.	2014)	
as	well	as	in	memory-based	task	switching	in	elderly	subjects	(Gajewski	et	al.	2011).		
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As	discussed,	there	are	multiple	proteolytic	enzymes	involved	in	BDNF	processing,	but	one	of	the	most	
attractive	 enzymes	 to	 target	 is	 the	 serine	 protease,	 tPA.	 TPA	 cleaves	 the	 precursor	 peptide	
plasminogen	to	form	plasmin,	which	is	then	available	to	process	pro-BDNF	into	BDNF.	Reduced	plasma	
levels	of	tPA	and	BDNF	are	associated	with	depression	(Shi	et	al.	2010),	although	this	study	did	not	
distinguish	 between	 pro-BDNF	 and	 mature	 BDNF.	 A	 recent	 study	 found	 that	 the	 anti-depressant	
effects	(increased	BDNF,	CREB	phosphorylation	and	TrkB	phosphorylation)	of	a	VGF-derived	peptide	
were	essentially	eliminated	following	block	of	tPA	or	TrkB	phosphorylation	(Lin	et	al.	2014).	Knock-
down	or	overexpression	of	tPA	using	lentiviral	vectors	resulted	in	significantly	reduced	or	increased	
levels,	respectively,	of	BDNF	in	the	mouse	hippocampus	(Bahi	and	Dreyer	2012).	A	study	by	Pang	et	
al.	demonstrated	that	tPA	and	plasminogen	knockout	mice	have	reduced	late-LTP	in	the	hippocampus,	
which	can	be	rescued	with	mature	BDNF,	but	not	uncleavable	pro-BDNF.	In	a	report	by	Scaini	et	al.	
administration	of	branched	chain	amino	acids	led	to	increased	pro-BDNF:BDNF,	as	well	as	decreased	
tPA	protein	level.	Since	there	were	no	changes	in	tPA	gene	expression	level,	the	effects	were	likely	at	
a	protein-level	 –	 the	authors	postulated	 that	 the	branched	 chain	amino	acids	 generated	oxidative	
stress,	which	increased	expression	of	plasminogen	activator	inhibitor-1,	an	inhibitor	of	tPA	(Scaini	et	
al.	2015).	This	work	provides	evidence	that	oxidative	stress,	which	is	commonly	generated	in	a	number	
of	neurodegenerative	disorders,	could	reduce	levels	of	tPA,	and	therefore	decrease	BDNF.		
The	studies	outlined	above	provide	strong	evidence	that	tPA	is	one	of	the	most	important	enzymes	
involved	in	BDNF	processing	when	considering	pharmaceutical	targets.	Further,	since	tPA	already	has	
FDA-approval	 for	 the	 treatment	of	numerous	conditions,	 including	 ischemic	stroke	and	myocardial	
infarction	 (Zivin	 2009),	 this	 enzyme	 may	 have	 potential	 as	 a	 treatment	 for	 a	 range	 of	
neurodegenerative	disorders	if	delivery	can	be	optimised.	Alternatively,	drugs	that	increase	levels	of	
tPA	could	be	used.	Statins	may	be	useful	in	treatment	of	depression	due	to	their	ability	to	induce	tPA	
and	inhibit	plasminogen	activator	inhibitor-1	(a	tPA	inhibitor)	(Tsai	2007).	This	research	may	explain	
the	association	between	cases	of	major	depressive	disorder	and	cardiovascular	disease;	lowered	levels	
of	tPA	could	increase	the	likelihood	of	both	of	these	disorders	(Hou	et	al.	2009).	
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Although	tPA	is	able	to	increase	BDNF	levels	via	plasmin	activation,	the	therapeutic	effect	of	increasing	
tPA	levels	may	instead	be	mediated	through	NMDA	receptor	activation	(Rodier	et	al.	2014).	It	has	been	
proposed	that	tPA	can	proteolytically	cleave	the	N-terminus	of	the	NR1	subunit	of	the	NMDA	receptor,	
which,	in	turn,	increases	Ca2+	influx	through	the	NMDA	receptor	(Nicole	et	al.	2001;	Benchenane	et	al.	
2007).	The	increased	intracellular	Ca2+	levels	upregulate	BDNF	transcription	via	binding	to	bdnf	CREs.	
This	potential	mechanism	of	action	of	tPA	should	be	carefully	considered	when	planning	the	use	of	
tPA	 as	 a	 therapeutic	 drug,	 since	 overactivation	 of	 NMDA	 receptors	 could	 lead	 to	 NDMA-induced	
excitotoxicity	(Traynelis	and	Lipton	2001).	Adverse	effects	of	this	include	widespread	cell	death	and	
seizures.	
A	number	of	recent	publications	have	investigated	the	observed	association	between	physical	exercise	
and	increased	BDNF	levels	(Neeper	et	al.	1995;	van	Praag	et	al.	1999;	Adlard	et	al.	2004).	One	study	
used	chronic	unpredictable	mild	stress	as	a	depression	model	to	provide	evidence	that	bdnf	expression	
is	decreased	with	stress.	In	this	model	physical	exercise	(swimming)	resulted	in	a	significant	increase	
in	 transcription	 level	 of	bdnf	 in	 both	 the	 stressed	and	normal	 groups.	 The	 increase	 in	bdnf	mRNA	
correlated	with	increased	transcription	levels	of	the	anti-apoptotic	protein	Bcl-xl	with	exercise	(Jiang	
et	al.	2014).	Further	research	suggested	that	 the	 increase	 in	BDNF	with	exercise	may	be	mediated	
through	upregulation	of	tpa	(Sartori	et	al.	2011).	
Dietary	intake	of	polyunsaturated	fatty	acids	has	been	shown	to	increase	levels	of	tPA	and	BDNF	in	
the	plasma	of	diabetic	rats	(Nobukata	et	al.	2000),	and	in	the	hippocampus	and	prefrontal	cortex	of	a	
rat	model	of	depression	(Tang	et	al.	2014).	The	effect	in	the	hippocampus	was	enhanced	when	the	
treatment	was	combined	with	physical	exercise	(Wu	et	al.	2008a).	This	work	may	begin	to	explain	the	
known	beneficial	effect	of	dietary	polyunsaturated	fatty	acids	on	mental	health.	
1.6.3	Manipulating	neurotrophin	signalling	as	a	neuroprotective	therapy	
BDNF	promotes	neuronal	survival	in	vitro	(Alderson	et	al.	1990;	Cheng	and	Mattson	1994;	Wilkins	et	
al.	2009).	BDNF	treatment	can	preserve	the	structure	of	cat	RGC	dendritic	arbors	in	vivo	(Weber	and	
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Harman	2008).	Neurite	outgrowth	is	stimulated	by	BDNF	application	in	cultured	neurons	(McAllister	
et	al.	1995;	McAllister	et	al.	1996;	Bosco	and	Linden	1999;	Baquet	et	al.	2004;	Bonnet	et	al.	2004)	as	
well	as	in	the	guinea	pig	auditory	nerve	(Miller	et	al.	2007).	However,	BDNF	is	unsuitable	for	chronic	
treatment	due	 to	 its	physical	properties:	 it	has	a	very	 short	half-life	 (T1/2<1	minute);	 it	 crosses	 the	
blood-brain	 barrier	 poorly	 (Poduslo	 and	 Curran	 1996);	 it	 is	 pharmacologically	 ‘sticky’	 (its	 highly	
positively	charged	residues	restrict	its	dispersion)	(Lu	2003);	and	it	has	some	affinity	for	p75NTR.	
Vector-based	delivery	of	BDNF	is	a	method	to	provide	sustained	supply	of	BDNF	to	the	target	tissue	
(Zhang	et	al.	2011;	Rodger	et	al.	2012).	One	caveat	with	this	approach,	however,	 is	 that	 the	BDNF	
processing	enzymes	could	become	saturated,	potentially	resulting	in	a	large	supply	of	pro-BDNF.	As	
outlined	above,	pro-BDNF	signalling	is	not	desirable	in	the	context	of	ameliorating	neurodegeneration,	
and	may	in	fact	worsen	the	condition.	
BDNF	mimetics	are	small	molecules	designed	to	bind	to	the	active	site	of	TrkB	that	BDNF	binds	to	in	
order	to	stimulate	downstream	signalling	events	(Bai	et	al.	2010).	Mimetics	are	typically	modelled	on	
the	binding	domain	of	BDNF	but	with	subtle	alterations	to	improve	binding	efficiency	(TON),	decrease	
unbinding	 efficiency	 (TOFF),	 improve	 blood	 brain	 barrier	 crossing	 (by	 making	 the	 molecule	 more	
lipophilic	or	creating	a	caging	structure),	or	decrease	degradation	time	(T1/2).	Mimetics	may	also	be	
able	 to	 better	 target	 desired	 signalling	 pathways	 by	 being	 designed	 to	 have	 poorer	 efficiency	 for	
p75NTR,	whilst	maintaining	high	efficiency	for	TrkB	(Qian	et	al.	2006;	Bai	et	al.	2010;	Massa	et	al.	2010;	
Brahimi	et	al.	2014;	Liu	et	al.	2016).	Mimetics	have	already	been	shown	to	have	at	 least	 the	same	
neuroprotection	efficacy,	with	respect	to	neuronal	survival,	as	BDNF	in	the	hippocampus	and	striatum	
(Massa	et	al.	2010).	The	TrkB	agonist,	LM22A-4,	has	been	shown	to	restore	wildtype	levels	of	TrkB	
phosphorylation	in	the	medulla	and	pons	in	a	mouse	model	of	Rett	syndrome	(Schmid	et	al.	2012).	
Finally,	TrkB	agonists	have	been	evidenced	to	increase	RGC	survival	in	models	of	glaucoma	(Bai	et	al.	
2010).	
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1.7	Extracellular	matrix	manipulation	
1.7.1	Perineuronal	net	structure	
The	PNN,	first	described	by	Camillo	Golgi	in	1873,	is	a	specialised	form	of	ECM	that	contacts	the	surface	
of	neurons	around	the	soma	and	proximal	dendrites	(Golgi	1873).	The	PNN	is	primarily	composed	of	
chondroitin	 sulphate	 proteoglycans	 (CSPGs),	 keratin	 sulphate	 proteoglycans,	 tenascin,	 and	 the	
scaffolding	molecule	hyluronan.	Importantly,	the	PNN	is	not	a	homogeneous	structure;	the	types	and	
ratios	of	components	are	specific	to	each	region	of	the	CNS	(Virgintino	et	al.	2009),	indicative	of	region-
specific	roles	of	the	PNN	(Mouw	et	al.	2014).	
The	 PNN	 is	 laid	 down	during	 development	 at	 the	 end	 of	 the	 critical	 period	 following	 secretion	 of	
cartilage	link	protein	Crtl1	(Carulli	et	al.	2010)	and	acts	to	stabilise	neuronal	networks	and	synaptic	
connections	(Guimaraes	et	al.	1990;	Pizzorusso	et	al.	2002).	This	is	achieved	partly	through	CSPGs	(e.g.	
neurocan)	and	keratin	sulphate	proteoglycans,	which	act	as	physical	barriers	to	synaptic	contacts	or	
inhibit	axonal	outgrowth	via	negatively	charged	elements	(Wang	and	Fawcett	2012).	Before	the	PNN	
is	present,	neuronal	networks	are	incredibly	plastic	and	experiments,	such	as	monocular	deprivation,	
can	 have	 dramatic	 effects	 on	 the	 re-wiring	 of	 the	 visual	 processing	 pathway	 (Gordon	 and	 Stryker	
1996).	Such	changes	occurring	after	the	PNN	has	been	laid	down,	however,	do	not	result	in	the	same	
rewiring	(Sur	et	al.	1988;	Pizzorusso	et	al.	2002).	The	PNN	has	also	been	reported	to	contain	astrocyte	
cell	(a	type	of	glial	cell)	processes,	intertwined	with	the	ECM	components	of	the	net.	These	astrocytes	
provide	a	buffering	role	by	mopping	up	excess	glutamate	from	the	extracellular	space,	mainly	through	
their	Na+-dependent	glutamate	transporters	(Bruckner	et	al.	1993;	Anderson	and	Swanson	2000).	In	
addition,	the	fact	that	CSPGs	are	highly	charged	may	allow	them	to	buffer	cations.	 In	this	way,	the	
PNN	 may	 protect	 neurons,	 particularly	 those	 with	 high	 activity	 levels,	 from	 oxidative	 stress	 and	
glutamate-induced	 excitotoxicity	 (Morawski	 et	 al.	 2004).	 Finally,	 CSPGs	 have	 been	 found	 to	 have	
binding	sites	 for	growth	 factors,	 including	TGF-beta	 (Wang	et	al.	1991)	and	bFGF	 (Rapraeger	et	al.	
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1991),	suggesting	that	the	PNN	may	play	a	role	in	the	modulation	and	localisation	of	growth	factor	
signalling	(Flaumenhaft	and	Rifkin	1991).	
1.7.2	ECM	remodelling	in	injury	and	disease	
Following	 injury	 to	 the	CNS	or	 in	models	 of	 neurodegeneration,	 including	Parkinson’s	 disease	 and	
Alzheimer’s	disease,	microglia	are	activated	by	lipopolysaccharides	and	other	factors	via	JNK	and	p38	
MAPK	pathways	 (Dheen	et	al.	2007).	 Initially,	activated	microglia,	characterised	by	their	amoeboid	
shape	(Kettenmann	et	al.	2011),	are	beneficial	as	they	phagocytose	damaged	cells	and	debris.	Chronic	
activation	of	microglia	results	in	accumulation	of	pro-apoptotic	cytokines	and	reactive	oxygen	species,	
therefore	may	be	detrimental	 to	neurons.	 Indeed,	microglial	activation	 is	evidenced	to	be	a	major	
cause	of	RGC	death	in	retinal	degeneration	(Yuan	and	Neufeld	2001).	Microglial	activation	is	one	of	
the	hallmarks	of	many	neuropathologies	(Dheen	et	al.	2007).	
Both	types	of	macroglia	in	the	retina,	astrocytes	and	Muller	cells,	are	also	activated	following	injury	
or	in	disease.	Astrocytes	play	important	roles	in	Amyotrophic	lateral	sclerosis	and	Alzheimer’s	disease	
(Wiese	et	al.	2012).	Activation	of	macroglia	involves	the	upregulation	of	glial	fibrillary	acidic	protein,	
nestin	and	glutamine	synthetase,	a	key	protein	in	the	prevention	of	glutamate-induced	excitotoxicity	
(Chang	et	al.	2007).	Activated	astrocytes	secrete	matricellular	proteins,	including	glycoproteins,	which	
play	 roles	 in	synaptic	plasticity,	 remodelling,	angiogenesis,	as	well	as	 recruitment	of	 immune	cells.	
Activated	astrocytes	 are	 implicated	 in	 the	maintenance	and	 repair	 of	 the	blood	brain	barrier,	 and	
ablation	of	astrocytes	can	lead	to	damaging	oedema	in	the	brain	(Sofroniew	2005).	Hevin	is	secreted	
by	activated	astrocytes	and	is	involved	in	the	regulation	of	pre-	and	post-synaptic	connections	(Singh	
et	al.	2016),	therefore	may	help	with	neuronal	re-wiring	post-injury.	Interestingly,	there	are	multiple	
combinations	of	secreted	factors	from	activated	astrocytes	depending	on	the	specific	injury	or	disease	
profile,	giving	each	disease	its	own	activated	astrocyte	‘fingerprint’	(Jones	and	Bouvier	2014).	If	ECM	
remodelling	is	to	be	a	target	for	neuronal	injury	and	disease	it	will	likely	be	important	to	identify	the	
matricellular	protein	makeup	in	each	case	so	that	treatment	can	be	tailored	as	appropriate.	
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Chronically	activated	astrocytes	make	up	the	majority	of	glial	scars,	which	function	as	physical	barriers	
around	 the	 site	 of	 injury	 to	 protect	 nearby	 cells	 from	 inflammation	 and	 invading	 macrophages.	
Unfortunately,	 the	 highly	 negatively	 charged	 CSPG	 components	 of	 the	 glial	 scar	 inhibit	 axonal	
outgrowth,	which	limits	the	regeneration	of	native	neurons	(Ekstrom	et	al.	1988;	Fawcett	and	Asher	
1999;	Chua	et	al.	2013).	If	the	site	of	damage	is	small	enough,	adjacent	neurons	may	be	able	to	re-
form	connections	through	a	process	termed	neural	remodelling,	as	demonstrated	in	the	outer	retina	
in	retinal	degeneration	and	in	the	visual	cortex	(Marc	et	al.	2003).	Although	compensation	is	possible,	
if	scarring	is	too	widespread	or	number	of	neurons	lost	is	too	large,	neural	remodelling	may	not	be	
capable	of	re-wiring	the	neuronal	network,	resulting	in	loss	of	function	(Hausmann	2003).	
In	addition	to	restricting	migration,	gliosis	may	 increase	RGC	death	by	causing	scarring	around	the	
lamina	 cribrosa,	 leading	 to	 RGC	 axonal	 damage	 (Howell	 et	 al.	 2007).	 Activation	 of	 microglia	 and	
astrocytes	 is	evidenced	to	be	a	major	cause	of	RGC	death	in	glaucoma	and	other	models	of	retinal	
degeneration	(Tezel	et	al.	2012;	Vecino	et	al.	2015).	The	PNN	may	play	a	role	in	the	pathology	other	
neurodegenerative	disorders,	for	example	in	Alzheimer’s	disease,	where	PNN	components	(Karetko	
and	Skangiel-Kramska	2009),	such	as	tenascin-C,	are	biomarkers	for	Alzheimer’s	disease	(Hall	2012).	
CSPGs	are	upregulated	following	CNS	injury	(Morgenstern	et	al.	2002),	including	in	the	degenerating	
retina	 (Barber	et	al.	2012).	PNN	disregulation	may	be	an	underlying	cause	of	epilepsy	 (McRae	and	
Porter	2012).	Digestion	of	PNN	components,	specifically	brevican,	by	MMPs	ADAMTS1	and	4	may	be	
induced	by	kainite-induced	seizures	(Yuan	et	al.	2002).	Indeed	it	should	be	noted	that	the	PNN	is	not	
a	fixed	structure;	endogenous	MMPs	continuously	remodel	ECM	components	according	to	neuronal	
activity	and	local	environmental	changes.	TPA	is	upregulated	following	monocular	deprivation	(Wiesel	
and	Hubel	1963)	and	spinal	cord	injury	(Bukhari	et	al.	2011).	It	has	been	postulated	that	the	substrate	
for	tPA	is	components	of	the	PNN	(Mataga	et	al.	2002).	It	should	also	be	considered	that	BDNF	may	
contribute	to	this	plasticity,	since	tPA	is	an	important	enzyme	in	BDNF	processing	(see	section	1.5.4).		
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1.7.3	Is	the	PNN	an	inhibitor	of	neuronal	plasticity?		
Although	some	areas	of	the	brain	do	respond	to	injury	by	stimulating	stem	cell	differentiation	(Magavi	
et	 al.	 2000)	 or	 upregulating	 neurotrophin	 receptors	 (Cui	 et	 al.	 2002),	 complete	 repair	 following	
moderate	to	severe	injury	is	rare.	In	these	cases,	therapeutic	approaches	are	required	to	replace	lost	
neurons,	 or	 to	 stimulate	 endogenous	 repair	mechanisms.	One	method	 is	 to	 stimulate	 the	 neurite	
outgrowth	of	resident	neurons.	This	can	be	attempted	by	application	of	growth	factors	(Thanos	et	al.	
1989),	 growth	 cone	 stimulation	 via	 Sema3a	 (Fenstermaker	 et	 al.	 2004),	 or	mechanical	 elongation	
(Magdesian	et	al.	2016).	Alternatively,	cells	could	be	replaced	by	stem	cell-derived	neurons	(see	stem	
cell	section	1.8).	These	approaches	have	shown	some	success,	but	the	presence	of	inhibitory	CSPGs	in	
the	PNN	has	been	theorised	to	limit	the	regenerative	capacity	of	neurons,	particularly	in	the	case	of	
spinal	cord	injury	(Bukhari	et	al.	2011).	It	has	therefore	been	postulated	that	CSPG	remodelling	may	
be	required	in	combination	with	other	therapeutic	strategies	for	complete	recovery	to	occur.		
1.7.4	Could	PNN	digestion	permit	neuronal	regeneration	or	is	it	an	essential	component	to	
protect	neurons?	
The	highly	negatively	charged	elements	of	glycoproteins	present	in	the	PNN	and	glial	scars	inhibit	the	
positively	 charged	 growth	 cone	 of	 axons,	 and	 present	 an	 obstacle	 for	 synaptic	 and	 dendritic	
remodelling.	 CSPGs	 in	 the	 PNN	 and	 glial	 scars	 can	 be	 partially	 digested	 by	 the	 bacterial	 enzyme	
chondroitinase	 (ChABC)	 (Bradbury	 et	 al.	 2002).	 ChABC	 cleaves	 chondroitin	 sulphate	
glycosaminoglycan	 (GAG)	chains	 (the	main	 inhibitory	components	of	 the	molecules)	 to	 leave	stubs	
(Figure	1.7)	 that	 can	be	detected	by	 immunohistochemistry	 (Bradbury	et	 al.	 2002;	 Lin	et	 al.	 2008;	
Orlando	et	al.	2012).		
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Figure 1.7. Basic structure of CSPG (top) with interaction points. Multiple CS-GAGs may be present 
but only one is shown for clarity. GAGs can be digested using the bacterial enzyme ChABC, leaving 
epitope stubs on the core protein (below). Note that ChABC digestion removes the inhibitory sulphate 
chains. G1, globular N-terminal domain; G3, globular C-terminal domain; PTPσ, protein tyrosine 
phosphatase σ; NCAM, neural cell adhesion molecule; Ig, immunoglobulin; EGF, epidermal growth 
factor; CRD, carbohydrate recognition domain; CBP, complement binding protein. Modified from 
(Bartus et al. 2012). 
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Degradation	of	GAG	chains	with	ChABC	 increases	the	 integration	efficiency	of	 transplanted	cells	 in	
spinal	cord	and	brain	injury	models.	ChABC	treatment	has	been	shown	to	increase	axonal	regeneration	
following	spinal	cord	injury	in	rats	(Bradbury	et	al.	2002;	Massey	et	al.	2006;	Garcia-Alias	et	al.	2009).	
On	the	other	hand,	 improvement	 in	visual	cortex	plasticity	was	 limited	following	ChABC	treatment	
with	 monocular	 deprivation	 in	 cats	 (Vorobyov	 et	 al.	 2013),	 suggesting	 that	 the	 success	 of	 CSPG	
digestion	may	be	 injury-specific,	 or	may	 require	 combination	 therapy.	 It	 has	been	postulated	 that	
ChABC	 treatment	may	 be	 effective	 in	 increasing	 integration	 of	 stem	 cells	 in	 retinal	 degeneration	
(Singhal	 et	 al.	 2008;	 Barber	 et	 al.	 2012).	Ma	 et	 al	 demonstrated	 that	 ChABC	 treatment	 increases	
synaptogenesis	between	transplanted	RPCs	and	recipient	neurons	in	models	of	retinal	degeneration	
(Ma	et	al.	2011).	The	Pearson	group	used	the	Rho-/-	mouse	model	to	investigate	the	effect	of	ChABC	
treatment	on	integration	of	photoreceptor	precursor	cells	into	the	ONL	of	the	retina.	The	Rho-/-	retina	
has	an	intact	OLM	and	reactive	gliosis	present,	resulting	in	large	CSPG	production.	In	this	model,	ChABC	
treatment	alone	 resulted	 in	an	8-fold	 increase	 in	 transplanted	 cell	 integration	 relative	 to	 controls.	
When	combined	with	a	siRNA	targeting	ZO-1	to	disrupt	the	OLM,	ChABC	treatment	also	significantly	
increased	 the	 percentage	 integration	 relative	 to	 control.	 However,	 one	 should	 interpret	 the	 data	
cautiously	as	it	is	not	clear	that	the	combined	treatment	offers	a	worthwhile	increase	in	percentage	
integration,	 relative	 to	 ChABC	 treatment	 alone.	 Optokinetic	 head-tracking	 behaviour	 experiments	
were	 used	 to	 assess	 how	 percentage	 integration	 relates	 to	 improved	 visual	 function.	 These	
behavioural	 experiments	 suggested	 improved	 visual	 function	 in	 mice	 with	 combined	 treatment	
compared	to	control	mice,	however	only	7	mice	were	used;	greater	n	numbers	are	required	to	verify	
the	result	(Barber	et	al.	2012).	Further,	it	would	be	interesting	to	know	how	the	behavioural	results	
differ	in	mice	with	ChABC	treatment	alone.	
Although	PNN	digestion	is	a	promising	strategies	for	some	models,	it	is	worth	adding	a	note	of	caution.	
The	PNN	protects	neurons	from	excitotoxicity	and	oxidative	stress.	Further,	activated	microglia	may	
not	target	neurons	that	are	in	contact	with	the	PNN	(Karetko	and	Skangiel-Kramska	2009),	therefore	
removal	of	PNN	components	may	not	be	advisable	in	cases	where	microglial	activation	is	prevalent.	
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Disruption	of	glial	scars	may	expose	neighbouring	tissue	to	the	highly	toxic	 immune	response,	and	
inhibit	functional	recovery	–	this	was	demonstrated	with	mild	to	moderate	spinal	cord	injury	where	
the	usual	return	of	function	was	impeded	(Sofroniew	2005).		
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1.8	Stem	cells	
1.8.1	Stem	cell	therapy	
Stem	cell	therapy	to	introduce	new	cells	into	the	retina	has	been	trialled	in	disease	models.	To	date	
this	method	has	had	 limited	success.	Several	groups	claim	 improved	visual	acuity	 (MacLaren	et	al.	
2006;	Pearson	et	al.	2012),	however	this	is	frequently	proposed	upon	the	incorrect	assumption	that	
the	improved	light	sensitivity	of	photoreceptors	results	 in	 increased	neuronal	processing.	Neuronal	
processing	 is	 extremely	 complex,	 so	 much	 so	 that	 if	 one	 connection	 is	 not	 correct,	 the	 result	 of	
photoreceptor	cell	stimulation	may	be	no	signal	is	passed	on	to	the	next	cell,	or	a	feedback	loop	may	
be	created,	whereby	the	stimulated	cell	re-stimulates	itself	(Rao	et	al.	2000).	For	both	of	these	results,	
increasing	the	light	intensity	would	increase	photoreceptor	cell	activation,	as	measured	by	increased	
cell	membrane	depolarisation,	however	 the	signal	would	not	be	passed	to	 the	visual	centre	 in	 the	
brain,	thus	there	would	be	no	improvement	in	visual	acuity.	Reactivating	plasticity	is	likely	to	be	key	
in	the	treatment	of	neuronal	degeneration	when	attempting	to	re-wire	neuronal	circuits	(Marc	et	al.	
2003;	Grimaldi	et	al.	2005;	Hong	and	Chen	2011;	Morimoto	2012).	
There	 are	 several	 different	 stem/progenitor	 cell	 niches	 have	 been	 investigated	 for	 use	 with	 cell	
replacement	 therapy	 in	 retinal	 degeneration.	All	 of	 these	protocols	 are	 associated	with	 their	 own	
advantages	and	disadvantages,	which	will	be	explored	in	this	section.	
Embryonic	stem	cells	
Embryonic	stem	cells	(ESCs)	are	an	attractive	option	for	cell	replacement	therapies	because	they	are	
pluripotent,	meaning	that	they	have	the	potential	to	differentiate	into	any	of	the	3	germ	layers.	The	
drawbacks	of	ESCs	include	the	risk	of	tumour	formation	if	their	proliferation	becomes	uncontrolled,	
and	controversial	ethical	issues.	There	is	also	the	risk	of	immune-rejection	(Schraermeyer	et	al.	2001;	
Baker	and	Brown	2009).	Studies	to	date	have	provided	mixed	results;	a	recent	study	in	humans	with	
macular	degeneration	 involving	ESC-derived	RPE	 suggested	 that	visual	 function	could	be	 stabilised	
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(Song	W		et	al.	2015),	although	since	the	duration	of	this	study	was	only	one	year,	one	must	remain	
cautious	when	making	inferences	about	the	potential	of	ESC-derived	cells	from	this	study.	The	recent	
initiation	of	another	clinical	trial,	in	which	stem	cell-derived	RPE	cells	were	transplanted	into	retinas	
of	AMD	patients	(https://www.mrc.ac.uk/news/browse/first-patient-treated-with-stem-cell-therapy-
for-wet-age-related-macular-degeneration/,	last	accessed	16.02.16),	suggests	that	there	may	be	hope	
for	 the	 treatment	 of	 AMD.	 It	 should	 be	 noted,	 however,	 that	 transplantation	 and	 integration	 of	
neuronal	 cells,	 as	 opposed	 to	 epithelial	 cells	 described	 here,	 is	 likely	 to	 be	 a	 substantially	 greater	
challenge	for	the	future.	ESCs	also	offer	a	virtually	limitless	supply	of	cells	that	can	be	differentiated	
into	 neurons	 in	 vitro	 with	 the	 application	 of	 retinoic	 acid	 (Bibel	 et	 al.	 2004).	 This	 has	 allowed	
researchers	to	investigate	genes/proteins	involved	in	neuronal	degeneration,	and	may	highlight	target	
pathways	for	neuroprotection	and	repair.	
Induced	pluripotent	stem	cells	
Induced	pluripotent	stem	cells	 (iPSCs)	are	cells	that	have	been	reprogrammed	by	expression	of	the	
transcription	factors	Oct4,	Sox2,	Klf,	and	Myc,	to	create	an	embryonic	stem	cell-like	cell	(Takahashi	
and	Yamanaka	2006).	These	cells	are	favoured	by	many	groups	because	they	offer	the	same	level	of	
pluripotency	as	ESCs	but	come	without	the	ethical	issues	and	rejection	problems	since	the	cells	can	in	
theory	 be	 derived	 from	 the	 patient’s	 own	 cells,	 creating	 an	 explosion	 in	 the	 field	 of	 personalised	
medicine.	 Despite	 this,	 iPSCs	 are	 in	 no	 way	 ideal	 because	 the	 teratoma	 risk	 remains,	 and	 their	
production	is	a	very	lengthy	process:	approximately	2	weeks	from	mouse	fibroblasts,	and	3-4	weeks	
from	human	fibroblasts	(Sommer	and	Mostoslavsky	2013).	In	addition,	it	should	be	noted	that	if	the	
disease	genotype	is	inherited,	the	iPSCs	made	from	the	patient’s	cells	will	contain	the	same	mutation,	
therefore	 the	 affected	 gene	must	 be	 corrected	prior	 to	 generation	of	 iPSCs	 (Tibbetts	 et	 al.	 2012).	
Despite	 these	 drawbacks,	 iPSCs	 have	 proved	 an	 invaluable	 research	 tool	 for	 modelling	
neurodegenerative	disorders,	including	ALS	(Dimos	et	al.	2008),	Rett	Syndrome	(Marchetto	et	al.	2010)	
Chapter	1:	Introduction	 62	
and	Huntington’s	disease	 (Zhang	et	al.	 2010),	 elucidating	 contributory	mechanisms	 to	disease	and	
repair.		
Neural	stem	cells	
Neural	stem	cells	(NSCs)	are	multipotent	stem	cells	that	are	capable	of	generating	all	cells	in	the	neural	
lineage	(neurons	and	glia).	The	advantage	of	using	NSCs	in	place	of	ESCs	or	iPSCs	for	the	purpose	of	
cell	replacement	therapy	is	their	lineage	is	restricted	so	they	are	more	likely	to	differentiate	into	the	
correct	cell	type,	whilst	maintaining	high	self-renewal	capability.	However,	the	price	of	self-renewal	is	
the	 risk	 of	 tumour	 formation,	 so,	 as	 always,	 the	 potential	 benefits	 must	 outweigh	 the	 risks.	
Nevertheless,	NSC	transplantation	has	been	shown	to	 improve	neuronal	survival	and/or	 functional	
outcome	in	a	range	of	neurodegenerative	disease	models,	 including	Alzheimer’s	disease	(Wu	et	al.	
2008b;	Blurton-Jones	et	al.	2009)	and	amyotrophic	lateral	sclerosis	(Mitrecic	et	al.	2010).	
	NSCs	 have	 proved	 useful	 for	 researching	 genes	 and	 signalling	 pathways	 implicated	 in	
neurodegenerative	 disorders.	 It	 has	 been	 recently	 reported	 that	 the	 forced	 expression	 of	 three	
transcription	factors,	Brn2,	Ascl1	and	Myt1l,	can	convert	fibroblasts	to	induced	neuronal	cells	(Pang	
et	al.	2011).	This	is	a	faster	method	of	producing	neuronal	cells	from	somatic	cells,	therefore	this	may	
improve	 the	 availability	 of	 patient-derived	 neurons	 or	 cells	 for	 the	 investigation	 of	 neuronal	
degeneration.	
Retinal	progenitor	cells	
Retinal	progenitor	cells	are	unipotent	cells,	usually	taken	from	embryonic	tissue.	Because	they	are	not	
true	stem	cells	there	is	a	reduced	risk	of	tumour	formation,	however	trials	to	date	have	demonstrated	
poor	integration	efficiency,	particularly	in	diseased	retinas	(Klassen	et	al.	2004;	Mansergh	et	al.	2010).	
It	may	be	that	CSPG	remodelling	is	required	to	improve	integration	efficiency		(Ma	et	al.	2011).	There	
may	be	some	promise	using	ESC-derived	retinal	progenitor	cells,	which	have	been	reported	to	increase	
visual	function	in	rats	(Qu	et	al.	2015).	
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Retinal	sheets	
An	 alternative	 approach	 for	 patients	who	 have	 complete	 photoreceptor	 loss	 is	 transplantation	 of	
retinal	sheets.	Embryonic	retinal	sheets	have	been	transplanted	into	retinal	degeneration	models	but	
may	stimulate	formation	of	a	glial	scar	(Peng	et	al.	2007).	Foetal	retinal	sheets,	with	attached	RPE,	are	
able	 to	 integrate	 into	 the	host	 IPL	 (Woch	et	 al.	 2001)	 and	 in	 some	 cases	 have	been	evidenced	 to	
increase	light	sensitivity	(Sagdullaev	et	al.	2003;	Seiler	and	Aramant	2012),	while	in	others	little	effect	
on	visual	function	was	measured	(Seiler	et	al.	2009).	Greater	success	has	been	achieved	with	retinal	
sheets	 that	 contain	 both	 photoreceptors	 and	 RPE	 because	 the	 RPE	 is	 required	 to	 support	
photoreceptors.	More	recently,	retinal	sheets	constructed	from	ESCs	and	iPSCs	have	been	shown	to	
be	capable	of	 integration	 into	the	host	retina	 in	mice	(Assawachananont	et	al.	2014)	and	primates	
(Shirai	et	al.	2016).	
Retinal	prostheses	
Artificial	electrical	stimulation	of	neurons	is	one	approach	to	treat	retinitis	pigmentosa	that	may	
address	the	problem	of	trying	to	connect	new	neurons	into	an	existing	neuronal	network.	
Implantation	of	an	electronic	prosthesis	does	not	result	in	good	visual	function	by	any	means,	
however	for	blind	patients	it	may	offer	some	level	of	contrast	sensitivity	for	identifying	obstructions,	
and	motion	detection	(Dobelle	et	al.	1974;	Veraart	et	al.	1998).	It	should	be	noted	that	this	approach	
is	only	suitable	for	patients	who	have	complete	vision	loss	as	the	prosthesis	is	likely	to	interfere	with	
native	retinal	outputs.	In	addition,	the	risk	of	side	effects	is	high;	30%	of	patients	experienced	severe	
adverse	effects	in	one	clinical	trial	with	electronic	implants	(Humayun	et	al.	2012).	
1.8.2	Photoreceptor	replacement	
A	large	proportion	of	the	literature	to	date	regarding	stem	cell	therapy	to	treat	retinal	degeneration	
focuses	 on	 photoreceptor	 transplantation.	 One	 approach	 involves	 the	 transplantation	 of	Nrl-GFP	
labelled	post-mitotic	photoreceptor	precursor	cells	into	the	OLM	of	wildtype	mice.	This	is	a	promising	
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method,	 but	 will	 likely	 be	 more	 successful	 if	 the	 efficiency	 can	 be	 improved.	 The	 current	
transplantation	efficiency	is	0.01%	and	the	percentage	integration	is	even	lower	(Ma	et	al.	2011).	If	
sufficient	 cell	 numbers	 could	 be	 introduced	 into	 the	 retina,	 the	 result	 could	 be	 therapeutically	
beneficial,	however	it	has	been	estimated	that	150,000	cells	are	required	to	produce	an	ERG	response	
across	 the	 whole	 retina	 (Pearson	 et	 al.	 2012).	 Despite	 this,	 the	 question	 remains	 as	 to	 whether	
integrated	 stem	cells	 are	 capable	of	 connecting	 to	 the	visual	 circuitry	and	 improving	visual	 acuity.	
Numerous	groups	claim	 improved	 light	sensitivity	with	transplanted	photoreceptor	precursor	cells,	
however,	as	outlined	previously,	increased	photoreceptor	cell	activation	in	response	to	light	does	not	
necessarily	equate	to	increased	neuronal	firing	to	the	visual	centre	in	the	brain.	If	transplanted	cells	
are	not	able	to	reliably	connect	to	the	neuronal	circuitry,	no	increase	in	number	of	integrated	cells	will	
increase	the	therapeutic	benefit	of	any	stem	cell	therapy.	Therefore,	future	work	 in	this	field	must	
endeavour	 to	 improve	 methods	 to	 measure	 connectivity	 of	 transplanted	 cells,	 and	 also	 develop	
techniques	 to	 facilitate	 formation	 of	 functional	 synapses	 between	 host	 neurons	 and	 transplanted	
cells.	
It	should	be	noted	that	a	lot	of	the	proclaimed	success	to	date	in	photoreceptor	transplantation	has	
been	in	wildtype	retinas.	The	environment	in	the	degenerating	retina	is	very	different	to	that	of	the	
wildtype	retina	(glial	scarring	is	just	one	example),	therefore	transplantation	efforts	are	likely	to	have	
very	different	outcomes	in	disease	models	(Barber	et	al.	2012).	The	normal	retina	has	an	intact	OLM,	
which	may	mean	that	the	transplantation	efficiency	is	better	in	disease	models	with	disrupted	OLM	
compared	to	wildtype	models.	
1.8.3	Cell-based	delivery	of	agents	
Cell-based	delivery	of	drugs	is	an	attractive	method	to	target	largely	inaccessible	areas,	such	as	the	
brain.	Cells	can	be	made	to	endocytose	drug-filled	endosomes	or	they	can	be	transfected	with	genes	
encoding	a	particular	protein.	In	both	cases,	the	cells	pump	out	the	agent	and	in	this	way	can	provide	
a	 more	 sustained	 delivery	 than	 alternative	 methods	 to	 cross	 the	 blood	 brain	 barrier,	 such	 as	
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nanocarriers	or	ultrasound	beams	(Hynynen	et	al.	2001;	Koo	et	al.	2006).	NSCs	and	ESCs	have	been	
used	to	deliver	neurotrophic	agents,	such	as	NGF,	with	neuroprotective	results	in	animal	models	of	
Alzheimer’s	 disease	 (Wu	 et	 al.	 2008b)	 and	 Huntington’s	 disease	 (Kordower	 et	 al.	 1997).	 Further	
advances	in	genetic	engineering	will	enable	greater	control	of	delivery	of	agents,	for	example	with	the	
use	of	the	light-sensitive	transcription	(Stuber	and	Mason	2013).	
	
1.8.4	Future	prospects	
Different	 models	 of	 retinal	 degeneration	 have	 different	 characteristics	 regarding	 speed	 of	
degeneration,	extent	of	OLM	disruption,	and	gliosis	(Barber	et	al.	2012).	Since	all	of	these	factors	affect	
the	 migration,	 integration,	 differentiation,	 and	 stability	 of	 donor	 cells,	 the	 disease	 aetiology	 will	
determine	the	most	appropriate	line	of	treatment.	Some	animal	models	with	varied	diseases	timelines	
are	currently	available,	such	as	the	Gnat1-/-	model,	which	loses	10%	of	photoreceptors	over	a	period	
of	12	months,	and	the	PDE6βrd1	model,	which	loses	virtually	all	the	photoreceptors	in	a	period	of	3	
weeks	(Barber	et	al.	2012).	More	models	with	a	greater	variety	of	neuropathologies	are	required	to	
aid	the	development	of	tailored	therapies.		
One	problem	limiting	stem	cell	replacement	therapy	is	the	need	for	transplanted	cells	to	be	stable	for	
several	years	to	reduce	the	need	for	repeated	surgery.	The	MacLaren	group	reported	that	33.3%	of	
twelve	eyes	from	rd1	mice	had	surviving	transplanted	photoreceptor	cells	by	week	12	 (Singh	et	al.	
2013),	 which	would	 not	 be	 an	 acceptable	 percentage	 nor	 survival	 period	 in	 human	 patients.	 Cell	
survival,	and	indeed	neuronal	connectivity,	remain	key	issues	to	be	addressed	if	injected	cells	are	to	
become	and	remain	part	of	a	functional	neural	network.	On	the	other	hand,	numerous	studies	have	
shown	promise	of	functional	recovery	in	models	of	a	number	of	disorders,	however	in	some	cases	the	
therapeutic	effect	measured	may	be	due	to	a	downstream	effect,	such	as	secretion	of	BDNF	(Blurton-
Jones	et	al.	2009),	rather	than	neuronal	activity	of	transplanted	cells.	
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1.9	Manipulation	of	stem	cell	migration	
Stem	cells	have	widespread	potential	 for	 the	 treatment	of	neurodegenerative	disorders.	However,	
since	many	target	areas	of	the	CNS	are	 largely	 inaccessible	and	stem	cells	may	not	be	viable	when	
injected	directly	next	the	injury	site	(Kelly	et	al.	2004),	there	is	a	need	for	stem	cell	migration	to	be	
controlled	in	a	way	that	is	safe	and	that	allows	deep	tissue	penetration.	
1.9.1	Electrical	fields	
All	cells	have	membrane	potentials	generated	by	the	distribution	of	 ions	and	charged	molecules.	 It	
was	proposed	as	early	as	the	19th	century	that	electric	fields	could	be	used	to	stimulate	cell	migration	
(McCaig	 et	 al.	 2005).	 In	 fact,	 endogenous	 electric	 fields	 have	 shown	 to	 be	 important	 for	 guiding	
mesenchymal	stem	cells	to	wound	sites,	including	the	rat	cornea	(Reid	et	al.	2005;	Zhao	et	al.	2006),	
therefore	 there	 has	 been	 interest	 in	 the	 utilisation	 of	 external	 electrical	 fields	 to	 direct	 stem	 cell	
migration.	Electrical	activation	(0.2	V)	has	been	shown	to	stimulate	neurite	extension	of	rodent	NSCs	
(Kobelt	et	al.	2014)	and	axonal	outgrowth	of	cultured	rat	RGCs	(Goldberg	et	al.	2002).	There	is	evidence	
that	direct	current	electrical	fields	can	direct	the	migration	of	rodent	NSCs	and	human	ESCs	towards	
the	cathode	in	vitro	(Li	et	al.	2008;	Meng	et	al.	2011;	Feng	et	al.	2012),	as	well	as	promoting	neuronal	
differentiation	from	neural	precursor	cells	(Thrivikraman	et	al.	2014;	Zhao	et	al.	2015).	
Electrical	field-directed	cell	migration	is	promising.	However,	it	is	important	to	consider	the	potentially	
serious	drawbacks	with	this	method,	the	main	one	of	which	is	that	application	of	an	electric	current	
over	long	time	periods	result	in	an	increase	in	temperature,	which	may	cause	protein	denaturation	or	
cytotoxicity.	
1.9.2	Magnetic	fields		
Magnetic	fields	have	been	widely	researched	for	their	potential	use	in	the	direction	of	cell	migration.	
Given	that	magnetic	fields	can	penetrate	non-transparent	tissue	very	well,	can	be	controlled	remotely,	
and	 are	 relatively	 safe	 (Long	 et	 al.	 2015),	 they	 may	 offer	 a	 better	 method	 of	 targeting	 largely	
inaccessible	areas	of	the	brain	compared	to	optogenetics.	It	is	known	that	iron	is	required	by	cells	(as	
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much	as	4	g	may	be	present	in	the	body	(Bulte	2009))	and	can	be	bound	to	proteins.	Further,	since	
iron	is	ferromagnetic,	it	seems	plausible	that	there	would	be	a	way	to	control	protein	function	using	
magnetic	fields.		
Magnetic	particles		
The	basic	principle	of	magnetism	is	 that	electrons	possess	the	property	of	spin	and	orbital	angular	
momentum,	which	together	contribute	to	the	electron’s	magnetic	moment.	If	the	magnetic	moments	
are	aligned	(intrinsically	or	due	to	an	external	magnetic	field)	the	atoms	are	said	to	have	the	property	
of	magnetism.	All	materials	are	magnetic	to	a	certain	degree.	Most	materials	are	only	magnetic	when	
in	the	presence	of	an	applied	magnetic	field,	i.e.	diamagnetic	or	paramagnetic.	This	type	of	magnetism	
is	 usually	 very	 weak.	 Ferromagnetism,	 however,	 is	 a	 much	 stronger	 type	 of	 magnetism;	 the	
magnetisation	value,	M,	may	be	104	times	greater	than	that	of	a	paramagnetic	material	(Whitesides	
et	al.	1983).	The	value	of	M	is	dependent	on	the	strength	of	the	external	magnetic	field,	H,	and	on	the	
temperature	(Sattler	2010).	Superparamagnetic	nanoparticles	(iron	oxide	particles)	are	often	favoured	
in	the	context	of	medicine,	since	they	lose	their	magnetism	in	the	absence	of	an	external	magnetic	
field,	meaning	they	do	not	aggregate	following	removal	of	the	magnetic	field	(Bonnemain	1998).		
Magnetic	particles	used	in	biological	research	usually	fall	into	two	categories:	nanoparticles	(diameter	
1-100	nm)	and	microparticles	(diameter	1-1000	µm).	The	size	of	magnetic	particle	is	a	very	important	
factor.	For	instance,	to	enable	targeting	to	specific	tissue	intercellular	space,	particles	should	ideally	
be	<10	nm	diameter,	or	<1	nm	for	the	brain	and	kidney	tubules	(Berry	and	Curtis	2003).	Nanoparticles	
are	optimally	endocytosed	 if	 their	diameter	 is	<60	nm	(Zhang	et	al.	2009),	but	 this	process	can	be	
promoted	with	larger	particles	using	a	polymer	coating	(Zhang	et	al.	2002).	The	maximum	number	of	
particles	that	may	be	taken	up	by	a	cell	is	predicted	to	be	500-5000	(Zhang	et	al.	2009).	
The	basic	structure	of	magnetic	nanoparticles	(mnps)	is	shown	in	Figure	1.8.	Due	to	their	ferrite	core,	
magnetic	 nanoparticles	 have	 the	 property	 of	 superparamagnetism:	 in	 the	 absence	 of	 an	 external	
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magnetic	field	mnps	have	a	magnetisation	value	of	essentially	zero;	and	in	the	presence	of	an	external	
magnetic	 field,	 the	 particles	 are	magnetised	 (Obaidat	 et	 al.	 2015).	 In	 the	 latter	 state	 they	 can	 be	
described	as	obeying	Coulomb’s	law	and	can	be	influenced	by	the	magnetic	gradient.	The	silicon-based	
coating	of	mnps	allows	the	iron	oxide	to	be	stable	in	aqueous	solution	and	has	the	added	benefit	of	
permitting	conjugation	of	drug	molecules	(Yang	et	al.	2012).	
Due	to	their	size,	 it	should	be	possible	to	use	mnps	to	target	cells,	proteins,	and	even	specific	DNA	
sequences.	In	the	era	of	genome	sequencing	and	rapid	advances	in	genetic	engineering	mnps	have	
great	 prospects	 in	 many	 areas	 of	 biomedicine	 and	 regenerative	 medicine.	 Mnps	 can	 be	 used	 to	
introduce	DNA	or	RNA	into	cells,	and	as	such	present	a	novel	transfection	method,	magnetofection,	
to	introduce	new	DNA	or	to	knock	down	genes	using	siRNA	(Schillinger	et	al.	2005).	In	magnetofection,	
DNA	of	interest	is	mixed	with	mnps	coated	with	a	charged	polymer,	which	allows	binding	of	the	DNA	
to	 the	particle	surface	via	electrostatic	 interactions.	The	DNA-coated	particles	are	 then	 introduced	
into	cells	with	the	use	of	an	external	magnetic	field.	Advances	in	this	technology	have	shown	that	an	
oscillating	 magnetic	 field	 increases	 the	 efficiency	 of	 transfection,	 as	 outlined	 by	 the	 Nanotherics	
website	(http://www.nanotherics.com/whatismat.htm,	last	accessed	15.02.2016).		
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Figure 1.8 Structure of a magnetic nanoparticle. The ferrite core (comprised of iron oxides plus a 
mixture of oxides of nickel, manganese and zinc) is surrounded by a silica coat, to which functional 
groups (x) may be attached. Adapted from (McBain et al. 2008). 
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Uses	in	drug	targeting	and	diagnostics	
The	use	of	magnetic	particles	as	a	drug	delivery	system	is	by	no	means	a	new	idea	(Senyei	et	al.	1978;	
Widder	et	al.	1980).	There	has	been	a	great	deal	of	interest	in	the	use	of	mnps	in	cancer	treatment.	It	
has	been	theorised	that	mnps	could	be	conjugated	to	an	anti-cancer	drug	or	to	radionucleotide	atoms,	
injected	into	the	bloodstream	and	directed	towards	the	tumour	using	an	external	magnet.	NSCs	have	
been	 used	 to	 deliver	 magnetic	 discs	 (2	 µm	 diameter)	 with	 an	 external	 magnetic	 field	 to	 cause	
mechanical	 destruction	 of	 malignant	 glioma	 cells	 (Muroski	 et	 al.	 2016).	 These	 treatments	 are	
attractive	since	the	procedure	is	non-invasive	and	the	particles	can	be	easily	tracked	using	MRI	(Mejias	
et	 al.	 2011).	 Further,	 by	 combining	 knowledge	 about	 specific	 cancer	 cell	markers,	mnps	 could	 be	
targeted	to	cancer	cells	using	cell	type-specific	antibodies	(Babincova	et	al.	2002).	This	would	mean	
that	 theoretically	 the	dose	of	 the	anti-cancer	drug	could	be	 increased	while	minimising	 the	 risk	of	
adverse	effects.		
Other	uses	of	magnetic	particles	in	targeted	drug	delivery	include	treatment	of	disorders	affecting	the	
brain.	The	blood-brain	barrier	is	an	important	structure	that	impedes	the	passing	of	molecules	that	
are	larger	than	400	Da	or	are	poorly	lipohillic	(Pardridge	2012)	to	protect	the	brain,	however,	this	can	
make	it	difficult	to	deliver	drugs	to	the	target	site.	Mnps	may	circumvent	this	problem.	Drug	molecules	
can	be	encapsulated	within	magnetic	particles,	 injected	 into	 the	bloodstream,	and	directed	 to	 the	
target	site	with	an	externally	positioned	magnet	(McBain	et	al.	2008).		
Other	therapeutic	uses	
When	an	alternating	magnetic	field	is	applied	following	the	magnetic	hysteresis	loop,	mnps	generate	
heat.	Since	mnp	solutions	tend	to	pool	around	tumour	cells,	rather	than	surrounding	normal	cells,	this	
technology	can	be	used	to	target	heat	to	cancer	cells	(Babincová	et	al.	2001;	Babincova	et	al.	2004).	
In	one	study,	median	temperatures	of	approximately	50°C	in	the	centre	of	tumours	were	achieved,	
causing	death	of	the	cancer	cells	(Kumar	and	Mohammad	2011).	It	should	be	noted	that	whilst	the	
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effect	to	surrounding	cells	was	minimal,	a	2°C	increase	is	not	negligible	and	therefore	caution	should	
be	 exercised,	 particularly	 in	 vulnerable	 tissue	 such	 as	 the	 brain,	 where	 cytotoxicity	 could	 be	
devastating.	In	order	to	minimise	damage	to	non-target	cells	these	mnps	are	usually	injected	into	the	
centre	of	the	tumour.	This	method,	using	temperatures	of	43-55°C,	is	termed	magnetic	thermoblation.	
A	similar	method,	magnetic	hyperthermia,	involves	temperatures	of	45-47°C	and	although	this	also	
causes	tumour	regression,	the	regression	is	often	not	permanent	(Hilger	et	al.	2001).	Magnetic	field-
induced	warming	technology	also	has	potential	 for	the	treatment	of	hypothermia	(Pankhurst	et	al.	
2003).	
Uses	in	cell	signalling	research	
As	eluded	to	previously,	specific	proteins	can	be	conjugated	to	magnetic	particles,	which	facilitates	
the	 investigation	 of	 signalling	 pathways.	 In	 addition,	 the	 protein	 concentration,	 using	 knowledge	
about	 the	number	of	mnps	per	protein,	and	the	spatiotemporal	effects,	using	controlled	magnetic	
fields,	 may	 be	 explored.	 Further,	 conjugation	 of	 mnps	 to	 ligands/agonists	 may	 enable	 magnet-
controlled	 manipulation	 of	 signalling	 cascades,	 which	 may	 be	 useful	 as	 a	 research	 tool	 and	 as	 a	
potential	therapeutic	approach.	It	should	be	noted	that	although	some	signalling	pathways,	such	as	
those	 downstream	of	 integrins,	 are	mechanosensitive,	 the	magnetic	 force	 applied	 to	 each	mnp	 is	
similar	to	that	required	to	stimulate	downstream	signalling	(Sniadecki	2010).	
Uses	in	whole	cell	migration	
Since	cells	can	be	made	to	take	up	mnps	via	endocytosis,	it	would	be	logical	to	hypothesise	that	it	may	
be	possible	to	control	the	migration	of	cells	containing	mnps	using	a	magnet.	Indeed,	this	has	been	
demonstrated	using	mnp-containing	stem	cells	in	vitro	(Raffa	et	al.	2009;	Song	et	al.	2010)	and	in	vivo	
(Song	 et	al.,	 2010).	By	applying	 the	 same	principle	as	 is	used	 in	 cell	 sorting,	 resident	 cells	may	be	
controlled	using	a	magnet	by	using	antibody-conjugated	mnps.	Permanent	magnet-directed	migration	
of	mnp-labelled	 stem/progenitor	 cells	 in	 vivo	 has	 been	 demonstrated	 in	 the	 repair	 of	 vasculature	
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injury	and	wound	healing	 (Kyrtatos	et	al.	2009;	Riegler	et	al.	2013).	Permanent	magnets	have	also	
been	reported	to	control	the	migration	of	cells	from	the	blood	to	a	lesion	site	using	mnps	bound	via	
cell	surface	antigens	in	vivo	in	the	rabbit.	In	this	study	mnps	were	coated	with	anti-CD34	antibodies	
via	 polyethylene	 glycol,	 which	 were	 injected	 intravenously	 and	 bound	 to	 stem	 cells	 via	 their	 cell	
surface	antigen	CD34.	A	permanent	magnet	was	then	held	next	to	a	femoral	artery	and	it	was	found	
that	mnp-bound	stem	cells	accumulated	at	a	lesion	site	in	the	femoral	artery	following	application	of	
a	magnetic	field	(Chen	et	al.	2013).	This	is	an	interesting	approach	as	it	would	permit	higher	specificity.	
Although	promising,	the	reach	of	this	approach	is	 limited	by	the	fact	that	the	strength	of	magnetic	
fields	 decreases	 exponentially	 as	 a	 function	 of	 distance	 from	 the	 magnet	 surface	 (Figure	 1.9).	
Consequently,	 it	 may	 be	 difficult	 to	 control	 the	 migration	 of	 cells	 deep	 in	 the	 brain	 without	 the	
implantation	of	magnets,	which	has	been	demonstrated	in	the	spinal	cord	(Tukmachev	et	al.	2015),	
retina	(Yanai	et	al.	2012)	and	brain	(Carenza	et	al.	2014).	Alternatively,	electromagnets	can	be	used	to	
generate	large	magnetic	fields	with	controlled	gradients,	and	since	MRI	machines	are	commonplace	
in	hospitals,	the	equipment	for	magnetic	field-directed	migration	may	already	be	available	(Riegler	et	
al.	2010).
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Figure 1.9 Magnetic field strength, Br, follows the inverse square law with distance from the magnet 
surface. 
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Mnp	toxicity	
The	potential	 toxicity	of	mnps	 is	a	concern	 in	 the	 field,	and	breakdown	of	 iron	within	cells	via	 the	
Fenton	reaction	produces	free	radicals	that	can	damage	DNA	(Imlay	et	al.	1988).	Despite	this,	there	
has	been	no	reported	adverse	effects	on	the	viability	or	migration	of	stem	cells	when	nanoparticles	
are	used	at	10	pg	iron/cell	(Bulte	2009;	Loebinger	et	al.	2009;	Richards	et	al.	2012).	One	recent	study	
demonstrated	that	neuronal	activity	 is	not	affected	by	the	movement	of	magnetic	nanoparticles	 in	
brain	slices	(Ramaswamy	et	al.	2015).	Mnps	have	been	widely	used	in	medicine	for	cell	tracking	and	
imaging	 (using	MRI	 scanning),	 and	are	 rapidly	 removed	 from	circulation	within	3	hours	 (Sun	et	 al.	
2008).	The	size	of	mnp	is	an	important	consideration	since	particles	with	a	diameter	of	<5.5	nm	are	
filtered	out	of	the	body	via	the	renal	system	(Choi	et	al.	2007)	and	particles	with	a	diameter	of	>500	
nm	are	removed	from	circulation	by	phagocytes	in	the	spleen	(Chen	and	Weiss	1973).	
1.9.3	Magnetic	field-sensitive	receptors	
Magnetoreception	describes	a	phenomenon	where	organisms	are	able	to	sense	the	Earth’s	magnetic	
field.	To	date,	evidence	for	the	existence	of	a	magnetic	field-sensitive	receptor,	or	magnetoreceptor,	
has	ben	limited	to	the	cases	of	migratory	organisms.	Magnetic	field-sensitive	migratory	behaviour	has	
been	detected	in	bacteria	(Baumgartner	et	al.	2013),	Drosophila	(Qin	et	al.	2016),	Zebrafish	(Takebe	
et	al.	2012),	sea	turtles	(Lohmann	et	al.	1999),	lobsters	(Boles	&	Lohmann	2002),	and	several	species	
of	bird,	 including	homing	pigeons	 (Leask	1977;	Mora	et	 al.	 2004).	 There	have	been	 three	possible	
mechanisms	 for	 magnetoreception	 proposed:	 electromagnetic	 induction,	 magnetite	
magnetoreception,	and	chemical	magnetoreception.	Electromagnetic	induction	is	proposed	to	involve	
detection	 of	magnetic	 fields	 using	 an	 electrical	 conductor.	When	 the	 conductor	 passes	 through	 a	
magnetic	 field,	 a	 force	 Is	 applied,	 termed	 Lorentz	 force,	 the	magnitude	of	which	 is	 relative	 to	 the	
parameters	 (strength,	 direction,	 etc.)	 of	 the	 magnetic	 field	 (Johnsen	 &	 Lohmann	 2005).	 There	 is	
evidence	for	electromagnetic	induction	in	studies	with	elasmobranch	fish	(e.g.	sharks	and	rays),	for	
example	 rays	 conditioned	 to	 respond	 to	 changes	 in	 a	magnetic	 field	 had	 their	 responses	 blocked	
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following	introduction	of	magnets	in	their	nasal	cavities	(Molteno	&	Kennedy	2009).	Magnetite	(Fe3O4)	
magnetoreception	 is	 proposed	 to	 involve	 a	 molecule	 containing	 iron,	 which	 aligns	 itself	 to	 the	
geomagnetic	field	and	rotation	of	the	magnetic	field	may	result	in	opening	of	a	connected	ion	channel	
(Kirschvink	et	al.	2001).	This	could	result	in	downstream	neuronal	firing	that	may	cause	a	change	in	
migratory	behaviour.	The	chemical	magnetoreception	hypothesis	relies	on	free	radical	reactions	that	
are	 influenced	 by	 the	 Earth’s	 magnetic	 field.	 Since	 light-absorbing	 reactions,	 such	 as	 in	
photoreceptors,	 typically	 involve	 free	 radical	 reactions,	 it	 has	 been	 proposed	 that	 chemical	
magnetoreception	may	be	associated	with	light-responsive	organs	(Ritz	et	al.	2000).	In	line	with	this,	
there	is	evidence	for	crytochromes	in	migratory,	but	not	non-migratory,	songbirds	(Mouritsen	et	al.	
2004).	
There	 is	 little	 evidence	 for	 a	magnetoreceptor	 in	 non-migratory	 animals,	 however	 if	 it	 does	 exist,	
perhaps	the	alignment	of	a	molecule	with	the	geomagnetic	field	may	have	a	use	for	the	detection	of	
orientation	during	embryogenesis,	but	there	have	been	no	studies	supporting	this	theory.	Although	
debated	 to	 be	 present	 in	 humans,	 a	 recently	 presented	 two	 models	 for	 a	 magnetically-sensitive	
receptor,	the	magnetoreceptor.	In	this	report,	one	model	suggested	that	magnetite	may	help	protein	
complexes	align	with	external	magnetic	fields	and	stimulate	movement	of	stretch	receptors,	while	a	
second	model	suggested	the	involvement	of	photoreceptors	where	phototransduction	leads	to	the	
exchange	of	radicals,	leading	to	different	chemical	products	in	the	presence	or	absence	of	an	external	
magnetic	field	(Lohmann	2016).	Rat	mesenchymal	stem	cells	have	been	shown	to	migrate	in	response	
to	 a	 permanent	 magnet	 array	 without	 mnps,	 which	 provides	 evidence	 of	 a	 mammalian	
magnetoreceptor.	 In	 this	study,	mesenchymal	stem	cells	 from	rats	were	grown	on	a	microarray	of	
magnets	for	up	to	3	days	and	at	the	end	of	the	culture	period	it	was	found	that	the	cells	grew	on	the	
surface	of	the	magnets,	unlike	in	the	non-magnetic	array	control,	where	cells	grew	in	a	more	random	
fashion	(Zablotskii	et	al.	2013).		
	
Chapter	1:	Introduction	 76	
1.9.4	Magnetogenetics	
The	 recent	 construction	of	 iron	 containing	proteins	has	brought	 the	 advent	of	magnetogenetics	 –	
control	of	transcription	by	the	application	of	an	external	magnetic	field.	Using	these	proteins,	neuronal	
action	potential	firing	(Long	et	al.	2015)	and	calcium-regulated	insulin	release	(Leibiger	and	Berggren	
2015)	 can	 be	 remotely	 controlled.	 It	may	 be	 possible	 to	 combine	 this	 technology	with	 cell-based	
delivery	of	neurotrophins,	particularly	as	bdnf	has	calcium	response	elements.	
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1.10	The	retinal	explant:	a	model	for	neurodegeneration	
The	retinal	explant	is	an	ideal	model	to	investigate	the	mechanisms	involved	in	neuronal	degeneration.	
The	axotomy,	performed	at	the	time	of	explantation,	is	a	consistent	injury,	unlike	the	optic	nerve	crush	
(Weber	and	Harman	2008).	The	resultant	 rapid	cell	death	 is	a	major	advantage	of	 this	model	over	
similar	in	vivo	models,	as	well	as	the	minimal	contribution	of	an	immune	response.	Experiments	with	
cell	culture	and	brain	slices	are	rapid,	but	do	not	permit	investigation	of	an	intact	neuronal	network.	
In	addition,	the	fact	that	the	concentration	and	location	of	agents	can	be	controlled	relatively	easily	
has	resulted	in	the	widespread	use	of	this	model	for	the	study	of		neuroprotective	strategies	(Ogilvie	
et	al.	1999;	Wang	et	al.	2002;	Koizumi	et	al.	2007;	Moritoh	et	al.	2010;	Niyadurupola	et	al.	2011)	and	
cell	replacement	therapies	(Johnson	and	Martin	2008;	Bull	et	al.	2011;	Denk	et	al.	2015).		
Results	from	explant	experiments	are	primarily	assessed	using	cell	counts	or	viability	markers,	such	as	
propidium	iodide	and	calcein-AM	(Grieshaber	et	al.	2010),	or	terminal	deoxynucleotidyl	transferase	
dUTP	nick	end	labelling	(TUNEL)	(Gavrieli	et	al.	1992),	which	can	underestimate	tissue	health.	Recent	
reports	indicated	that	retinal	explants	are	viable	for	at	least	7	days	(Lye	et	al.	2007;	Johnson	and	Martin	
2008;	Kobuch	et	al.	2008).	However,	 it	should	be	noted	that	a	retina	containing	‘viable’	cells	 is	not	
necessarily	capable	of	transmitting	signals	along	the	entire	visual	pathway.	RGCs	that	contain	active	
esterases,	and	therefore	stain	positive	 for	calcein-AM,	may	not	be	capable	of	 receiving	 input	 from	
bipolar	cells	and	amacrine	cells	 if	dendritic	pruning	has	occurred.	Lack	of	morphometric	analysis	of	
RGCs,	from	which	functional	potential	may	be	inferred,	is	a	major	limitation	of	work	to	date.	
In	order	for	morphometric	analysis	of	RGCs	to	be	carried	out,	cells	must	be	labelled	in	a	sparse	and	
random	manner.	Golgi	staining	remains	a	gold	standard	staining	method	but	does	not	combine	well	
with	other	histological	techniques	(Golgi	1873).	Microinjection	of	dyes	is	technically	challenging	and	
is	biased	towards	larger	cells.	Retrograde	labelling	with	fluoro-gold	(Chiu	et	al.	2008)	relies	on	intact	
axons	 and	 commonly	 results	 in	 over-labelling.	 The	 use	 of	 transgenic	 animals,	 for	 example	 Thy1-
dependent	expression	of	green	fluorescent	protein	(GFP)	for	 labelling	of	RGCs,	can	produce	sparse	
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labelling	but	underreports	dendritic	pruning	(Williams	et	al.	2013a).	Ballistic	labelling	(diolistics	and	
biolistics)	 (Lo	et	al.	1994;	Christianson	and	Lo	2011)	 labels	cells	 in	a	 sparse	manner.	Diolistics	uses	
tungsten	particles	as	microcarriers	of	lipophilic	dyes,	which	are	delivered	to	cells	under	high	pressure	
helium	blasts.	The	lipophilic	dyes	diffuse	through	cell	membranes	in	a	temperature-dependent	nature,	
therefore	the	resultant	 labelling	 is	considered	random	since	 it	 is	 independent	of	cell	health	or	ATP	
machinery.	Biolistics	uses	gold	particles	to	deliver	plasmids	to	cells	using	helium	blasts.	In	addition	to	
labelling	cell	morphology	by	transfection	with,	for	example	GFP,	biolistiocs	also	permits	visualisation	
of	synaptic	or	mitochondrial	markers,	which	may	be	useful	to	monitor	in	parallel	with	changes	to	the	
whole	cell	morphology.	
	
1.10.1	TrkB	signalling	in	the	retinal	explant	
Since	 the	 retinal	 explant	 is	 an	 axotomy	model,	 it	 is	 important	 to	 consider	 the	 potential	 signalling	
pathways	initiated	by	axotomy	that	may	contribute	to	dendritic	retraction	and	neuronal	cell	death	in	
this	 model.	 Wallerian	 degeneration	 describes	 the	 degenerative	 events	 contributing	 to	 axotomy-
induced	 axonal	 retraction	 (Gerdts	 et	 al.	 2016).	 The	 study	 of	Wallerian	 degeneration	 has	 provided	
target	proteins	and	signalling	cascades	that	would	be	interesting	to	study	in	the	context	of	dendritic	
atrophy	 and/or	 neuroprotection.	 Following	 axotomy,	 Sarm1	 (a	 protein	 with	 multiple	 protein	
interaction	sites)	activation	leads	to	upregulation	of	MKK4	and	MKK7	(Gerdts	et	al.	2013;	Yang	et	al.	
2015).	A	resultant	energy	deficit,	possibly	due	to	the	disruption	of	a	stem	in	glycolysis	by	Sarm1-MAPK,	
results	in	intracellular	build-up	of	Ca2+.	Calpain	(a	cysteine	protease)	can	be	activated	by	caspases,	or	
independently	 activated	 by	 high	 intracellular	 levels	 of	 calcium	 (George	 et	 al.	 1995).	 In	 axotomy	
models,	 calpain	 is	 postulated	 to	 be	 activated	 in	 a	 caspase-independent	manner.	Activated	 calpain	
digests	actin,	resulting	in	axonal	retraction	(Yang	et	al.	2015).	MKK4	is	antagonised	by	Akt,	which	is	
upregulated	by	BDNF-TrkB	signalling.	From	this	we	can	postulate	that	BDNF	treatment	of	axotomised	
RGCs	may	retard	axonal	retraction.	Further,	BDNF	signalling	is	capable	of	inducing	neurite	extension	
via	Ras-activated	actin	polymerisation,	therefore	BDNF	treatment	has	the	potential	to	not	only	retard	
Chapter	1:	Introduction	 79	
axonal	degeneration	but	to	stimulate	outgrowth,	as	observed	in	adult	rodent	retinal	explants	(Thanos	
et	al.	1993;	Goldberg	et	al.	2002).	
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1.11	Aims	and	hypothesis	
Based	on	the	evidence	that	dendritic	retraction	precedes	cell	loss	in	neurodegenerative	disorders,	I	
hypothesise	that	morphometric	analysis	of	RGCs	in	adult	mouse	retinal	explants	will	provide	a	more	
sensitive	 readout	 of	 neuronal	 cell	 health,	 compared	 to	 cell	 counts.	 Further,	 I	 postulate	 that	 the	
quantification	 of	 dendritic	 morphology	 in	 these	 neurons	 will	 aid	 identification	 of	 mechanisms	
implicated	in	neuronal	degeneration	and	therefore	targets	for	neuroprotection	and	repair.	
	
Specific	aims	of	this	thesis	will	be:	
• To	assess	the	timeline	of	onset	of	dendritic	retraction	versus	cell	loss	of	RGCs	in	the	mouse	
retinal	explant.	
• To	test	whether	dendritic	retraction	may	be	retarded	following	treatment	with	neurotrophic	
agents	(pan-caspase	inhibitor	and	BDNF).	
• To	 investigate	 the	 potential	 inhibitory	 role	 of	 the	 PNN	 on	 neuronal	 plasticity;	 specifically,	
whether	PNN	digestion	will	facilitate	dendritic	remodelling	of	RGCs	following	axotomy.		
• To	test	whether	external	magnetic	fields	can	increase	migration	depth	of	NSCs	into	the	GCL	of	
mouse	 retinal	 explants,	 and	 thereby	 test	 this	 a	 potential	 method	 to	 deliver	 neurotrophic	
agents	to	specific	cell	layers	in	the	central	nervous	system.	
	
The	methods	to	be	used	in	this	thesis	will	now	be	outlined.
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Chapter	2.	Materials	and	Methods	
2.1	Animal	use	
2.1.1	Housing	of	animals	
Mice	were	housed	in	a	12	h	light/dark	cycle	with	access	to	food	and	water	ad	libitum.	
2.1.2	Animals	used	
C57/Bl6	mice	of	either	sex	aged	6	weeks	–	8.5	months	were	used	for	all	experiments	(Table	2.1).	
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Table 2.1. Animal numbers for all experiments. 
Experiment	 Number	of	explants	 Number	of	animals	
Explant	area	measurements	 4	 4	
Nuclear	staining	 18	 15	
Immunohistochemistry	 21	 17	
TUNEL	 14	 13	
Calcein-AM	 13	 13	
Diolistics	 123	 88	
ELISA	 29	 15	
Neural	stem	cell	migration	 6	 3	
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2.2	Retinal	explant	preparation	and	culture	
Mice	were	 killed	 by	 cervical	 dislocation	 in	 accordance	with	 the	 Home	 Office	 (UK)	 and	 eyes	 were	
marked	for	nasal	orientation	using	a	sterile	18	gauge	needle.	Eyes	were	enucleated,	washed	with	1x	
phosphate-buffered	saline	(PBS,	pH	7.4)	to	remove	blood	and	hair,	and	placed	into	 ice-cold	Hanks-
balanced	 Salt	 Solution	 (Life	 Technologies	 Ltd.,	 Paisley,	 UK)	 supplemented	 with	 1%	 penicillin-
streptomycin.	Under	a	light	dissecting	microscope	(Leica	DFC	420C)	the	retina	was	rapidly	dissected	
as	outlined	in	Figure	2.1.	The	prepared	explant	was	cultured	on	a	0.4	µm	PTFE	culture	insert	(Millipore,	
Watford,	 UK)	 in	 a	 35	mm	 culture	 dish	 (Millipore)	 containing	 1.2	mL	 supplemented	Neurobasasl-A	
culture	media	(Table	2.2).	Explants	were	cultured	at	37°C,	5%	CO2.	For	culture	periods	of	>1	day	the	
media	was	changed	with	fresh	pre-warmed	(37°C)	media	to	prevent	accumulation	of	toxins.	
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Table 2.2. Components of culture media. All components were purchased from Life Technologies Ltd. 
The medium was made up in a sterile 100 mL DURAN® bottle at stored at 4°C for no longer than 2 
weeks. 
Component	 Concentration	 Role	
Neurobasal-A	 -	 Maintenance	of	adult	neurons.	
Penicillin-
Streptomycin	
1%	 (100	 U/mL	 penicillin;	
100	µg/mL	streptomycin)	
Antibiotics	to	minimise	contamination	caused	by	
both	gram-positive	and	gram-negative	bacteria.	
L-glutamine	 0.8	mM	 Amino	acid	to	improve	viability	of	cells.	
N-2	supplement	 1%	 Supports	 growth	 of	 post-mitotic	 neurons	 in	
primary	culture.	
B-27	supplement	 2%	 Supports	growth	and	viability	of	CNS	neurons.	
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Figure 2.1. Preparation of retinal explant. (A) A cut was made from the nasal mark towards the optic 
nerve head and the anterior chamber was removed by cutting around the ciliary margin zone. (B) The 
lens was removed. (C) The retina was gently separated from the retinal pigment epithelium. (D) The 
retina was transferred to a culture insert, GCL facing up. Two additional cuts were made to create a 
three leaf clover shape and permit the retina to lie flat. Dashed lines indicate cut sites. Scale bars: 1 
mm.
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2.2.1	Pan-caspase	inhibition	
Explants	were	cultured	in	the	culture	medium	as	described	previously.	The	pan-caspase	inhibitor	Q-
VD	(R&D	Systems,	Abingdon,	UK)	was	added	as	a	topical	aliquot	(100	µL)	directly	onto	each	explant	at	
a	concentration	of	100	µM	(total	concentration	7.7	µM	in	culture	medium)	in	dimethyl	sulphoxide.	
Controls	had	a	100	µL	 topical	aliquot	of	dimethyl	 sulphoxide.	After	1	day	 the	culture	medium	was	
replaced	and	fresh	aliquots	were	applied.	After	2	days	in	culture,	explants	were	labelled	diolistically	
(section	2.8).	
2.2.2	BDNF	treatment	
Explants	were	treated	with	100	ng/mL	BDNF	(Regeneron/Amgen)	for	3	d	initiated	at	day	0	(3	d	total)	
or	 at	 day	 3	 (6	 d	 total).	 Prior	 to	 BDNF	 treatment,	 delayed	BDNF-treated	 explants	were	 cultured	 in	
normal	culture	medium	for	3	d.	BDNF	was	diluted	in	1xPBS	+	0.1%	bovine	serum	albumin	(BSA)	and	
added	to	the	culture	medium	to	make	a	final	concentration	of	100	ng/mL	or	1000	ng/mL.	Controls	had	
the	same	volume	of	vehicle	added	to	the	culture	medium	(2	µL/mL	for	100	ng/mL	BDNF,	20	µL/mL	for	
1000	ng/mL	BDNF).	All	medium	was	replaced	daily	and	cells	were	labelled	diolistically	(section	2.8).	
2.2.3	ChABC	treatment	
To	digest	the	PNN,	explants	were	treated	with	ChABC	(a	kind	gift	from	Prof.	Bruce	Caterson,	Cardiff	
University)	for	1	d.	ChABC	was	stored	at	a	stock	concentration	of	10	U/mL	in	1xPBS	+	0.1%	BSA	and	
applied	as	a	topical	aliquot	(50	µL)	diluted	in	1xPBS.	Controls	had	a	topical	aliquot	(50	µL)	of	vehicle.		
To	 visualise	 chondroitin	 sulphate	 (CS)	 digestion	 explants	 were	 treated	with	 ChABC,	 and	 after	 1	 d	
explants	 were	 fixed	 and	 processed	 for	 immunohistochemistry	 as	 described	 in	 section	 2.5.	 To	
investigate	the	effect	on	RGC	dendritic	morphology	explants	were	treated	with	ChABC	for	1	d	and	
cultured	for	a	further	2	d	(3	d	total)	or	5	d	(6	d	total),	and	at	the	end	of	the	culture	period	explants	
were	 diolistically	 labelled.	 To	 investigate	 a	 potential	 synergistic	 role	 of	 CS	 digestion	 and	 BDNF	
treatment,	explants	were	treated	with	BDNF	for	3	d	from	day	0	or	from	day	3,	as	outlined	in	section	
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2.2.2,	in	conjunction	with	1	d	ChABC	treatment	initiated	at	day	0.	Explants	were	labelled	with	diolistics	
at	the	end	of	the	culture	period	(section	2.8).	
2.2.4	BDNF	blocking	with	mAb#9	
In	 order	 to	 investigate	 the	 role	 of	 endogenous	 BDNF,	 explants	were	 treated	with	 a	mouse	 IgG2b	
monoclonal	antibody	raised	against	BDNF	(as	described	by	Kolbeck	at	al.(Kolbeck	et	al.	1999)),	mAb#9	
(a	generous	gift	from	Prof.	Yves	Barde,	Cardiff	University).	MAb#9	(3.8	µg/µL)	was	added	to	the	culture	
medium	to	generate	a	final	concentration	of	10	µg/mL.	Controls	had	mAb#9	omitted.	Explants	were	
treated	with	mAb#9	±BDNF	(100	ng/mL)	for	3	d,	and	then	diolistically	labelled	(section	2.8).		
2.3	Cryosectioning	
At	the	end	of	the	culture	period	the	medium	was	replaced	with	1	mL	4%	paraformaldehyde	(PFA,	pH	
7.4).	A	topical	aliquot	(500	µL)	of	PFA	was	applied	onto	the	explant	to	ensure	complete	submersion	of	
the	tissue.	Explants	were	fixed	for	4	hours	at	4°C,	followed	by	replacement	of	PFA	with	30%	sucrose,	
including	a	topical	aliquot	(500	µL)	of	sucrose	onto	the	explant.	Explants	were	cryoprotected	overnight	
at	 4°C.	 Explants	 were	 then	 carefully	 placed	 into	 moulds	 containing	 optimal	 cutting	 temperature	
compound	 and	 labelled	 for	 orientation.	 Explants	 were	 rapidly	 frozen	 using	 liquid	 nitrogen-cooled	
isopentane	and	stored	at	-20°C.	
Explants	were	cut	using	a	cryostat	(Leica	CM	3050S).	Sagittal	sections	were	cut	(10-14	µm)	in	the	nasal-
temporal	 direction	 and	 placed	 onto	 coated	 Superfrost®	 slides	 (Scientific	 Laboratory	 Supplies	 Ltd.,	
Yorkshire,	 UK).	 Slides	 were	 left	 covered	 at	 room	 temperature	 overnight	 to	 allow	 any	 water	 to	
evaporate,	and	then	stored	at	-20°C.	
To	use	as	positive	controls	for	apoptotic	markers,	spleen	from	mice	used	for	explants	were	dissected,	
washed	with	 saline	 and	 fixed	 overnight	 in	 4%	 PFA.	 The	 spleen	was	 cryoprotected	 in	 30%	 sucrose	
overnight,	 frozen	 in	optimal	 cutting	 temperature,	 and	 stored	at	 -20°C.	 Spleen	was	 cut	 into	14	µm	
sections	using	a	cryostat,	placed	onto	coated	Superfrost®	plus	slides,	and	stored	at	-20°C.	To	use	as	
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positive	 controls	 for	 neuronal/CS	markers,	 brains	 were	 fixed,	 frozen	 and	 section	 as	 described	 for	
spleen.	The	brains	were	cut	anterior	to	posterior	in	the	coronal	plane.	
2.4	Nuclear	staining	
For	 all	 staining	 protocols	 using	 frozen	 sections	 the	 following	method	was	 used	 prior	 to	 labelling:	
sections	were	left	at	room	temperature	(RT)	for	30	min	to	allow	all	water	to	evaporate,	then	washed	
3x	with	1xPBS.	The	slides	were	carefully	dried	and	a	pap	pen	(Sigma-Aldrich,	5	mm	tip)	was	used	to	
draw	a	hydrophobic	barrier	around	each	section.	
2.4.1	Staining	method	
Sections	were	incubated	with	TO-PRO-3	(Table	2.3;	Life	Technologies	Ltd.)	for	10	min	(RT)	in	the	dark.	
Sections	were	washed	3x	with	1xPBS,	the	slides	were	carefully	dried	and	sections	were	coverslipped	
with	Prolong	Gold	anti-fade	reagent®	(Life	Technologies	Ltd.)	and	sealed	with	nail	varnish.	Sections	
were	stored	in	the	dark	to	prevent	photobleaching.	
2.4.2	Confocal	microscopy	
Sections	were	imaged	by	confocal	microscopy	(Zeiss,	LSM	510,	release	version	4.2	SP1)	using	the	633	
nm	laser	with	651-704	nm	detector.	Z-stacked	images	(1024x1024	pixels)	were	taken	in	1	µm	intervals	
through	the	entire	section.		
2.4.3	Image	analysis	
Images	were	imported	into	the	image	processing	software	FIJI	(Schindelin	et	al.	2012)	as	RGB	(8-bit)	
images.	To	prevent	inaccurate	measurements	caused	by	overlapping	cells	the	central	1	µm	z-slice	was	
analysed	in	each	case.	In	order	to	minimise	inaccuracies	introduced	by	changes	in	volume	in	the	z-
plane	of	the	tissue,	nuclear	counts	were	taken	linearly	in	two-dimensions.	The	number	of	cells	in	a	250	
µm	line	were	counted	using	the	multi-point	tool,	and	the	number	was	then	calculated	as	number	of	
cells/mm.	Cell	layer	thicknesses	were	measured	using	the	line	tool,	with	three	measurements	taken	
for	each	section.	
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2.5	Immunohistochemistry	
2.5.1	Staining	method	
All	incubations	were	at	room	temperature,	unless	stated	otherwise.	Sections	were	incubated	with	5%	
chicken	serum	in	1xPBS	(Invitrogen,	heat	 inactivated	at	56°C)	for	30	min.	Sections	were	washed	3x	
with	 1xPBS	 and	 then	 incubated	with	 primary	 antibody	 for	 4	 h	 or	 overnight	 at	 4°C.	 Sections	were	
washed	3x	with	1xPBS,	 followed	by	 incubation	with	secondary	antibody	 for	1.5	h.	For	all	antibody	
concentrations	see	Table	2.3.	Sections	were	washed	3x	with	1xPBS	and	counter-stained	with	TO-PRO-
3	as	previously	described	or	Hoechst	(Table	2.3).	Finally,	sections	were	coverslipped	with	Prolong	Gold	
anti-fade	reagent	and	stored	in	the	dark	before	imaging.	
2.5.2	Fluorescence	microscopy	
Sections	were	imaged	by	confocal	microscopy	(488	nm	argon	laser	with	500-530	nm	bandpass	filter	
for	secondary	antibodies	and	633	nm	laser	with	651-704	nm	detector	for	TO-PRO-3)	or	fluorescence	
microscopy	 (488	nm	with	 FITC	 filter	 for	 secondary	antibodies	 and	361	nm	excitation	with	497	nm	
detection	for	Hoechst).	Confocal	images	were	taken	as	z-stacks	in	1	µm	intervals.	Fluorescence	images	
were	taken	as	single	plane	images	in	the	centre	of	the	section.		
2.5.3	Image	analysis	
Images	were	imported	as	RGB	(8-bit)	images	into	FIJI	and	the	central	1	µm	z-slice	was	analysed	in	each	
case.	Fluorescence	was	quantified	either	by	counting	the	number	of	cells	double	stained	for	TO-PRO-
3	and	the	antibody	or	by	measuring	the	mean	channel	intensity	of	the	cell	layer.	The	mean	channel	
intensity	was	normalised	 for	background	 fluorescence	by	 subtracting	 the	channel	 intensity	 for	 the	
same	cell	layer	in	the	negative	control.		
	
	
	
Chapter	2:	Materials	and	Methods	
	
90	
Table 2.3. Nuclear stains and antibodies used. 
Primary	antibodies	and	nuclear	stain	
Specificity	 Target	 Source	 Clone	 Working	
concentration	
Diluent	
	
Company	
Thy1.2	 RGCs	 Rat	
IgG2b	
Monoclonal	 2.5	µg/mL	 PBS	 +	 0.1%	
triton	
Abcam	
Active	
caspase-3	
Apoptotic	
cells	
Rabbit	 Polyclonal	 10	µg/mL	 PBS	 	
Chemicon	
1B5	 Unsulphated	
CS	
disaccharide	
Mouse	
IgG	
Monoclonal	 1:5	 PBS	 Bruce	
Caterson	lab	
2B6	 4-sulphated	
CS	
disaccharide	
Mouse	
IgG	
Monoclonal	 1:5	 PBS	 Bruce	
Caterson	lab	
3B3	 6-sulphated	
CS	
disaccharide	
Mouse	
IgM	
Monoclonal	 1:5	 PBS	 Bruce	
Caterson	lab	
TO-PRO-3	
iodide	642	
Nucleic	acids	 -	 -	 1	µM	 ddH2O	 Life	
Technologies	
Ltd.	
Hoechst	 Nucleic	acids	 -	 -	 20	µM	 PBS	 Life	
Technologies	
Ltd.	
Secondary	antibodies	
Specificity	 Conjugate	 Source	 Working	
concentration	
Diluent	 Company	
Rat	IgG	 AlexaFluor	
488	
Goat	 4	µg/mL	 PBS	 Abcam	
Rabbit	IgG	 AlexaFluor	
488	
Goat	 4	µg/mL	 PBS	 Life	
Technologies	
Ltd.	
Mouse	
IgG	
AlexaFluor	
488	
Goat	 4	µg/mL	 PBS	 Life	
Technologies	
Ltd.	
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Mouse	
IgM	
AlexaFluor	
488	
Goat	 4	µg/mL	 PBS	 Life	
Technologies	
Ltd.	
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2.6	TUNEL	assay	
2.6.1	Staining	method	
Sections	 were	 labelled	 for	 apoptosis	 using	 the	 TUNEL	 assay	 (Millipore)	 according	 to	 the	
manufacturer’s	instructions.	All	incubations	were	at	room	temperature,	unless	stated	otherwise,	and	
took	place	in	a	humidified	incubation	chamber.	Briefly,	sections	were	digested	with	proteinase	K	for	
20	min	at	37°C	and	incubated	with	end-labelling	cocktail	for	60	min	at	37°C.	Sections	were	blocked	
with	blocking	buffer	for	20	min	and	broken	DNA	was	labelled	by	incubation	with	Avidin-FITC	for	30	
min	at	37°C.	Sections	were	nuclear	stained	with	TO-PRO-3	and	coverslipped	with	Prolong	Gold	anti-
fade	 reagent.	 Positive	 controls	were	 sections	pre-incubated	with	proteinase	K	 for	 60	min	 at	 37°C.	
Negative	controls	had	the	Avidin-FITC	incubation	step	omitted.	Labelled	sections	were	stored	in	the	
dark	prior	to	imaging	to	prevent	photobleaching.	
2.6.2	Confocal	microscopy	
1024x1024	pixel	8-bit	 images	of	 labelled	sections	were	obtained	by	confocal	microscopy	(Zeiss).	Z-
stacked	images	were	taken	in	1	µm	steps	through	the	entire	section.	Separate	channels	were	used	for	
FITC	(488	nm	laser	with	500-530	nm	bandpass	filter)	and	TO-PRO-3.	
2.6.3	Image	analysis	
Images	 were	 imported	 into	 FIJI	 and	 the	 central	 z-slice	 was	 analysed	 in	 each	 case	 to	 prevent	
inaccuracies	 caused	 by	 overlapping	 cells.	 TUNEL	 staining	 was	 quantified	 as	 mean	 green	 channel	
intensity	for	each	cell	layer,	normalised	for	negative	control	fluorescence	in	the	respective	cell	layer.	
2.7	Calcein-AM	assay	
2.7.1	Staining	method	
At	 the	 end	of	 the	 culture	 period	 explants	were	 labelled	with	 Calcein-AM	 (Biotium,	 Inc.,	 CA,	USA),	
applied	as	a	200	µL	topical	aliquot	(10	µM	in	1xPBS)	for	30	min	at	37°C.	Controls	were	incubated	with	
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the	same	volume	aliquot	of	vehicle	only.	Explants	were	washed	3x	with	1xPBS,	counterstained	with	
TO-PRO-3,	and	coverslipped	with	Prolong	Gold	anti-fade	reagent.		
2.7.2	Confocal	microscopy	
Explants	were	imaged	immediately	after	labelling	to	prevent	fading	of	fluorescence.	TO-PRO-3	staining	
was	used	to	identify	the	GCL.	Z-stacked	images	(1024x1024	pixels)	in	1	µm	intervals	through	the	entire	
GCL	were	taken	using	separate	channels	for	calcein	(488	nm	laser	with	500-530	nm	bandpass	filter)	
and	TO-PRO-3.	Images	were	taken	at	four	locations	(Figure	2.2).	
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Figure 2.2. Locations imaged for calcein staining. X=0, Y=0 µm was set at the optic nerve and images 
were collected at the four locations indicated (x=±1000 µm, y=±850 µm). 
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2.7.3	Image	analysis	
Calcein	positive	cells	were	cells	double	stained	for	TO-PRO-3	and	calcein.	The	number	of	positive	cells	
in	a	300x300	µm2	square	were	counted	in	each	quadrant	of	each	explant	and	the	mean	count	was	
calculated	as	number	of	cells/mm2.	
2.8	Diolistics	
2.8.1	Bullet	preparation	
Diolistics	bullets	were	prepared	with	modifications	to	the	protocol	described	previously	(Gan	et	al.	
2000).	200	mg	tungsten	particles	(1.7	µm	diameter)	were	split	between	two	glass	slides.	Separately,	3	
mg	 1-1ʹ-dioctade-cyl-3,3,3ʹ,3ʹ-tetramethylindocarbocyanine	 perchlorate	 (DiI)	 and	 6	 mg	 3,3	
dioctadecyloxacarbocyanine	perchlorate	(DiO)	were	dissolved	in	800	µL	methylene	chloride	and	mixed	
with	half	of	the	tungsten	particles	to	coat.	DiI/DiO-coated	tungsten	particles	were	distributed	inside	
Tefzel	 tubing	 (Bio-rad,	Hertfordshire,	UK),	which	was	 then	 sealed	at	both	ends	and	mounted	on	a	
Tubing	Prep	station	(Bio-rad)	overnight	to	ensure	even	coating.	The	tubing	was	wrapped	in	aluminium	
foil	to	protect	from	light	and	stored	in	the	dark	to	prevent	photobleaching.	
2.8.2	Diolistic	labelling	method	
DiI/DiO-coated	tubing	was	cut	into	1.2	cm	‘bullets’,	which	were	placed	inside	the	cartridge	holder	of	
a	hand-held	Helios	gene	gun	(Bio-rad,	Figure	2.3).	The	gen	gun	was	mounted	on	a	stand	(built	in-house)	
to	ensure	that	the	barrel	was	perpendicular	to	the	retinal	surface.	DiI/DiO-coated	tungsten	particles	
were	 propelled	 at	 120	 psi	 (helium)	 through	 a	 3	 µm	 polyethylene	 terephthalate	 membrane	 filter	
(Scientific	Laboratory	Supplies	Ltd.)	to	prevent	clumping.	Explants	were	incubated	at	37°C	for	30	min	
to	allow	the	dye	to	distribute	through	the	cell	membranes.	Explants	were	cut	out	of	the	culture	inserts,	
mounted	on	glass	slides	(Scientific	Laboratory	Supplies	Ltd.),	washed	with	1xPBS,	and	fixed	in	4%	PFA	
for	10	min	in	a	moist	incubation	chamber.	Explants	were	washed	with	1xPBS	and	nuclear	stained	with	
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TO-PRO-3	 for	10	min.	Explants	were	washed	with	1xPBS,	 coverslipped	with	Prolong	gold	anti-fade	
reagent,	sealed	with	nail	varnish,	and	stored	in	the	dark	prior	to	imaging.
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Figure 2.3. Hand-held gene gun for ballistic delivery of lipophilic dye-coated tungsten particles 
(diolistics). The ‘bullets’ are loaded in the cartridge holder (white arrowhead). The particles are fired 
through a 3 µm filter (black arrowhead) into the retina (black arrow), with the barrel (white arrow) at a 
distance of 5 cm from the explant. 
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2.8.3	Confocal	microscopy	
Diolistically-labelled	explants	were	imaged	by	confocal	microscopy	(Zeiss)	within	24	hours	of	labelling	
to	prevent	 fading	of	 fluorescence.	RGCs	were	 identified	as	having	a	 soma	 in	 the	GCL	and	an	axon	
projecting	towards	the	optic	nerve.	512x512	or	1024x1024	pixel	8-bit	z-stacked	images	were	taken	in	
1	µm	intervals	through	the	entire	cell,	using	separate	channels	for	each	dye	(DiI,	523	nm	laser	and	
565-615	nm	bandpass	filter;	DiO,	488	nm	argon	laser	and	500-530	nm	bandpass	filter).	The	eccentricity	
relative	to	the	optic	nerve	head	was	recorded	for	each	cell.		
2.8.4	Neuron	tracing	and	Sholl	analysis	validation	
Images	were	imported	into	FIJI,	split	into	a	single	channel	image	(8-bit),	and	the	dendritic	arbor	was	
traced	in	three-dimensions	using	the	plug-in	Simple	Neurite	Tracer	(Longair	et	al.	2011).	The	longest	
primary	dendrite	was	extended	back	to	the	soma	centre	and	Sholl	analysis	(Sholl	1953)	was	carried	
out	in	10	µm	steps	up	to	a	maximum	radius	of	300	µm.	For	sub-type	analysis,	RGCs	were	divided	into	
ON	and	OFF	cells	based	on	their	stratification	depth.	Cells	with	dendrites	terminating	in	the	first	55%	
of	the	IPL	were	classified	as	ON,	those	with	dendrites	terminating	in	the	last	45%	of	the	IPL	were	OFF,	
and	cells	with	dendrites	in	both	layers	were	bistratified.	
In	order	to	validate	the	Simple	Neurite	Tracer	Sholl	analysis	method,	62	cells	were	also	analysed	using	
the	manual	method.	Concentric	rings	were	digitally	traced	onto	the	8-bit	tracing	image	(Figure	2.4)	
and	the	number	of	dendrites	on	each	ring	were	counted	and	plotted	as	a	function	of	eccentricity.	The	
Sholl	profiles	 for	both	methods	were	almost	 identical	and	Bland-Altman	plots	did	not	 indicate	 the	
presence	of	any	systematic	errors	(Binley	et	al.	2014).		
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Figure 2.4. 8-bit tracing of RGC with digitally overlain concentric (10 µm apart) circles centred on the 
soma centre for manual Sholl analysis. The number of dendrites on each ring were counted. Arrow 
indicates axon (not counted in analysis). Scale bar: 100 µm. 
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2.8.5	Branching	index	and	dendritic	field	area	calculations	
The	branching	index	was	calculated	using	the	Sholl	analysis	output	and	equation	2.1	(Garcia-Segura	
and	Perez-Marquez	2014),	
!"#$%ℎ'$(	'$*+, = 	 ./ −	 ./12/345/367 . ,	
Where	,9:2 = 10	µ> 
 ,9?/ = 300	µ>		
 $ = 10	µ> 
 ./ −	 ./12 	> 0 
Equation 2.1. Branching index calculation. 
 
The	 dendritic	 field	 area	 was	 measured	 as	 the	 area	 within	 a	 polygon	 connecting	 the	 terminal	
dendrites	of	a	dendritic	arbor	(Figure	2.5).	
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Figure 2.5. Dendritic field area was measured in FIJI by drawing a polygon connecting the terminal 
dendrites of an 8-bit tracing image. Arrow indicates axon (not included in measurement). Scale bar: 
100 µm. 
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2.9	Bacterial	culture	and	plasmid	preparation	
For	the	transformation	reaction	Luria-Bertani	(LB)	agar	(Sigma-Aldrich)	was	made	at	a	concentration	
of	32	g/L	in	a	sterile	250	mL	DURAN®	bottle.	To	dissolve,	the	mixture	was	microwaved	in	30	second	
periods	until	boiling	and	translucent,	and	autoclaved	on	a	25	min	liquid	cycle	(135°C)	to	sterilise.	The	
agar	was	allowed	to	cool	to	approximately	55°C,	at	which	point	ampicillin	(40	mg/mL	stock;	0.2	µm	
filtered	 (Scientific	 Laboratory	 Supplies	 Ltd.);	 Sigma-Aldrich)	 was	 added	 1:1000	 to	 create	 a	 final	
concentration	of	40	µg/mL.	The	plates	were	poured	(5	mm	depth)	and	allowed	to	set	(20	minutes)	
with	the	lids	slightly	off	to	allow	water	to	evaporate.	The	lids	were	replaced	and	plates	stored	inverted	
to	prevent	condensation	at	4°C.	
DH5α	cells	were	used	as	competent	cells.	The	competent	cells	and	plasmids	(PSD-95-GFP,	BDNF-myc,	
CAG-GFP)	were	put	on	ice	for	2	minutes	to	defrost.	25	µL	competent	cells	and	1	µL	plasmid	were	added	
to	the	same	tube,	followed	by	incubation	on	ice	for	30	minutes.	The	cells	were	then	heatshocked	at	
42°C	for	30	seconds,	put	on	ice	for	3	minutes,	and	50	µL	SOC	was	added	to	each	tube.	The	tubes	were	
incubated	at	37°C,	200	rpm	for	60	minutes.	Finally,	the	cells	were	plated	on	LB	agar	(as	described)	
using	glass	spreaders	(Sigma-Aldrich)	and	incubated	inverted	overnight	(17-24	hours)	at	37°C.	Sterile	
10	µL	pipette	tips	were	used	to	select	individual	colonies	that	were	uniform	in	shape	and	smaller	than	
4	mm	in	diameter.	The	tips	were	placed	in	separate	T75	flasks	containing	10	mL	LB	broth	(+80	µg/mL	
ampicillin;	Sigma-Aldrich),	which	were	incubated	on	a	rotatory	incubator	at	37°C,	170	rpm	overnight	
until	cloudy.		
For	 the	mini-prep	 reaction,	 2	mL	 culture	 broth	was	 removed	 and	 the	 plasmid	 purified	 as	 per	 the	
manufacturer’s	protocol.	The	plasmid	concentration	was	measured	using	a	nanodrop.	
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2.10	Enzyme-linked	immunosorbent	assay	(ELISA)	
2.10.1	Tissue	preparation	
Explants	were	cultured	as	described.	At	the	end	of	the	culture	period	retinas	(left	and	right	retinas	
pooled)	were	gently	placed	into	tubes	containing	50	µL	RIPA	buffer	+	10	µL	protease	inhibitor	(Roche,	
Welwyn	Garden	City,	UK)	and	snap	frozen	in	liquid	nitrogen.	Samples	were	stored	at	-80°C.	
Retinas	were	 re-suspended	 in	 a	 total	 of	 300	 µL	 lysis	 buffer	 (3.5	mL	 RIPA	 buffer	 +	 35	 µL	 protease	
inhibitor	 +	 35	 µL	 phosphatase	 inhibitor	 +	 17.5	 µL	 6-amihexanoic	 acid	 +	 3.5	 µL	 aprotinin	 +	 3.5	 µL	
phenotroline)	 and	 sonicated	 on	 ice	 with	 a	 probe	 sonicator	 until	 homogeneity	 was	 achieved.	
Homogenates	were	kept	on	ice	for	30	min,	sonicated	on	ice,	and	centrifuged	at	1500	rpm,	4°C	for	10	
min.	The	supernatants	were	transferred	to	clean	Eppendorf	tubes	and	the	pellets	discarded.		
2.10.2	Bicinchoninic	acid	(BCA)	assay	
The	protein	concentrations	of	homogenates	were	measured	using	a	BCA	kit	(Life	Technologies	Ltd.).	
Nine	BSA	protein	standards	(0.20	mg/mL,	0.15	mg/mL,	0.10	mg/mL,	0.075	mg/mL,	0.050	mg/mL,	0.025	
mg/mL,	0.0125	mg/mL,	0.00625	mg/mL,	0	mg/mL)	were	prepared	and	100	µL	of	each	standard	was	
added	to	100	µL	working	solution	(50	parts	reagent	A,	1	part	reagent	B),	in	triplicate,	in	a	96-well	plate.	
Tissue	samples	were	run	in	duplicate;	to	each	well	5	µL	sample	was	added	to	95	µL	dH2O	+	100	µL	
working	solution.	The	plate	was	covered	and	incubated	at	37°C	for	1	hour	and	the	absorbance	at	562	
nm	was	measured	using	a	luminometer	(Wallac	Victor2	1420	Multilabel	Counter;	Perkin	Elmer,	Akron,	
Ohio,	USA).	
2.10.3	Sandwich	ELISA	method	
The	Sandwich	ELISA	method	is	outlined	in	figure	2.6.	The	wells	of	a	96-well	plate	were	coated	with	
200	µL/well	of	3	µg/mL	mAb#1	in	coating	buffer	(50	mM	NaHCO3,	50	mM	Na2CO3,	pH	9.7).	The	plate	
was	covered	and	incubated	overnight	at	RT.	The	coating	solution	was	removed	and	the	plate	washed	
3x	with	washing	buffer	(1xPBS,	0.1%	Tween-20).	200	µL/well	blocking	buffer	(1xPBS,	4%	BSA	(Sigma-
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Aldrich))	was	incubated	for	2	hours	at	30°C.	The	plate	was	washed	3x	with	washing	buffer.	150	µL/well	
incubation	buffer	(0.1	M	KH2PO4,	0.1	M	Na2HPO4,	pH	7.6)	was	added,	along	with	50	µL/well	sample	or	
standard	 (25	ng/mL,	12.5	ng/mL,	6.25	ng/mL,	3.13	ng/mL,	1.56	ng/mL,	0.781	ng/mL,	0.391	ng/mL,	
0.195	ng/mL,	97.7	pg/mL,	48.8	pg/mL,	24.4	pg/mL,	12.2	pg/mL,	0	pg/mL)	in	triplicate,	and	incubated	
for	3	hours	on	a	rotating	platform	(300	rpm)	at	RT.	The	plate	was	washed	5x	with	washing	buffer	and	
200	µL/well	1:4000	(diluted	in	 incubation	buffer	+	4%	BSA)	mAb#9	(3.8	µg/µL	stock)	conjugated	to	
horseradish	peroxidase	 (HRP;	Roche)	was	added	and	the	plate	 incubated	for	3	hours	on	a	rotating	
platform	 (300	 rpm)	 at	 RT.	 The	 plate	 was	 washed	 5x	 with	 washing	 buffer.	 100	 µL/well	
chemiluminescent	substrate	(Roche)	was	added	and	luminescence	measured	using	a	luminometer.
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Figure 2.6. Sandwich ELISA method. (A) The plate is coated with mAb#9. (B) After blocking, the 
homogenised sample tissue is added to the plate and the target protein (BDNF) binds to the antibody. 
(C) The detecting Ab (mAb#9 conjugated to HRP) is added and binds to BDNF. (D) The substrate 
(luminol) is added and HRP catalyses the oxidation of luminol into 3-aminophthalate. This reaction is 
accompanied by a 428 nm emission, which is detected by the luminometer and can be converted into 
protein concentration. 
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2.11	NSC	culture	
All	work	with	NSCs	was	carried	out	in	a	laminar	flow	hood	using	sterile	equipment	to	minimise	risk	of	
contamination.	NSCs	were	originally	isolated	from	lysed	whole	brains	of	transgenic	C57/Bl6	mice	with	
GFP	 downstream	 of	 the	 actin	 promoter.	 NSCs	were	 cultured	 in	 12	mL	 DMEM/F-12	medium	 (+)L-
glutamine	(+)HEPES,	supplemented	as	outlined	in	Table	2.4,	at	37°C,	5%	CO2.	The	culture	medium	was	
made	up	in	a	sterile	100	mL	DURAN®	bottle	and	used	immediately.	Cells	were	cultured	in	upright	T25	
flasks	to	prevent	adherence	to	the	side	of	the	flask,	which	stimulates	auto-differentiation.	Cells	were	
grown	as	neurospheres	and	split	weekly	to	twice-weekly	to	prevent	cell	death	 in	the	centre	of	the	
neurospheres.	To	split	NSCs,	T25	flask	contents	were	decanted	into	25	mL	universal	tubes	and	spun	at	
1000	 rpm	 for	 5	min.	 The	medium	was	 aspirated,	 cells	were	 re-suspended	 in	 2	mL	Accutase®	 (Life	
Technologies	Ltd.)	and	incubated	in	a	37°C	water	bath	for	10-30	min,	or	until	the	neurospheres	were	
no	longer	visible.	Cells	were	then	spun	at	1000	rpm	for	5	min,	the	Accutase®	was	aspirated	and	cells	
were	re-suspended	in	the	previously	aspirated	12	mL	medium.	Finally,	cells	were	split	into	2	sterile	
T25	 flasks	 (6	 mL	 each)	 and	 flasks	 were	 topped	 up	 to	 12	mL	 using	 freshly	 prepared	 DMEM/F-12,	
supplemented	as	described	previously,	and	flasks	were	replaced	at	37°C,	5%	CO2.	
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Table 2.4. Culture medium and supplements for NSC culture. 
Component	 Concentration	 Role	 Company	
DMEM/F-12	(+)L-
glutamine	
(+)HEPES	
As	supplied	 Maintenance	of	mammalian	
cells	in	culture.	
Life	Technologies	
Ltd.	
Penicillin-
Streptomycin	
1%	(100	U/mL	
penicillin;	100	
µg/mL	
streptomycin)	
Antibiotics	to	minimise	
contamination	caused	by	both	
gram-positive	and	gram-
negative	bacteria.	
Life	Technologies	
Ltd.	
Non-Essential	
Amino	Acids	
Solution	
1%	 Growth	and	viability	of	cells.	 Life	Technologies	
Ltd.	
B-27	supplement	 2%	 Supports	growth	and	viability	
of	CNS	neurons.	
Life	Technologies	
Ltd.	
Fibroblast	growth	
factor	
10	ng/mL	 Maintenance	of	stem	cells	in	
an	undifferentiated	state.	
Peprotech,	London,	
UK	
Epidermal	growth	
factor	
10	ng/mL	 Mitogenic	factor.	 Peprotech	
Accutase®	 As	supplied	 Protease/collagenase	to	
dissociate	NSCs.	Gentler	action	
than	trypsin.	
Life	Technologies	
Ltd.	
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2.12	Magnetic	field	manipulation	of	NSC	migration	
Ten	 µg/mL	 laminin	was	 prepared	 by	 diluting	 1	mg/mL	 stock	 laminin	 in	 PBS	 (pH	 7.4),	 followed	 by	
filtration	through	a	0.2	µm	filter	to	sterilise.	1.5	mL	10	µg/mL	laminin	was	added	to	each	35	mm	culture	
dish	and	allowed	to	coat	the	bottom	of	the	dish	for	2	h	in	a	class	II	hood.	Dishes	were	washed	with	
sterile	PBS	and	allowed	to	dry	for	15	min.	Laminin-coated	dishes	were	stored	for	up	to	1	month,	sealed,	
at	4°C	prior	to	use.		
To	seed	NSCs,	the	laminin-coated	dishes	were	first	pre-conditioned	with	1.5	mL	DMEM/F-12	per	dish	
for	5	min	at	RT.	Meanwhile,	NSCs	were	dissociated	with	Accutase®	to	obtain	single	cells	in	suspension.	
The	medium	in	the	pre-conditioned	dishes	was	replaced	with	3	mL	NSC	suspension,	plated	at	a	density	
of	1.2-1.9	X	105	cells/cm2.	The	cells	were	incubated	overnight	at	37°C,	5%	CO2	to	allow	adherence	to	
laminin.			
Iron	 nanoparticles	 (100	 nm	 diameter;	 nTMag,	 Nanotherics	 Ltd.,	 Newcastle	 under	 Lyme,	 UK)	were	
introduced	into	the	NSCs	using	a	magnefect	nano	II	(Nanotherics).	1.5	µL	or	3	µL	mnps	were	inserted	
into	the	culture	medium	of	the	seeded	NSCs	and	the	35	mm	dish	was	placed	on	one	of	the	35	mm	
magnets	of	 the	6-well	 plate	magnefect	plate.	 The	magnefect	was	placed	at	37°C,	 5%	CO2	and	 the	
introduction	of	nanoparticles	into	the	cells	was	stimulated	for	30	min	using	0.2	mm	displacement	at	2	
Hz.	 The	medium	was	 replaced	with	Accutase®	 and	 cells	were	 incubated	 at	 37°C,	 5%	CO2	 for	 5-10	
minutes	until	>90%	of	cells	had	dissociated	from	the	laminin.	Cells	were	spun	down	at	1000	rpm	for	5	
minutes	and	resuspended	in	culture	medium	in	a	clean	35	mm	dish.	NSCs	were	immediately	imaged	
by	brightfield	microscopy	using	an	inverted	lens	(X10).	Images	of	NSCs	in	suspension	were	collected	
every	2.5	seconds	for	a	total	of	125	seconds,	and	images	of	NSCs	on	the	bottom	surface	of	the	dish	
were	collected	every	minute	for	a	total	of	9	minutes.	To	investigate	the	effect	of	magnetic	fields	on	
NSC	migration,	a	6.7	kg,	23	kg	or	38	kg-pull	permanent	NdFeB	magnet	(Supermagnete,	Germany)	or	a	
25	kg-pull	electromagnet	(EmagnetsUK,	Hertfordshire,	UK;	operated	at	0.2	A,	24	VDC)	was	positioned	
against	the	edge	of	the	culture	dish	(6.7	kg-pull	magnet)	or	10	mm	away	from	the	edge	of	the	culture	
Chapter	2:	Materials	and	Methods	
	
109	
dish	(all	other	magnets).	The	magnet	properties	are	outlined	in	Table	2.5	and	the	theoretical	magnetic	
field	strengths	are	shown	in	Figure	2.7.	The	imaging	protocol	described	previously	in	the	absence	of	
magnet	were	then	repeated.	 Imaging	was	always	carried	out	 immediately	after	the	introduction	of	
mnps	as	nanoparticles	are	degraded	by	cells	as	part	of	their	normal	iron	metabolism	pathway	(Bulte	
and	Kraitchman	2004)	and	to	prevent	NSCs	adhering	to	the	dish	surface.	
The	 magnetic	 field	 strengths	 for	 all	 the	 magnets	 at	 the	 distances	 used	 were	 measured	 using	 a	
Gaussmeter	 (built	 in-house,	 Dr.	 Turgut	 Meydan	 group,	 Wolfson	 Centre	 for	 Magnetics,	 Cardiff	
University).	The	theoretical	field	strengths,	calculated	using	Equation	2.2,	are	shown	in	Figure	2.7.	
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Table 2.5. Magnet properties for migration of NSCs. All magnets are cylindrical. Flux density values 
from http://www.ndfeb-info.com/neodymium_grades.aspx, last accessed 27.02.16. 
Magnet	(grade)	 Diameter	(mm)	 Height	(mm)	 Residual	flux	
density,	Br	(mT)	
Pull-force	(kg)	
NdFeB	(N42)	 15	 8	 1280	 6.7	
NdFeB	(N42)	 30	 15	 1280	 23	
NdFeB	(N45)	 35	 20	 1320	 38	
Electromagnet	 18	 20	 -	 25	
 
	
! B = 	!"2 D + BFG + D + B G − BFG + BG 	
	
Where			 B	=	Magnetic	flux	density	
	 	 X	=	distance	from	magnet	surface	
	 	 Br	=	Residual	flux	density	
	 	 H	=	Height	of	magnet	
	 	 R	=	Radius	of	magnet	
	
Equation 2.2. Magnetic field strength, B, for permanent cylindrical magnets at a given distance from 
the magnet surface (https://product.tdk.com/en/products/magnet/pdf/e371_circuit.pdf, last accessed 
28.02.16). 
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Figure 2.7. Hypothetical magnetic field strengths of all NdFeB magnets used as a function of distance 
from the magnet surface calculated using the properties in Table 2.5 and Equation 2.2. 
	
Chapter	2:	Materials	and	Methods	
	
112	
Images	were	exported	as	TIFF	files	and	imported	into	FIJI	for	cell	tracking	analysis.	To	measure	the	
migration	paths	of	the	cells,	the	manual	tracking	plugin	(http://fiji.sc/Manual_Tracking;	last	accessed	
14.01.16)	was	used	to	track	all	cells	present	in	the	first	1200	µm	from	the	edge	of	the	dish	next	to	the	
magnet	 surface	 (6.7	 kg-pull	 magnet)	 or	 in	 the	 first	 900	 µm	 from	 the	 edge	 of	 the	 dish	 (all	 other	
magnets).	 The	 track	 data	 were	 then	 imported	 into	 Chemotaxis	 plugin	
(http://ibidi.com/xtproducts/en/Software-and-Image-Analysis/Manual-Image-Analysis/Chemotaxis-
and-Migration-Tool;	 last	 accessed	 14.01.16),	 which	 was	 used	 to	 analyse	 the	 mean	 accumulated	
distance,	mean	euclidean	distance	(figure	2.8),	mean	velocity,	x	forward	migration	index,	y	forward	
migration	index,	x	centre	of	mass,	and	y	centre	of	mass	for	all	experiments.	Equations	S1-S4	for	all	
calculated	indices	can	be	found	in	the	Appendix.	
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Figure 2.8. The accumulated distance is calculated as the distance covered by a cell throughout its 
migration track. The euclidean distance is the straight-line distance connecting the start and end 
positions of the cell, as shown. Both distances are calculated automatically using the Chemotaxis 
plugin. 
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2.13	Cell	transplantation	into	explants	
To	test	 the	depth	and	speed	of	migration	of	NSCs	within	 tissue,	 retinal	explants	were	prepared	as	
described	in	2.2	and	a	topical	2	mL	aliquot	of	NSCs	immediately	post-splitting	(re-suspended	in	NSC	
culture	medium)	at	a	density	of	1	X	105	cells/cm2	was	placed	directly	on	the	explant.	The	explant	was	
incubated	at	37°C,	5%	CO2	for	3	h	with	the	35	mm	dish	positioned	on	top	of	a	38	kg-pull	magnet,	or	
on	the	incubator	shelf	only	as	control.	At	the	end	of	the	culture	period	the	explant	was	fixed	in	4%	PFA	
for	15	minutes,	nuclear	 stained	using	TO-PRO-3	 (10	min),	and	coverslipped	with	Slo-fade	diamond	
mountant	(Invitrogen).	Explants	were	immediately	imaged	by	confocal	microscopy	using	the	633	nm	
laser	for	TO-PRO-3	visualisation,	and	the	488	nm	argon	laser	(500-530	nm	bandpass	filter)	for	GFP.	
The	stage	was	centred	on	the	optic	nerve	(X=0,	Y=0)	and	four	z-stacked	images	in	each	quadrant	of	
the	retina	were	collected.	Z-stacked	1024x1024	pixel	8-bit	images	were	taken	in	1	µm	slices	from	the	
start	of	the	GCL	to	the	INL.	The	green	channel	settings	were	kept	constant	for	all	images.	Images	were	
imported	into	FIJI	and	in	each	case	the	depth	of	the	IPL	was	measured.	All	GFP+ve	cells	were	drawn	
around	using	the	polygon	tool	and	the	green	channel	intensity	was	measured	in	every	slice.	The	green	
channel	intensity	was	expressed	as	%	IPL	depth.
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Chapter	3:	Characterisation	of	the	Mouse	Retinal	Explant	
3.1	Introduction	
The	murine	retinal	explant	remains	a	popular	model	for	the	investigation	of	CNS	disorders	(Johnson	
and	Martin	2008;	Guerin	et	al.	2011;	Wood	et	al.	2011).	Since	the	neuronal	cell	 loss	resulting	from	
axotomy	performed	at	the	time	of	dissection	is	a	common	end	point	in	all	neurodegenerative	diseases,	
this	 model	 has	 widespread	 applications.	 Further,	 short	 experimental	 time	 and	 the	 acquisition	 of	
translatable	data	are	major	advantages	of	the	explant	over	in	vivo	and	in	vitro	models,	respectively.	
The	primary	readout	for	this	model	is	typically	cell	loss,	which	fails	to	provide	information	regarding	
synaptic	 and	 structural	 changes	 to	 the	 cells	 prior	 to	 cell	 death,	 nor	 does	 it	 allow	 investigation	 of	
mechanisms	under	a	pathological	state.	The	lack	of	morphometric	data	is	a	major	limitation	of	this	
work	to	date.		
Predicated	on	widespread	evidence	 that	dendritic	pruning	precedes	cell	 loss	 in	neurodegenerative	
diseases	 including	 Parkinson’s	 disease	 (Patt	 et	 al.	 1991),	 Alzheimer’s	 disease	 (Selkoe	 2002)	 and	
glaucoma	(Weber	et	al.	1998),	I	investigated	whether	morphometric	analysis	of	RGC	dendritic	arbors	
could	provide	information	about	neuronal	cell	health.	Sholl	analysis	(Sholl	1953)	quantifies	dendrites	
as	a	function	of	eccentricity,	with	loss	of	distal	dendrites	manifesting	as	a	leftward	shift	in	the	Sholl	
profile,	 and	 a	 reduced	peak	 amplitude	 indicates	 a	 loss	 of	 proximal	 dendrites.	 The	data	 from	Sholl	
analysis	can	be	used	to	derive	the	branching	index,	described	by	Garcia-Segura	and	Perez-Marquez	
(Garcia-Segura	and	Perez-Marquez	2014),	which	quantifies	the	shape	of	the	dendritic	arbor	(Figure	
3.1).	
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Figure 3.1. The branching index is an indicator of cell shape. A small branching index indicates a low 
number of branching events or that branching is predominantly proximal. A large branching index 
indicates a high number of branching events or that branching mainly occurs distally. Note that the two 
cells on the far right have the same number of dendrites, but due to different branching eccentricities 
they have very different branching indices. The branching index is calculated using Equation 2.1 (see 
Materials and Methods). 
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In	order	to	quantify	dendritic	arbors,	cells	must	be	discretely	labelled.	Morphologically,	RGCs	are	an	
extremely	 heterogeneous	 population	 of	 neurons;	 their	 shape	 varies	 with	 sub-type	 as	 well	 as	
eccentricity	(Sun	et	al.	2002;	Coombs	et	al.	2006).	In	order	to	reduce	bias,	it	is	essential	that	labelling	
is	random.	Techniques	such	as	the	use	of	transgenic	animals	that	rely	on	reporter	gene	expression	are	
inherently	 biased	 since	 they	 select	 for	 the	 healthiest	 cells	 that	 can	 afford	 the	 energy	 demands	 of	
translating	reporter	proteins.	Consequently,	the	unhealthiest	cells,	which	may	have	undergone	the	
greatest	 morphological	 changes,	 are	 less	 likely	 to	 express	 the	 reporter	 protein,	 thus	 resulting	 in	
underreporting	 of	 dendritic	 pruning,	 as	 demonstrated	 by	 Williams	 et	 al.	 (2013a).	 Further,	 the	
expression	of	Thy1,	a	commonly	used	driver	for	RGC-specific	expression,	has	been	found	to	be	both	
downregulated	(Huang	et	al.	2006)	and	upregulated	(Lee	et	al.	1998;	Astafurov	et	al.	2014)	following	
optic	nerve	 injury	or	 stress.	 Single	 cell	 filling	 is	 technically	 challenging	and	may	be	biased	 towards	
larger	cells.	Retrograde	labelling	commonly	results	in	dense	staining	patterns	and	requires	an	intact	
axon,	 which	may	 result	 in	 bias	 towards	 cells	 resistant	 to	 axonal	 degeneration	 or	 cells	 with	more	
efficient	 axonal	 transport	 machinery.	 Ballistic	 delivery	 of	 dye	 particles	 (diolistics)	 or	 plasmids	
(biolistics)	labels	cells	in	a	random	manner.	Since	biolistics	requires	a	2	d	incubation	period	to	permit	
sufficient	expression	 levels	of	XFP	and	 the	only	 requirement	 for	 successful	diolistics	 labelling	 is	 an	
intact	plasma	membrane,	I	used	diolistics	to	label	RGCs	for	their	morphometric	analysis	over	a	3	day	
period.	This	was	compared	to	cell	counts	data	in	order	to	delineate	degenerative	events	in	this	model.	
3.2	Gross	tissue	morphology	
En-face	photographs	were	taken	of	4	explants	immediately	after	dissection,	after	6	h,	1	d	and	daily	
thereafter	up	to	14	d.	Images	were	used	to	measure	the	surface	area	of	explants	in	order	to	account	
for	potential	oedema,	which	has	been	reported	to	occur	in	organotypic	culture	(Wurm	et	al.	2009).	
Measurements	 indicated	 no	 significant	 change	 in	 area	 (P>0.05	 by	 ANOVA	 with	 TUKEY	 post-hoc)	
throughout	the	14	d	culture	period	(Figure	3.2).
Chapter	3:	Characterisation	of	the	Mouse	Retinal	Explant	
	
118	
Figure 3.2 Gross tissue area measurements of explants cultured for up to 14 d. (a) En face 
photographs of explants at each time point. (b) Mean areas of explants. P>0.05, ANOVA with TUKEY 
post-hoc. Scale bar: 1 mm. Error bars: SEM. N=4 retinas, 4 animals for all time points. 
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3.3	Retinal	layer	architecture	
Cryosections	of	18	explants	cultured	for	up	to	14	d	were	nuclear	stained,	with	half	of	sections	in	each	
group	defined	as	peripheral	and	the	remainder	as	central.	To	minimise	the	effects	of	oedema,	linear	
cell	counts	of	the	GCL	were	made.	Cell	layer	thickness	was	measured	for	the	INL	and	ONL	to	complete	
histological	analysis	of	cell	layers.		
GCL	 nuclear	 counts	 remained	 relatively	 constant	 until	 14	 d,	when	 there	was	 a	 decrease	 of	 37.5%	
(P=0.001	by	ANOVA	with	Tukey	post-hoc).	The	INL	and	ONL	both	showed	thinning	after	3	d,	which	
subsequently	plateaued.	The	INL	thickness	reduced	by	24.5%	(P<0.001	by	ANOVA	with	TUKEY	post-
hoc)	after	3	d,	and	25.2%	(P<0.001)	by	14	d.	The	ONL	thickness	reduced	by	16.4%	(P<0.001	by	Mann-
Whitney	with	Bonferroni	correction)	after	3	d,	and	by	25.3%	(P<0.001)	by	14	d	(Figure	3.3).	
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Figure 3.3. Retinal cell layer measurements for explants cultured for up to 14 days, as shown. (a) 
Confocal images of TO-PRO-3 stained sagittal cryosections. (b) Nuclei counts for GCL (left) and 
measured thicknesses of INL (middle) and ONL (right). **P<0.005, ***P<0.001, ANOVA with TUKEY 
post-hoc (GCL and INL), Mann-Whitney with Bonferroni correction (ONL). Scale bar: 100 µm. Error 
bars: SEM. N=5 retinas (0 days), n=6 retinas (3 days), n=3 retinas (7 days), n=4 retinas (14 days). 
GCL=ganglion cell layer, INL=inner nuclear layer, ONL=outer nuclear layer. At least 3 sections from 
each retina were used at each time point. 
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3.4	Thy1.2	and	active	caspase-3	levels	
Frozen	sections	of	explants	cultured	for	0	d,	3	d,	7	d	and	14	d	were	analysed	immunohistochemically	
for	the	expression	of	neuronal	marker	Thy1.2	and	apoptotic	marker	active	caspase-3.	Thy1.2	levels	
were	significantly	higher	in	the	GCL	and	IPL	relative	to	the	other	layers,	and	could	therefore	be	used	
to	 successfully	 identify	 the	GCL	 at	 all	 time	 points.	 In	 the	GCL	 and	 IPL	 Thy1.2	 staining	 significantly	
increased	after	day	0	(3.5-fold	increase	at	day	3,	P<0.005,	ANOVA	with	TUKEY	post-hoc),	and	remained	
elevated	for	the	remainder	of	the	experiment	(Figure	3.4a-b).	The	number	of	active	caspase-3	positive	
cells	in	the	GCL	and	INL	showed	a	trend	of	increasing	with	the	number	of	days	cultured	but	this	did	
not	reach	statistical	significance	(P>0.05,	Mann-Whitney	tests	with	Bonferroni	correction;	Figure	3.4c-
e).	 After	 14	 d	 active	 caspase-3	 staining	 increased	 4.4-fold	 (P<0.05,	 Mann-Whitney	 tests	 with	
Bonferroni	correction)	in	the	ONL	(Figure	3.4f).
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Figure 3.4. Immunohistochemistry staining for the neuronal marker Thy1.2 and the apoptotic marker 
active caspase-3. (a) Frozen sections of retinas cultured for up to 14 d, as indicated. White arrows 
indicate active caspase-3 positive cells in magnified sections of the above images, as indicated. Scale 
bars: 100 µm (top and middle); 10 µm (bottom). (b) Quantification of Thy1.2 staining in each layer 
measured by mean green channel intensity. **P<0.005, ***P<0.001, ANOVA with TUKEY post-hoc. (c) 
The number of active caspase-3 positive cells in the GCL. (d) The number of active caspase-3 positive 
cells in the GCL expressed as a percentage of total number of cells in the GCL. (e) The number of 
active caspase-3 positive cells in the INL. (f) The number of active caspase-3 positive cells in the ONL. 
*P<0.05, Mann-Whitney with Bonferroni correction. Error bars: SEM. Thy1.2: n=3 retinas, 2 animals (0 
d); n=3 retinas, 3 animals (3 d); n=3 retinas, 3 animals (7 d); n=5 retinas, 5 animals (14 d). Active 
caspase-3: n=5 retinas, 3 animals (0 d); n=3 retinas, 3 animals (3 d); n=3 retinas, 3 animals (7 d); n=5 
retinas, 5 animals (14 d).
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3.5	Cell	viability	in	the	degenerating	explant	
Frozen	sections	of	explants	cultured	for	0	d,	3	d,	7	d	and	14	d	were	analysed	for	DNA	breakdown,	a	
marker	of	apoptosis,	by	TUNEL	assay.	 In	all	 layers	 there	was	minimal	 staining	at	day	0.	 In	 the	GCL	
staining	peaked	at	day	3	(4.0-fold	increase,	P<0.001).	In	the	other	two	layers	staining	peaked	at	day	7	
(INL	3.5-fold	 increase,	P<0.05;	ONL	24-fold	 increase,	P<0.001,	Mann-Whitney	tests	with	Bonferroni	
correction	for	all;	Figure	3.5).
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Figure 3.5. TUNEL staining. (a) Frozen sections of retinal explants cultured for up to 14 d labelled for 
DNA breakdown using TUNEL assay. TUNEL positive cells are stained for both FITC (green) and TO-
PRO-3 nuclear stain (blue). Positive controls were sections pre-incubated in proteinase K for 1 hour. 
Negative controls had no incubation with Avidin-FITC. White arrows indicate TUNEL positive cells in 
magnified sections of the above images, as indicated. Scale bars: 100 µm (top), 10 µm (bottom). (b) 
Quantification of TUNEL staining in each layer measured by green channel fluorescence. *P<0.05, 
**P<0.005, ***P<0.001 (Mann-Whitney with Bonferroni correction). Error bars: SEM. N=4 retinas, 3 
animals (0 d); n=4 retinas, 4 animals (3 d); n=3 retinas, 3 animals (7 d); n=3 retinas, 3 animals (14 d). 
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The	number	of	viable	cells	was	quantified	in	13	whole,	unfixed	explants	cultured	for	0	d,	1	d,	7	d	and	
14	d	using	the	calcein-AM	assay.	Calcein-AM	passes	across	cell	membranes	and	if	the	cell	contains	
active	esterases,	 the	AM	is	cleaved,	allowing	the	fluorescent	protein,	calcein,	 to	be	quantified	as	a	
measure	of	cell	viability	(Decherchi	et	al.	1997).	Although	there	was	a	trend	towards	a	decrease	 in	
calcein	positive	cells	after	1	d,	this	did	not	reach	statistical	significance	at	any	point	(P>0.05,	ANOVA	
with	 TUKEY	 post-hoc).	 Indeed,	 it	 was	 noted	 that	 there	 was	 a	 large	 amount	 of	 variation	 between	
explants	at	the	same	culture	period,	as	indicated	by	the	large	error	bars	in	Figure	3.6.	
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Figure 3.6. Calcein staining. (a) En face images of retinal wholemounts stained with calcein (green) 
and TO-PRO-3 (blue) immediately after dissection (0 d) and after 1, 7 and 14 days in culture, as 
indicated. Cells stained for both calcein and TO-PRO-3 were counted in the central 300x300 µm, as 
shown. Scale bars: 100 µm. (b) Quantification of calcein staining measured as number of calcein 
positive cells per mm2 at the same locations in each explant (x=1000 µm, y=850 µm; x=1000 µm, y=-
850 µm; x=-1000 µm, y=-850 µm; x=-1000 µm, y=850 µm where the origin is the optic nerve as 
described in Figure 2.2). Error bars: SEM. N=4 retinas, 4 animals (0 d), n=3 retinas, 3 animals (1 d), 
n=3 retinas, 3 animals (7 d), n=3 retinas, 3 animals (14 d). P>0.05, ANOVA with TUKEY post-hoc. 
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3.6	Morphometric	analysis	of	RGCs	over	3	days	
One	hundred	and	ninety-five	RGCs	from	fifty	explants	(n=38	animals	of	both	sex,	aged	1.5	–	5	months)	
cultured	for	0	d,	6	h,	1	d,	2	d	and	3	d	were	labelled	diolistically	and	their	dendritic	arbors	quantified	by	
Sholl	analysis.	There	was	an	obvious	loss	of	dendrites	over	the	3	d	culture	period	(Figure	3.7a-c),	which	
was	quantified	as	a	leftward	shift	in	the	Sholl	profile	over	the	first	24	h,	proceeded	by	a	reduction	in	
peak	 amplitude	 between	 day	 1	 and	 day	 2	 (Figure	 3.7d).	 The	 Sholl	 area	 under	 the	 curve	 (AUC)	
decreased	by	14.5%	(P<0.05)	after	6	h,	and	continued	to	decrease	by	a	maximum	of	56.7%	(P<0.001,	
Mann-Whitney	tests	with	Bonferroni	correction	for	both)	at	day	3	(Figure	3.7e).	The	branching	index	
decreased	by	41.9%	(P<0.005,	ANOVA	with	TUKEY	post-hoc)	after	1	d	and	remained	relative	constant	
thereafter	(Figure	3.7f).	
In	 order	 to	 account	 for	 sub-type	 bias,	 all	 RGCs	 were	 grouped	 based	 on	 stratification	 depth	 and	
categorised	as	ON,	OFF	or	bistratified	(see	section	2.8.4).	There	was	no	significant	difference	in	Sholl	
AUC	between	sub-groups	within	the	same	culture	period	(P>0.05).	Sholl	AUC	showed	a	general	trend	
of	reducing	with	increased	culture	period,	irrespective	of	sub-group.	ON	cells	showed	a	reduction	in	
Sholl	AUC	of	49.0%	(P<0.001)	after	2	d	and	61.0%	(P<0.001)	after	3	days	(Figure	3.7g).	OFF	cells	had	a	
decreased	Sholl	AUC	of	37.9%	(P<0.005)	after	1	day	and	30.1%	(P<0.05)	after	2	days	(Figure	3.7h).	The	
Sholl	 AUC	 of	 ON-OFF	 cells	 was	 reduced	 by	 49.9%	 (P<0.05,	 Mann-Whitney	 tests	 with	 Bonferroni	
correction	for	all)	after	2	days	(Figure	3.7i).
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Figure 3.7 (previous page). Morphometric analysis of RGCs. (a) Representative fluorescent images 
of RGCs labelled by diolistics after 0 days, 6 hours, 1 day, 2 days, and 3 days explant culture, as shown. 
Images are 512x512 pixels (0 d) or 1024x1024 pixels (rest). Scale bars: 100 µm. Arrows indicate axons. 
(b) Locations of all analysed RGCs at each time point where the origin in the optic nerve. All plots show 
no evidence of bias in terms of eccentricity. (c) Diagram of prepared explant for orientation of location 
plots. D = dorsal, T = temporal. Scale bar: 1 mm. (d) Sholl profiles for RGCs at each time point, with 
the number of cells indicated. (e) Sholl AUC at each time point calculated using the trapezoidal model. 
(f) Branching index for RGCs at each time point, calculated using the Sholl analysis output as described 
in chapter 2.8.5. (g) Sholl AUC plots for ON stratifying cells only. N=28 cells (0 d), n=14 cells (6 h), n=13 
cells (1 d), n=26 cells (2 d), n=28 cells (3 d). (h) Sholl AUC plots for OFF stratifying cells only. N=12 
cells (0 d), n=4 cells (6 h), n=8 cells (1 d), n=8 cells (2 d), n=5 cells (3 d). (i) Sholl AUC plots for ON-
OFF stratifying cells only. N=11 cells (0 d), n=6 cells (6 h), n=11 cells (1 d), n=7 cells (2 d), n=4 cells (3 
d). *P<0.05, **P<0.005, ***P<0.001 (Mann-Whitney tests with Bonferroni correction for all Sholl AUC; 
ANOVA with TUKEY post-hoc for branching index). Error bars: SEM.  
	
To	check	that	labelling	was	random,	all	61	cells	labelled	at	0	d	were	classified	according	to	the	RGC	
classification	system	outlined	by	Sun	et	al.	using	soma	diameter,	DF	diameter	and	stratification	depth	
(Sun	et	al.	2002).	The	proportion	of	cells	in	each	classification	group	were	found	to	be	similar	to	those	
reported	by	Sun	et	al.	and	more	importantly,	there	was	a	good	spread	of	different	sub-types	of	RGC	
labelled	(Table	3.1).	
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Table 3.1. Proportion of RGC sub-types from 0 d explants classified according to Sun et al., 2002. 
Group	 Number	 %	of	population	 %	in	Sun	et	al.	
A1	 2	 3.3	 4.5	
A2	 8	 13.1	 5.5	
Total	A	 10	 16.4	 10.0	
B1	 4	 6.6	 4.5	
B2	 2	 3.3	 9.0	
B3	 11	 18.0	 10.6	
B4	 3	 4.9	 5.7	
Total	B	 20	 32.8	 29.8	
C1	 1	 1.6	 3.1	
C2	 8	 13.1	 10.2	
C3	 0	 0.0	 2.4	
C4	 2	 3.3	 5.9	
C5	 3	 4.9	 11.2	
C6	 4	 6.6	 4.5	
Total	C	 18	 29.5	 37.3	
D1	 3	 4.9	 7.3	
D2	 10	 16.4	 15.5	
Total	D	 13	 21.3	 22.8	
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In	order	to	check	that	there	were	no	confounding	variables	that	may	have	affected	Sholl	analysis	data,	
a	multiple	regression	analysis	was	carried	out	on	all	Sholl	AUC	results	from	all	explants	cultured	for	0	
–	3	days.	The	dependent	variable	was	AUC,	and	the	independent	variables	were	culture	period,	age,	
and	sex.	This	regression	model	was	described	to	be	a	good	fit	of	the	data	(P<0.001,	ANOVA).	Culture	
period	was	the	only	explanatory	variable	of	Sholl	AUC	(B	=	-228,	P<0.001,	Table	3.2),	indicating	that	
the	length	of	culture	period	was	the	only	factor	that	caused	a	change	in	the	RGC	dendritic	morphology.		
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Table 3.2. Multiple regression model exploring predictive factors of Sholl AUC (dependent variable). In 
this model culture period (0=0 d, 1=6 h, 2=1 d, 3=2 d, 4=3 d), age (number of months), and sex (1=male, 
2=female) were predictors. 
Variable	 Coefficient	(B)	 P	
Culture	period	 -228	 7.08	X	10-10	
Age	 93.6	 0.126	
Sex	 -82.4	 0.410	
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3.7	Pan-caspase	inhibition	
To	explore	 the	 involvement	of	pan-caspase	activation	 in	dendritic	atrophy	of	RGCs	and	to	 test	 the	
sensitivity	 of	 the	 morphometric	 readout	 in	 the	 explant	 model	 9	 explants	 (n=6	 animals,	 aged	 3-4	
months,	female)	were	cultured	with	the	pan-caspase	inhibitor	Q-VD	for	2	d.	A	2	d	treatment	window	
was	selected	based	on	the	evidence	that	there	is	substantial	dendritic	atrophy	within	this	time	frame.	
RGCs	were	diolistically	labelled	(Figure	3.8a-b)	and	their	dendritic	arbors	quantified	by	Sholl	analysis,	
as	outlined	previously.	Q-VD-treated	cells	were	partially	protected	from	dendritic	retraction;	3	points	
on	the	Sholl	profile	10-30	µm	from	the	soma	(Figure	3.8c)	were	increased	relative	to	control	(P<0.05,	
Kruskal-Wallis),	 indicating	 an	 effect	 on	 proximal	 dendrites	 only.	 Although	 none	 reached	 statistical	
significance	(P>0.05),	all	three	morphometric	parameters	measured	(Sholl	AUC,	branching	index	and	
dendritic	 field	 area)	 showed	 the	 trend	 of	 an	 increase	 with	 Q-VD	 treatment,	 relative	 to	 controls,	
although	all	measurements	for	control	and	Q-VD-treated	cells	were	significantly	reduced	(P<0.001,	
ANOVA	with	 TUKEY	 post-hoc)	 compared	 to	 0	 d	 cells	 (Figure	 3.8d-f).	 The	 experimental	 timeline	 is	
illustrated	in	Figure	3.8g.	
To	account	for	cell	sub-type	bias	and	to	investigate	any	group-specific	effects	of	pan-caspase	inhibition	
the	cells	were	split	into	ON,	OFF	and	ON-OFF,	according	to	their	stratification	depth	in	the	IPL.	There	
was	no	significant	difference	(P>0.05)	between	Sholl	AUC	for	control	cells	and	Q-VD-treated	cells	that	
were	ON	or	OFF	stratified,	however	for	both	treatment	groups	both	ON	and	OFF	subtypes	had	Sholl	
AUCs	that	were	significantly	reduced	(P<0.05,	ANOVA	with	TUKEY	post-hoc)	relative	to	0	d	cells	of	the	
same	 subtype	 (Figure	 3.8h-i).	 There	 were	 no	 control	 cells	 that	 were	 bistratified	 so	 comparisons	
between	controls	and	Q-VD-treated	cells	could	not	be	made	for	this	subtype,	however	Q-VD-treated	
ON-OFF	cells	had	a	significantly	reduced	(P<0.05,	ANOVA)	Sholl	AUC	relative	to	0	d	cells	(Figure	3.8j).	
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Figure 3.8 (previous page). Morphometric analysis of RGCs treated with the pan-caspase inhibitor Q-
VD over 2 d. (a) Representative fluorescent images (left) of diolistically labelled RGCs and their 
respective 8-bit tracing images (right) from explants treated with Q-VD or vehicle only as control. Arrows 
indicate axons. Scale bars: 100 µm. (b) Locations of all analysed cells in each treatment group plotted 
relative to the optic nerve (origin). Neither group displayed any sign of bias in terms of eccentricity. (c) 
Sholl plots for both treatment groups with the number of cells analysed for each group shown *P<0.05, 
Kruskal-Wallis. (d) Sholl AUC for both treatment groups shown with the value for 0 d cells for 
comparison. ***P<0.001, ANOVA with TUKEY post-hoc. (e) Branching index for both treatment groups 
shown with the value for 0 d cells for comparison. ***P<0.001, ANOVA with TUKEY post-hoc. (f) 
Dendritic field area for both treatment groups shown with the value for 0 d cells for comparison. 
***P<0.001, ANOVA with TUKEY post-hoc. (g) Experimental time scale. (h) Sholl AUC plots for ON 
stratifying cells only. N=28 cells (0 d), n=2 cells (control), n=10 cells (Q-VD). *P<0.05, **P<0.005, 
ANOVA with TUKEY post-hoc. (i) Sholl AUC plots for OFF stratifying cells only. N=12 cells (0 d), n=9 
cells (control), n=13 cells (Q-VD). **P<0.005, ***P<0.001, ANOVA with TUKEY post-hoc. (j) Sholl AUC 
plots for ON-OFF stratifying cells only. N=11 cells (0 d), n=0 cells (control), n=1 cell (Q-VD). *P<0.05, 
ANOVA. Error bars: SEM.	
In	order	to	check	that	age	was	not	a	confounding	factor,	a	multiple	regression	analysis	was	run	on	
Sholl	AUC	 values	 for	Q-VD-treated	 cells.	 The	model	was	 a	 good	 fit	 of	 the	data	 (p<0.005,	ANOVA).	
Culture	 condition	 (i.e.	Q-VD	 treatment)	 and	 age	were	 explanatory	 variables	 (p<0.05)	 of	 Sholl	 AUC	
(Table	3.3).	
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Table 3.3. Multiple regression model exploring predictive factors of Sholl AUC (dependent variable). In 
this model culture condition (1=control, 2=Q-VD), age (number of months), were explanatory variables. 
Variable	 Coefficient	(B)	 P	
Culture	condition	 464	 0.005	
Age	 538	 0.001	
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3.8	Conclusions	
In	this	chapter	the	aim	was	to	characterise	the	mouse	retinal	explant	in	terms	of	cellular	changes	
over	time	and	to	investigate	the	potential	of	morphometric	analysis	of	RGCs	to	quantify	neuronal	
cell	health.		
Prior	work	(Johnson	and	Martin	2008)	has	shown	that	the	retinal	architecture	can	be	maintained	for	
at	least	14	d.	Although	the	number	of	cells	in	the	INL	and	ONL	were	not	counted,	the	respective	
layer	thicknesses	can	be	used	as	a	reasonable	estimate	of	cell	loss	since	there	was	no	evidence	of	
lateral	expansion	of	the	tissue	over	time.	It	was	interesting	to	note	that	the	INL	and	ONL	begun	to	
show	signs	of	degeneration	11	days	before	the	GCL,	in	line	with	the	literature	(Mazzoni	et	al.	2008;	
Garcia-Ayuso	et	al.	2010).	This	is	likely	because	photoreceptors	are	more	susceptible	to	oxidative	
stress	and	degeneration	has	been	shown	to	pass	along	neuronal	pathways	by	a	process	termed	
‘transneuronal	degeneration’	(Lei	et	al.	2008).	
The	pattern	of	viability	markers	did	not	correlate	with	cell	loss	in	the	GCL.	Further,	the	timelines	of	
viability	assays	were	inconsistent	with	one	another;	in	the	GCL	active	caspase-3	and	calcein	staining	
did	not	change	over	14	d	but	TUNEL	staining	peaked	at	3	d.	Although	the	patterns	of	TUNEL	and	active	
caspase-3	labelling	resembled	those	in	the	literature	(Johnson	and	Martin	2008;	Ferrer-Martin	et	al.	
2014),	measurement	of	DNA	damage	may	not	be	a	good	indicator	of	apoptosis.	It	has	been	proposed	
that	it	is	the	ability	of	cells	to	repair	DNA	damage,	and	not	the	DNA	damage	itself,	that	determines	the	
likelihood	of	cell	death	(Brown	and	Wilson	2003).	Further,	the	TUNEL	assay	also	labels	DNA	breaks	
associated	 with	 normal	 DNA	 turnover	 and	 necrosis	 (Elmore	 2007),	 the	 latter	 of	 which	 has	 been	
reported	to	be	a	major	cause	of	cell	death	in	axotomy	models	(Kashimoto	et	al.	2008).	Additionally,	
active	caspase-3	may	not	be	a	reliable	marker	of	apoptosis,	particularly	as	 it	 remained	constant	 in	
every	cell	layer,	other	than	the	ONL.	This	suggests	that	active	caspase-3	was	not	implicated	in	cell	loss	
in	 the	 explant.	 This	 idea	 is	 supported	 by	 the	 evidence	 that	 cultured	 RGCs	 can	 die	 by	 caspase-
independent	apoptosis	(Tezel	and	Yang	2004;	McKernan	et	al.	2007).	The	lack	of	significant	apoptotic	
Chapter	3:	Characterisation	of	the	Mouse	Retinal	Explant	
	
138	
staining	reported	here	could	 indicate	that	cell	death	occurred	rapidly,	 i.e.	the	period	 in	which	cells	
were	undergoing	apoptosis	and	would	be	 labelled	as	 such	was	 so	 short	 that	 cells	either	appeared	
healthy	or	were	completely	degraded,	however	this	seems	unlikely	since	cell	loss	in	the	GCL	was	not	
significant	 until	 14	 days.	 A	 more	 plausible	 explanation	 is	 that	 caspase-independent	 cell	 death	
pathways	had	been	triggered,	resulting	 in	DNA	damage,	but	cell	death	did	not	begin	to	occur	until	
after	7	days.	These	data	 support	 the	use	of	 cell	 loss	 to	quantify	 cell	death.	The	 lack	of	 supporting	
calcein	staining	is	likely	due	to	poor	tissue	penetration	and	therefore	would	require	future	validation	
–	 calcein	 staining	may	be	more	appropriate	 to	 test	 viability	 in	 cell-based	assays	 rather	 than	 tissue	
preparations.	Although	it	has	been	reported	in	the	rat	retinal	explant	(Grieshaber	et	al.	2010),	calcein	
staining	 is	 more	 commonly	 used	 to	 label	 cells	 (Goldberg	 et	 al.	 2002;	 Kador	 et	 al.	 2013).	 Tissue	
penetration	is	a	confounding	factor	for	assays	that	require	access	to	cells	deeper	than	40	µm,	such	as	
antibody	labelling	(Melvin	and	Sutherland	2010),	therefore	the	reliability	of	calcein	staining	in	tissues	
cannot	be	assured.	This	may	explain	some	of	the	inconsistencies	observed	between	viability	assays	
presented	here.	
Dendritic	retraction	of	RGCs	preceded	cell	loss	by	at	least	7	d.	It	should	be	kept	in	mind	that	RGCs	are	
a	heterogeneous	population	of	neurons,	as	evidenced	by	the	large	number	of	sub-types	identified	in	
the	mouse	(Coombs	et	al.	2006).	It	is	therefore	important	that	labelling	is	random	so	as	to	ensure	that	
any	 difference	 in	 morphology	 is	 not	 due	 to	 sub-type	 bias.	 Labelling	 bias	 can	 be	 discounted	 here	
because	the	distribution	of	sub-types	identified	at	0	d	closely	matched	that	reported	by	Sun	et	al.	(Sun	
et	 al.	 2002).	Other	 factors,	 such	 as	 age	 and	 sex	 of	 the	 animal,	 can	 be	 discounted	 as	 confounding	
factors,	since	culture	time	or	treatment	group	were	found	to	be	the	only	predictive	factors	of	dendritic	
arbor	morphology	(for	0-3	d	cells).		
It	 is	 important	 to	 point	 out	 that	 absence	 of	 evidence	 for	 bias	 does	 not	 necessarily	 exclude	 this	
possibility.	The	small	number	of	cells	analysed	for	some	conditions,	such	as	the	Q-VD	controls,	was	
perhaps	too	small	for	the	presence	of	bias	to	be	tested.	Indeed,	this	may	be	the	reason	that	age	was	
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an	explanatory	variable	of	cell	morphology,	despite	age	not	being	a	factor	with	any	other	set	of	cells	
analysed	(some	of	which	had	a	much	larger	age	range).	However,	since	the	Sholl	profile	for	these	cells	
was	very	similar	to	that	of	the	untreated	2	d	cells	(Figure	3.7),	it	is	likely	that	these	results	are	reliable.	
Finally,	 it	 is	 important	 to	 consider	 the	 limitations	 of	 the	 experiment	 investigating	 pan-caspase	
inhibition,	given	that	a	single	concentration	of	Q-VD	was	used.	In	the	future	a	dose-response	assay	
should	be	carried	out	to	obtain	the	most	optimal	concentration	of	Q-VD	in	order	to	validate	the	results	
presented	here.	
Given	the	well-evidenced	role	of	caspases	 in	dendritic	pruning	during	development	(Williams	et	al.	
2006;	D'Amelio	et	al.	2010;	Erturk	et	al.	2014)	it	was	surprising	to	find	that	pan-caspase	inhibition	had	
only	a	modest	protective	effect	on	dendritic	pruning	of	RGCs	in	the	explant.	There	are	several	possible	
explanations	 for	 this.	Firstly,	 the	number	of	cells	may	have	been	 insufficient	 for	a	difference	to	be	
measured.	Secondly,	2	days	may	not	have	been	a	long	enough	time	course	for	the	protective	effect	to	
have	 been	 identified.	 Thirdly,	 dilution	 of	 the	 Q-VD	 aliquot	 in	 the	 remaining	 culture	medium	may	
resulted	in	a	sub-optimal	concentration	(7.7	µM).	Finally,	the	age	distribution	may	have	masked	the	
effect	of	Q-VD.	Age	was	found	to	positively	correlate	with	an	increase	in	Sholl	AUC,	but	all	control	cells	
were	 from	mice	aged	4	months	and	Q-VD-treated	cells	were	split	equally	 from	mice	aged	3	and	4	
months.	
3.9	Summary	
Retinas	from	adult	mice	were	cultured	as	wholemounts	for	up	to	14	d.	In	the	GCL	significant	cell	loss	
was	not	observed	until	day	14,	whilst	significant	dendritic	pruning	of	RGCs	occurred	after	6	hours.	
This	suggests	a	treatment	window	between	6	hours	and	14	days	where	neuronal	structure	may	be	
restored.	In	addition,	the	sensitivity	of	this	assay	was	demonstrated	by	pan-caspase	inhibition,	which	
successfully	retarded	dendritic	retraction	of	RGCs	within	the	time	frame	investigated.
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Chapter	4:	BDNF-TrkB	Signalling	in	the	Mouse	Retinal	Explant	
4.1	Introduction	
In	chapter	3	I	provided	evidence	that	morphometric	analysis	of	axotomised	RGCs	in	the	adult	mouse	
retinal	explant	provides	a	rapid	readout	of	neuronal	cell	health.	 I	next	sought	to	use	this	model	to	
investigate	the	mechanisms	involved	in	neuronal	degeneration	and	to	test	the	utility	of	the	assay	to	
evaluate	 neuroprotective	 agents.	 In	 this	 context,	 the	 most	 promising	 agent	 to	 prevent	 dendritic	
atrophy	is	BDNF,	which	has	well-evidenced	roles	in	the	outgrowth	and	maintenance	of	dendrites	in	
the	brain	and	retina	(Thanos	et	al.	1989;	McAllister	et	al.	1995;	Bosco	and	Linden	1999).		
There	is	considerable	evidence	that	BDNF	mRNA	and	protein	levels	are	reduced	in	models	of	neuronal	
degeneration	 (Fahnestock	et	 al.	 2002;	Weickert	 et	 al.	 2003;	Baydyuk	and	Xu	2014),	 therefore	one	
therapeutic	avenue	to	explore	is	the	restoration	of	normal	levels	of	BDNF	to	repair	neuronal	function.	
Although	 the	 levels	 of	 BDNF	 in	 the	 rodent	 retinal	 explant	 have	 been	 reported	 (Seki	 et	 al.	 2003;	
Domenici	 et	 al.	 2014),	 these	 have	 not	 been	 published	 in	 parallel	 with	 morphometric	 changes.	 I	
therefore	investigated	the	temporal	relationship	between	endogenous	BDNF	protein	levels	and	RGC	
dendritic	 retraction,	 and	 then	 to	 explore	 whether	 dendrite	 loss	 could	 be	 accelerated	 by	 blocking	
endogenous	BDNF.		
BDNF	 treatment	 has	 been	 shown	 to	 be	 neuroprotective	 in	 a	 range	 of	 neurodegeneration	models	
(Weber	and	Harman	2008;	Nagahara	et	al.	2009;	Rodger	et	al.	2012),	however	the	physical	properties	
of	BDNF	(pharmacologically	‘sticky’	and	short	half-life	(Poduslo	and	Curran	1996;	Lu	2003))	make	it	
difficult	to	precisely	control	its	concentration	and	location	in	vivo.	Given	that	the	mouse	retina	is	only	
approximately	200	µm	thick	(Ferguson	et	al.	2013),	the	explant	is	an	ideal	model	in	which	to	examine	
the	effects	of	BDNF	treatment	on	axotomy-induced	neuronal	degeneration.	Finally,	given	that	a	major	
limitation	 in	 this	 field	 is	 the	 lack	 of	 clinically-relevant	 data,	 I	 sought	 to	 investigate	 whether	 the	
neuroprotective	effects	of	BDNF	could	be	achieved	when	treatment	was	initiated	after	injury.	
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4.2	Levels	of	endogenous	BDNF	in	the	retinal	explant	
Twenty-nine	adult	mouse	retinal	explants	(n=15	animals	of	both	sex,	aged	4-7	months)	were	cultured	
ex	vivo	for	0	d,	1	d,	3	d,	7	d,	and	14	d,	after	which	time	right	and	left	explants	were	pooled	and	snap	
frozen	in	RIPA	buffer	containing	20%	protease	inhibitor.	Pooled	explants	were	lysed	and	total	protein	
content	was	quantified	by	BCA	assay	and	BDNF	protein	was	quantified	by	ELISA	using	mouse	anti-
BDNF	antibody	mAb#9	(see	2.10).		
Total	retinal	protein	decreased	by	22.0%	(p<0.05)	after	1	d,	and	was	lowest	after	14	d	(50.0%	decrease,	
p<0.001,	ANOVA,	Figure	4.1a).	This	correlates	with	cell	loss	in	the	INL	and	ONL	(the	majority	protein	
components	of	the	retina)	as	shown	in	Figure	3.3	(see	Chapter	3).	BDNF	protein	levels	in	the	explant	
followed	a	similar	trend,	but	did	not	reach	significance	at	any	time	point	(p>0.05,	ANOVA,	Figure	4.1b).	
The	level	of	BDNF	protein,	when	expressed	per	mg	total	protein,	also	did	not	change	(p>0.05,	ANOVA)	
over	14	d	(Figure	4.1c-d).	
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Figure 4.1 Quantification of total protein (BCA assay) and BDNF protein (ELISA) in retinal explants 
after culture periods of up to 14 d. (a) Total protein. *p<0.05, **p<0.005, ***p<0.001, ANOVA. (b) Total 
BDNF protein levels. p>0.05, ANOVA. (c) BDNF protein relative to total protein. p<0.05, ANOVA. (d) 
BDNF protein relative to total protein, expressed as a percentage of the value at 0 d. n=6 explants, 3 
animals (0 d); n=6 explants, 3 animals (1 d); n=6 explants, 3 animals (3 d); n=6 explants, 3 animals (7 
d); n=5 explants, 3 animals (14 d). All values were calculated per retina. Means ±SD. 
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4.3	BDNF	treatment	retards	RGC	dendritic	atrophy	
Seven	explants	(n=7	mice	of	either	sex,	aged	2-5.5	months)	were	treated	with	100	ng/mL	BDNF	for	3	
d,	at	which	point	RGCs	were	diolistically	 labelled	and	their	dendritic	arbors	quantified.	The	culture	
timeline	is	shown	in	Figure	4.2a.	BDNF-treated	cells	had	visibly	more	complex	dendritic	arbors	(Figure	
4.2b-c).	 Following	 BDNF	 treatment,	 Sholl	 curve	 peaks	 were	 greatly	 increased	 20-80	 µm	 (p<0.05,	
Kruskal-Wallis)	 from	 the	 soma	 centre	 (Figure	 4.2d).	 BDNF	 treatment	 resulted	 in	 a	 75.8%	 increase	
(p<0.005,	ANOVA	with	Tukey	post-hoc)	 in	Sholl	AUC	and	an	81.0%	 increase	 (p<0.001,	ANOVA	with	
Tukey	 post-hoc)	 in	 branching	 index,	 relative	 to	 controls,	 but	 neither	 measures	 were	 significantly	
different	from	0	d	cells	(Figure	4.2e-f).	The	dendritic	field	area	of	BDNF-treated	cells	was	61.2%	larger	
(p<0.05)	than	control	cells	but	28.8%	smaller	(p<0.005,	test)	than	0	d	cells	(Figure	4.2g).	RGCs	were	
divided	into	ON,	OFF	and	ON-OFF	based	on	INL	stratification	(see	section	2.8.4)	to	check	for	sub-type-
specific	 effects	 of	 BDNF.	 Following	BDNF	 treatment,	 the	 Sholl	 AUC	of	ON	 cells	 increased	by	 109%	
(p<0.005)	relative	to	controls	but	was	not	significantly	different	(p>0.05,	ANOVA	with	Tukey	post-hoc)	
from	0	d	cells	(Figure	4.2h).	The	Sholl	AUC	for	BDNF-treated	OFF	cells	was	73.6%	increased	(p<0.05)	
relative	to	controls,	but	was	not	significantly	different	(p>0.05,	ANOVA	with	Tukey	post-hoc)	from	0	d	
cells	(Figure	4.2i).	There	was	no	significant	difference	(p>0.05,	ANOVA	with	Tukey	post-hoc)	between	
groups	for	Sholl	AUC	of	bistratified	cells	(Figure	4.2j).	
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Figure 4.2 (previous page) Morphometric analysis of RGCs from explants treated with 100 ng/mL 
BDNF for 3 d. (a) Culture timeline of experiment. (b) Fluorescent images (left) and 8-bit tracing images 
(right) of diolistically labelled RGCs. Scale bar: 100 µm. Arrows indicate axon. (c) Locations of all 
analysed RGCs relative to the optic nerve (origin). (d) Sholl profiles for control cells and BDNF-treated 
cells demonstrating increased dendritic complexity with BDNF treatment. The number of cells in each 
group is shown. *p<0.05, **p<0.005, ***p<0.001, Kruskal-Wallis. (e) Area under the Sholl profile for 
each group, shown with the value for 0 d cells for comparison. **p<0.005, ***p<0.001, ns not significant, 
test. (f) Branching index for each group, shown with the value for 0 d cells for comparison. ***p<0.001, 
ns not significant, test. (g) Dendritic field area for each group, shown with the value for 0 d cells. *p<0.05, 
**p<0.005, ***p<0.001, test. (h) Area under the Sholl profile for ON-stratifying cells in each group. 
**p<0.005, ***p<0.001, test. (i) Area under the Sholl profile for OFF-stratifying cells in each group. 
*p<0.05, test. (j) Area under the Sholl profile for bistratified cells in each group. p>0.05, test. Means 
±SEM. 
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In	order	to	check	that	age	and	sex	were	not	confounding	factors,	a	multiple	regression	analysis	was	
run	on	Sholl	AUC	values	for	BDNF-treated	cells.	The	model	provided	a	good	fit	of	the	data	(p<0.05,	
ANOVA).	Culture	condition	(i.e.	BDNF	treatment)	was	the	only	explanatory	variable	(p<0.05)	of	Sholl	
AUC	(Table	4.1).	
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Table 4.1. Multiple regression model to test the possible confounding effects of variance in age and sex 
on Sholl AUC (dependent variable). Culture condition (1=control, 2=BDNF), age (number of months), 
and sex (1=male, 2=female) were the predictors.  
Variable	 Coefficient	(B)	 P	
Culture	condition	 665	 0.008	
Age	 -29.4	 0.797	
Sex	 51.5	 0.831	
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4.4	Delayed	BDNF	treatment	retards	RGC	dendritic	atrophy	
To	investigate	the	mechanism	of	BDNF	action	and	to	test	BDNF	treatment	in	a	more	clinically	relevant	
paradigm	that	could	be	translated	to	clinical	treatment	6	explants	(n=6	mice,	male,	aged	8.5	months)	
were	cultured	 in	normal	culture	medium	for	3	d,	at	which	point	100	ng/mL	BDNF	was	added	for	a	
further	3	d	(6	d	total).	The	culture	timeline	is	outlined	in	Figure	4.3a.	Delayed	BDNF	treatment	resulted	
in	RGCs	with	more	complex	dendritic	arbors	(Figure	4.3b-c),	in	which	the	Sholl	profile	was	increased	
20-100	µm	 from	 the	 soma	 centre	 (p<0.05,	 Kruskal-Wallis)	 (Figure	 4.3d).	 The	 Sholl	 AUC	of	 delayed	
BDNF-treated	 cells	 was	 increased	 by	 136%	 (p<0.001)	 compared	 to	 controls,	 decreased	 by	 32.9%	
(p<0.05)	relative	to	0	d	cells,	and	increased	by	56.6%	(p<0.005,	ANOVA	with	Tukey	post-hoc)	compared	
to	3	d	cells	 (Figure	4.3e).	Delayed	BDNF	 treatment	 resulted	 in	a	107%	 increase	 in	branching	 index	
(p<0.05),	relative	to	controls,	but	a	45.1%	decrease	in	branching	index	(p<0.005,	ANOVA	with	Tukey	
post-hoc)	compared	to	0	d	cells	(Figure	4.3f).	The	dendritic	field	area	of	delayed	BDNF-treated	cells	
was	134%	increased	(p<0.001)	relative	to	controls	but	was	43.1%	decreased	(p<0.001,	ANOVA	with	
Tukey	post-hoc)	compared	to	0	d	cells	(Figure	4.3g).	Cells	were	split	into	ON,	OFF,	and	ON-OFF	to	check	
for	sub-type-specific	effects	of	delayed	BDNF	treatment.	Following	delayed	BDNF	treatment	the	Sholl	
AUC	of	ON	cells	was	95.8%	increased	(p<0.05)	relative	to	controls,	55.3%	increased	(p<0.05)	relative	
to	3	d	cells,	and	39.5%	decreased	(p<0.05,	ANOVA	with	Tukey	post-hoc)	compared	to	0	d	cells	(Figure	
4.3h).	The	Sholl	AUC	of	delayed	BDNF-treated	OFF	cells	was	253%	increased	(p<0.005)	compared	to	
controls	but	was	not	significantly	different	(p>0.05,	ANOVA	with	Tukey	post-hoc)	from	any	other	group	
(Figure	4.3i).	No	control	cells	were	identified	as	ON-OFF	cells	and	for	all	other	groups	the	Sholl	AUCs	
were	not	significantly	different	(p>0.05,	ANOVA	with	Tukey	post-hoc,	Figure	4.3j).	
Although	age	and	sex	were	constant	in	this	group,	a	multiple	regression	analysis	was	used	to	check	
the	predictive	effect	of	delayed	BDNF	treatment	on	Sholl	AUC.	The	model	was	a	good	fit	of	the	data	
(p=0.001,	ANOVA)	with	the	culture	condition	(i.e.	delayed	BDNF	treatment/no	BDNF)	was	a	significant	
explanatory	variable	for	the	change	in	Sholl	AUC	(B=671,	p=0.001).	
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Figure 4.3 (previous page) Morphometric analysis of RGCs from explants treated with 100 ng/mL 
BDNF initiated 3 d-post axotomy. (a) Culture timeline. (b) Fluorescent images (left) and 8-bit tracing 
images (right) of RGCs from each group. Scale bars: 100 µm. Arrows indicate axons. (c) Locations of 
all analysed RGCs relative to the optic nerve (origin) showing no evidence of labelling bias. (d) Sholl 
profiles for each group. The number of cells in each group is shown. *p<0.05, **p<0.005, ***p<0.001, 
Kruskal-Wallis. (e) Area under the Sholl profile, shown with the values for 0 d and 3 d cells for 
comparison. *p<0.05, **p<0.005, ***p<0.001, ns not significant, ANOVA with Tukey post-hoc. (f) 
Branching index with 0 d and 3 d cell values. *p<0.05, **p<0.005, ***p<0.001, ns not significant, ANOVA 
with Tukey post-hoc. (g) Dendritic field area with 0 d cell value. *p<0.05, **p<0.005, ***p<0.001, ns not 
significant, ANOVA with Tukey post-hoc. Areas under the Sholl profile split by RGC sub-type (i-k) 
provide no evidence of sub-type-specific effects of delayed BDNF treatment. (i) Sholl AUCs for ON 
cells, with the corresponding value for 0 d and 3 d cells for comparison. *p<0.05, ***p<0.001, ANOVA 
with Tukey post-hoc. (j) Sholl AUCs for OFF cells, with the corresponding value for 0 d and 3 d cells. 
**p<0.005, ***p<0.001, ANOVA with Tukey post-hoc. (k) Sholl AUCs for bistratified cells, with the 
corresponding value for 0 d and 3 d cells for comparison. p>0.05, ANOVA with Tukey post-hoc. Means 
±SEM. 
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4.5	The	effect	of	BDNF	is	dose-dependent	
To	test	for	the	presence	of	a	dose-dependent	effect	of	BDNF,	6	explants	(n=3	animals,	female,	aged	2	
months)	were	treated	with	1000	ng/mL	BDNF	for	3	d	initiated	at	day	3	(6	d	total).	At	the	end	of	the	
culture	period	RGCs	were	labelled	and	analysed	as	before.	The	culture	timeline	is	shown	in	Figure	4.4a.	
RGCs	 treated	with	1000	ng/mL	BDNF	had	visibly	 larger	and	more	complex	dendritic	arbors	 (Figure	
4.4b-c),	quantified	as	a	large	increase	in	Sholl	peak	amplitude	between	30-110	µm	and	130-160	µm	
from	the	soma	centre	(p<0.05,	Kruskal-Wallis)	as	well	as	a	rightward	shift	in	the	Sholl	profile	(Figure	
4.4d).	Delayed	1000	ng/mL	BDNF-treated	cells	had	Sholl	AUCs	that	were	119%	increased	(p<0.001)	
relative	 to	 controls	 and	 136%	 increased	 (p<0.001)	 relative	 to	 3	 d	 cells,	 but	were	 not	 significantly	
different	(p>0.05,	ANOVA	with	Tukey	post-hoc)	from	0	d	cells	(Figure	4.4e).	The	branching	index	of	
delayed	1000	ng/mL	BDNF-treated	cells	was	increased	by	83.6%	(p<0.05)	relative	to	controls	and	by	
95.1%	(p<0.005)	relative	to	3	d	cells.	The	index	did	not	differ	significantly	(p>0.05,	ANOVA	with	Tukey	
post-hoc)	compared	with	0	d	cells	(Figure	4.4f).	The	soma	diameters	of	treated	cells	were	unchanged	
(p>0.05,	ANOVA	with	Tukey	post-hoc)	compared	to	controls	(Figure	4.4g).	The	dendritic	field	area	of	
delayed	1000	ng/mL	BDNF-treated	cells	was	67.9%	increased	(p<0.05)	relative	to	controls,	but	was	
not	significantly	different	(p>0.05,	ANOVA	with	Tukey	post-hoc)	compared	to	0	d	cells	(Figure	4.4h).	
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Figure 4.4 (previous page) Morphometric analysis of RGCs from explants treated with 1000 ng/mL 
BDNF initiated at day 3. (a) Culture timeline. (b) Fluorescent images (left) and 8-bit tracings (right) of 
diolistically labelled RGCs in each treatment group. The number of cells in each group is shown. Scale 
bars: 100 µm. Arrows indicate axons. (c) Locations of all analysed cells relative to the optic nerve 
(origin) showing no evidence of labelling bias. (d) Sholl profile for each group. The number of cells in 
each group is shown. *p<0.05, **p<0.005, ***p<0.001, Kruskal-Wallis. (e) Area under the Sholl profile, 
shown with the values for 0 d and 3 d cells for comparison. ***p<0.001, ANOVA with Tukey post-hoc. 
(f) Branching index with 0 d and 3 d cell values. *p<0.05, **p<0.005, ***p<0.001, ANOVA with Tukey 
post-hoc. (g) Soma diameter. p>0.05, test. (h) Dendritic field area with 0 d cell value for reference. 
*p<0.05, ***p<0.001, ANOVA with Tukey post-hoc. Means ±SEM. 
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4.6	Blocking	endogenous	BDNF	has	no	effect	on	RGC	morphology	
To	investigate	the	effect	of	endogenous	BDNF	on	dendritic	retraction	of	RGCs,	9	explants	(n=7	animals	
of	both	sex,	aged	4-6	months)	were	cultured	for	3	d	with	the	mouse	anti-BDNF	antibody	mAb#9	(10	
µg/mL)	 to	 block	 endogenous	 BDNF.	 To	 ensure	 that	 mAb#9	 was	 binding	 to	 its	 target	 protein,	 11	
explants	(n=10	animals	of	both	sex,	aged	2-5	months)	were	cultured	for	3	d	with	100	ng/mL	BDNF	±10	
µg/mL	mAb#9.	At	the	end	of	the	culture	period	RGCs	were	labelled	and	analysed	as	before.	The	culture	
timeline	 is	 shown	 in	Figure	4.5a.	There	was	no	visible	effect	of	mAb#9	treatment	on	 the	dendritic	
arbors	 of	 RGCs,	 compared	 to	 controls,	 and	 RGCs	 treated	 with	 both	 BDNF	 and	 mAb#9	 appeared	
unchanged	relative	to	control	cells,	 in	contrast	to	the	highly	branched	arbors	of	BDNF-treated	cells	
(Figure	4.5b-c).	These	observations	were	quantified	by	Sholl	analysis,	indicating	no	difference	(p>0.05,	
Kruskal-Wallis)	in	Sholl	profile	between	controls	and	mAb#9-treated	cells	(Figure	4.5d),	and	combined	
treatment	of	mAb#9	with	BDNF	completely	abolished	the	effect	of	BDNF	on	the	Sholl	profile	(Figure	
4.5e).	 The	 area	 under	 the	 Sholl	 profile	 and	 branching	 index	 of	 BDNF-treated	 cells	were	 increased	
(p<0.05)	relative	to	the	other	three	treatment	groups,	which	were	all	unchanged	(p>0.05,	ANOVA	with	
Tukey	post-hoc)	from	each	other	(Figure	4.5f-g).	The	soma	diameter	of	RGCs	was	constant	(p>0.05,	
ANOVA	with	Tukey	post-hoc)	throughout	every	treatment	group	(Figure	4.5h).	The	dendritic	field	area	
of	BDNF-treated	cells	was	55.2%	increased	(p<0.005)	relative	to	control	cells,	but	there	were	no	other	
differences	(p>0.05,	ANOVA	with	Tukey	post-hoc)	between	treatment	groups	(Figure	4.5i).	
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Figure 4.5 (previous page) Morphometric analysis of RGCs from explants treated with BDNF blocking 
antibody mAb#9 or 100 ng/mL BDNF for 3 d. (a) Culture timeline. (b) Fluorescent images of diolistically 
labelled RGCs from each treatment group. Scale bars: 100 µm. Arrows indicate axons. (c) Locations of 
all analysed cells relative to the optic nerve (origin). (d) Sholl profiles for mAb#9-treated cells and control 
cells, showing no effect of blocking endogenous BDNF. p>0.05, Kruskal-Wallis. (e) Sholl profiles for 
BDNF-treated cells ±mAb#9, showing that mAb#9 treatment blocks the positive effect of exogenously-
applied BDNF. *p<0.05, Kruskal-Wallis. The number of cells in each treatment group (d-e) is shown. (f) 
Area under the Sholl profile for all treatment groups shows no difference between groups, except BDNF-
treated cells. **p<0.005, ANOVA	with	 Tukey	post-hoc. (g) Branching index for all groups. *p<0.05, 
**p<0.005, ANOVA	with	Tukey	post-hoc. (h) Soma diameter for each group. p>0.05, ANOVA	with	Tukey	
post-hoc. (i) Dendritic field area measurements. **p<0.005, ANOVA	with	Tukey	post-hoc. Means ±SEM.  
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4.7	Conclusions	
In	this	chapter	I	used	the	morphometric	analysis	assay	established	in	Chapter	3	to	test	the	roles	of	
exogenous	and	endogenous	BDNF	in	the	maintenance	of	dendritic	arbor	structure.	The	data	indicate	
that	 endogenous	 BDNF	 does	 not	 play	 a	 role	 in	 the	 dendritic	 retraction	 of	 RGCs	 and	 that	 BDNF	
treatment	can	retard	RGC	dendrite	loss.	In	addition,	I	present	for	the	first	time	evidence	that	delayed	
application	 of	 BDNF	 can	 not	 only	 protect	 against	 dendritic	 retraction	 but	may	 stimulate	 dendritic	
outgrowth	in	RGCs.	
The	data	presented	 in	 this	chapter	demonstrate	 that	BDNF	 is	a	potent	neuroprotective	agent	 that	
prevents	dendrite	loss	in	RGCs,	although	this	protection	was	mainly	seen	for	primary	and	secondary	
dendrites	(20-80	µm	from	the	soma)	in	the	case	of	3	d	treatment	initiated	immediately	after	axotomy	
(Figure	4.2d).	The	limited	protective	effect	on	terminal	dendrites	may	restrict	the	number	of	synaptic	
connections	 that	can	be	protected,	 therefore	may	be	 important	 to	consider	 for	 the	strategy	of	 re-
wiring	neuronal	networks	as	only	partial	restoration	of	neuronal	function	may	be	achievable.	
The	 evidence	 presented	 here	 is	 consistent	 with	 a	 neurite	 outgrowth	mechanism	 of	 BDNF.	 This	 is	
particularly	exciting	because	it	demonstrates	that	it	may	be	possible	to	treat	neuronal	degeneration	
even	after	a	significant	amount	of	neuronal	damage	has	occurred.	Application	of	a	compound	such	as	
BDNF	 could	 theoretically	 promote	 re-wiring	 of	 neuronal	 networks,	 thereby	 restoring	 neuronal	
function.	It	is	important	to	note	that	this	mechanism	of	BDNF	cannot	be	confirmed	with	the	results	
shown	here;	it	may	simply	be	a	consequence	of	biased	populations	of	cells.	As	outlined	in	section	1.2	
(Introduction),	 RGCs	 are	 an	 extremely	 heterogeneous	 population	 morphologically,	 therefore	 it	 is	
possible	that	the	evidence	for	BDNF-mediated	dendritic	outgrowth	demonstrated	here	is	a	result	of	
BDNF	selecting	for	the	survival	of	RGC	sub-types	that	are	more	highly	branched	with	larger	dendritic	
field	areas,	resulting	in	this	morphology	becoming	a	higher	proportion	of	the	remaining	population.	
Nevertheless,	the	data	are	convincing,	given	the	lack	of	evidence	of	labelling	bias	and	the	evidence	
that	age	and	sex	were	not	confounding	factors.	However,	the	absence	of	sampling	bias	may	simply	be	
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due	 to	 the	 low	 number	 of	 cells	 in	 some	 groups.	 Although	 this	 weakens	 the	 statistical	 power	 of	
differences	between	groups,	 the	Sholl	profiles	 for	 control	 cells	were	very	 similar	 to	 those	 for	 cells	
cultured	for	the	same	time	period.	Nevertheless,	time-series	imaging	is	required	in	order	to	validate	
this	mechanism.	
The	evidence	shown	here	supports	the	theory	that	endogenous	BDNF	does	not	play	a	role	in	dendritic	
retraction	of	RGCs	in	the	explant,	however	two	points	should	be	considered.	Firstly,	the	ELISA	did	not	
measure	 the	 location	of	BDNF	within	 the	 retina.	 Secondly,	mAb#9	was	 shown	 to	block	exogenous	
BDNF,	 but	 if	 it	 could	 not	 penetrate	 the	 tissue	 sufficiently,	 it	 would	 have	 been	 unable	 to	 bind	
endogenous	 BDNF.	 In	 both	 cases,	 the	 possibility	 that	 endogenous	 BDNF	 secretion	 was	 reduced	
following	axotomy	cannot	be	discounted.	
4.8	Summary	
In	 the	 retinal	explant	 total	protein	 rapidly	decreased	after	1	d,	however	 the	 level	of	BDNF	protein	
remained	constant	for	at	least	14	d.	BDNF	treatment	initiated	immediately	after	axotomy	or	3	d-post	
axotomy	retarded	RGC	dendritic	retraction	and	these	data	support	the	theory	that	BDNF	can	promote	
dendritic	outgrowth	in	RGCs.	There	was	also	evidence	of	a	dose-dependent	effect	of	BDNF.	Blocking	
endogenous	BDNF	had	no	effect	on	RGC	dendrite	loss	over	3	d.		These	data	support	the	use	of	BDNF	
a	therapeutic	agent	for	the	treatment	of	neuronal	degeneration.
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Chapter	5:	CSPG	Digestion	to	Enhance	RGC	Remodelling	in	the	
Retinal	Explant	
5.1	Introduction	
In	Chapter	4	I	demonstrated	that	application	of	BDNF	protects	RGCs	from	dendritic	retraction	and	may	
promote	dendritic	outgrowth.	However,	it	was	noted	that	the	protective	effect	of	BDNF	was	largely	
limited	 to	 the	primary	and	secondary	dendrites.	 In	order	 to	 improve	neuronal	network	 rewiring,	a	
method	was	sought	to	stimulate	outgrowth	of	terminal	dendrites.	
CSPGs	are	a	major	component	of	the	PNN,	which	is	laid	down	at	the	end	of	the	critical	period	to	limit	
neuronal	plasticity	(Pizzorusso	et	al.	2002;	Carulli	et	al.	2010;	Wang	and	Fawcett	2012).	Following	CNS	
injury,	the	secretion	of	CSPGs	is	increased	and,	along	with	activated	astrocytes,	these	form	a	glial	scar	
to	protect	neighbouring	healthy	tissue	from	an	immune	response	(Sofroniew	2005).	Although	CSPGs	
have	a	protective	role,	they	can	also	limit	remodelling	of	dendrites	and	synapses,	which	is	essential	
after	 injury	 if	 neuronal	 function	 is	 to	 be	 repaired.	 It	 has	 been	 proposed	 that	 CSPG	 digestion	may	
increase	 synaptic	 plasticity	 via	 the	 removal	 of	 inhibitory	 signals	 (Bradbury	 et	 al.	 2002),	 as	
demonstrated	in	the	kitten	visual	cortex	(Gordon	and	Stryker	1996).	However,	it	should	be	noted	that	
there	may	be	a	limit	to	plasticity	in	the	adult	(Pizzorusso	et	al.	2002).	
The	retinal	explant	is	an	excellent	model	to	test	the	effect	of	CSPG	digestion	on	dendritic	remodelling	
since	it	contains	an	intact	neuronal	network,	unlike	the	brain	slice.	In	this	chapter	I	tested	the	effect	
of	ChABC	treatment	on	RGC	dendritic	remodelling,	primarily	focussing	on	terminal	dendrites.	I	also	
explored	whether	 this	 treatment	 could	be	used	 in	 combination	with	BDNF	application	 to	enhance	
dendritic	outgrowth.	
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5.2	ChABC	digests	CSPGs	in	each	retinal	layer	
To	confirm	that	ChABC	treatment	could	be	used	to	digest	CSPGs	in	the	retinal	explant,	particularly	in	
and	around	the	GCL,	5	explants	were	treated	with	a	topical	50	µL	aliquot	of	0.25	U/mL	or	0.5	U/mL	
ChABC,	 or	 vehicle	 as	 control,	 for	 1	 d.	 Explants	 were	 then	 fixed	 and	 processed	 for	
immunohistochemistry	to	visualise	presence	of	GAG	stubs	1B5,	2B6	and	3B3.	Antibodies	to	1b5,	2B6	
and	 3B3	 bind	 to	 the	 stubs	 generated	 following	 ChABC	 digestion.	 3B3	 antibodies	 also	 bind	 to	
undigested	CSPGs.	Following	treatment	with	0.25	U/mL	ChABC	only	faint	staining	of	CS	stubs	could	be	
seen,	compared	to	the	untreated	state.	With	0.5	U/mL	ChABC	treatment	there	was	strong	staining	for	
1B5	and	2B6	in	the	GCL,	 INL	and	ONL,	and	staining	for	3B3	was	faint	but	stronger	than	in	explants	
treated	with	vehicle	only	(Figure	5.1).	These	results	support	the	use	of	a	topical	aliquot	of	0.5	U/mL	
ChABC	for	1	d	to	digest	CSPGs	in	the	GCL.		
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Figure 5.1 (previous page). Immunohistochemical staining for products of CSPG digestion in frozen 
sections of the retinal explant following 1 d treatment with 0.25 U/mL and 0.5 U/mL ChABC. CS stubs 
(1B5, 2B6 and 3B3) are visualised in green and nuclear staining (Hoechst) is displayed in monochrome 
above to the corresponding antibody staining panel. (a) Negative controls: retinal sections stained for 
the corresponding antibody with omission of either primary or secondary antibody displaying negligible 
fluorescence. (b) Positive controls (retina): explants were cultured under normal culture conditions for 
1 d and their sections were pre-incubated in 0.5 U/mL ChABC for 2 h at 37°C, 5% CO2 prior to 
immunohistochemical staining. (c) Positive controls (brain): untreated mouse brain sections to visualise 
normal levels of the CS stubs in the brain. (d) PBS control: an explant was cultured with a PBS aliquot 
for 1 d to visualise normal levels of each CS stub following 1 d ex vivo culture. N=1 explant. (e) An 
explant treated with 0.25 U/mL ChABC displays faint, dispersed staining for all epitopes in all retinal 
layers. N=1 explant. (f) Explants treated with 0.5 U/mL ChABC shows strong staining for 1B5 (left) and 
2B6 (middle) in each retinal layer. N=3 explants, 3 mice. Scale bars: 50 µm. 
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5.3	Over	3	d	ChABC	treatment	blocks	the	protective	effect	of	BDNF	
In	order	to	verify	that	ChABC	treatment	 is	not	toxic	to	RGCs,	6	explants	 (n=4	mice,	male,	aged	2-7	
months)	were	treated	with	0.5	U/mL	ChABC	as	a	topical	aliquot,	or	vehicle	as	control,	 immediately	
after	wholemount	 preparation.	 After	 3	 d	 culture	 RGCs	were	 labelled	 and	 analysed	 as	 before.	 The	
culture	timeline	is	shown	in	Figure	5.2a.	There	was	no	visible	difference	in	morphology	of	RGCs	from	
ChABC-treated	explants	compared	to	controls	(Figure	5.2b-c)	and	this	was	confirmed	by	quantification	
with	Sholl	analysis	(p>0.05,	Kruskal-Wallis,	Figure	5.2d).	
Next,	to	test	whether	ChABC	treatment	could	enhance	the	effect	of	BDNF	on	RGC	dendritic	arbors,	7	
explants	(n=5	mice	of	either	sex,	aged	2-7	months)	were	treated	with	0.5	U/mL	ChABC	as	a	topical	
aliquot,	or	vehicle	as	control,	and	BDNF	was	added	to	the	medium	to	make	a	final	concentration	of	
100	ng/mL.	Explants	were	treated	with	BDNF	for	3	d,	at	which	point	RGCs	were	labelled	and	analysed	
as	before.	The	culture	timeline	is	shown	in	Figure	5.3a.	RGCs	from	explants	treated	with	BDNF	were	
characteristically	highly	branched,	but	 cells	with	 combined	BDNF	and	ChABC	 treatment	had	 fewer	
dendrites	 (Figure	 5.3b-c).	 This	 was	 quantified	 by	 Sholl	 analysis;	 the	 Sholl	 profile	 was	 significantly	
(p<0.05,	Kruskal-Wallis)	increased	40	µm,	210	and	220	µm	from	the	soma	centre	in	BDNF-treated	cells	
compared	to	ChABC+BDNF-treated	cells	(Figure	5.3d).		
The	outlined	patterns	in	dendritic	arbor	shape	were	supported	by	morphometric	analysis.	There	was	
no	difference	(p>0.05,	ANOVA	with	Tukey	post-hoc)	in	soma	diameter	between	groups	(Figure	5.4a).	
There	 was	 no	 significant	 difference	 (p>0.05,	 ANOVA	 with	 Tukey	 post-hoc)	 between	 groups	 for	
dendritic	field	area	(Figure	5.4b),	but	the	results	followed	the	same	trend	as	the	other	morphometric	
measures;	area	under	the	Sholl	profile	was	66.3%	increased	(p<0.05,	ANOVA	with	Tukey	post-hoc)	in	
BDNF-treated	cells	relative	to	ChABC-treated	cells	(Figure	5.4c).	The	branching	index	of	BDNF-treated	
cells	was	78.5%	increased	(p<0.05)	compared	to	ChABC-treated	cells	and	89.6%	increased	(p<0.005,	
ANOVA	with	Tukey	post-hoc)	compared	to	ChABC+BDNF-treated	cells	(Figure	5.4d).	
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Figure 5.2 (previous page) Morphometric analysis of RGCs from explants treated with 0.5 U/mL 
ChABC as a topical aliquot from day 0 for 1 d and cultured for 3 d. (a) Culture timeline. (b) 1024x1024 
pixel confocal images (top) and 8-bit tracings (bottom) of diolistically labelled RGCs from each treatment 
group show no visible difference between treatment conditions. Arrows indicate axons. Scale bars: 100 
µm. (c) Locations of all cells analysed relative to the optic nerve (origin) demonstrating no evidence of 
labelling bias. (d) Sholl profiles show no difference between treatment groups. p>0.05, Kruskal-Wallis. 
The number of cells for each group is indicated. Means ±SEM.
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Figure 5.3 (previous page) Morphometric analysis of RGCs from explants treated with 100 ng/mL 
BDNF for 3 d, combined with 0.5 U/mL ChABC applied as a topical aliquot from day 0 for 1 d. (a) Culture 
timeline. (b) 1024x1024 pixel confocal images (top) and 8-bit tracings (bottom) of diolistically labelled 
RGCs from each treatment group show increased dendritic branching in the absence of ChABC. Arrows 
indicate axons. Scale bars: 100 µm. (c) Locations of all cells analysed relative to the optic nerve (origin) 
demonstrating no evidence of labelling bias. (d) Sholl profiles show increased number of dendrites 
when ChABC was omitted. *p<0.05, Kruskal-Wallis. The number of cells for each group is indicated. 
Means ±SEM. 
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Figure 5.4 Morphometric measures of RGCs from explants treated with 0.5 U/mL ChABC, or vehicle 
as control, ±100 ng/mL BDNF over 3 d. (a) Soma diameters show no difference between groups. 
p>0.05, ANOVA with Tukey post-hoc. Measures of dendritic arbor morphology (b-d) demonstrate a 
general trend of increased dendritic arbor complexity and size with BDNF –ChABC. (b) Dendritic field 
area for each group. p>0.05, ANOVA with Tukey post-hoc. (c) Area under the Sholl profile. *p<0.05, 
ANOVA with Tukey post-hoc. (d) Branching index. *p<0.05, **p<0.005, ANOVA with Tukey post-hoc. 
Means ±SEM. 
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5.4	Over	6	d	ChABC	treatment	is	neuroprotective	but	offers	no	extra	protection	in	
combination	with	BDNF	
To	investigate	whether	CSPG	digestion	is	toxic	over	a	longer	time	period,	6	explants	(n=3	animals	of	
either	sex,	aged	2-4	months)	were	treated	with	a	topical	aliquot	of	0.5	U/mL	ChABC	at	day	0,	followed	
by	culture	for	a	total	of	6	d,	at	which	point	RGCs	were	labelled	and	analysed	as	before.	The	culture	
timeline	 is	 shown	 in	 Figure	 5.5a.	 ChABC-treated	 RGCs	 had	 visibly	 larger,	 more	 densely	 branched	
dendritic	arbors,	compared	to	control	cells	(Figure	5.5b-c).	This	observation	was	quantified	by	Sholl	
analysis,	which	demonstrated	a	significant	increase	(p<0.05,	Kruskal-Wallis)	in	Sholl	peak	amplitude	
20-120	µm	from	the	soma	centre	and	a	rightwards	shift,	relative	to	controls	(Figure	5.5d).	
To	investigate	whether	ChABC	treatment	could	enhance	the	neuroprotective	effect	of	BDNF	over	a	
longer	time	period	and	to	test	a	possible	inhibitory	interaction	between	ChABC	and	BDNF	(Figure	5.3),	
6	 explants	 (n=3	 animals,	male,	 aged	 2-6	months)	were	 treated	with	 a	 topical	 aliquot	 of	 0.5	U/mL	
ChABC,	or	vehicle	as	control,	at	day	0,	followed	by	delayed	100	ng/mL	BDNF	treatment	(6	d	total).	The	
culture	timeline	 is	outlined	 in	Figure	5.6a.	RGCs	from	each	treatment	group	were	 indistinguishable	
from	each	other	(Figure	5.6b-c),	which	was	confirmed	by	Sholl	analysis	(p>0.05,	Kruskal-Wallis,	Figure	
5.6d).	
Morphometric	measures	further	supported	the	described	effects	of	ChABC	and	BDNF	treatment	over	
6	d.	There	was	no	difference	(p>0.05,	ANOVA	with	Tukey	post-hoc)	in	soma	diameter	between	groups	
(Figure	5.7a).	The	dendritic	field	area	and	Sholl	AUC	of	RGCs	in	every	group	treated	with	ChABC	or	
BDNF	were	significantly	(p<0.05,	ANOVA	with	Tukey-post	hoc)	larger	than	RGCs	treated	with	vehicle	
only	(Figure	5.7b-c).	The	branching	index	followed	the	same	trend	as	the	results	for	dendritic	field	area	
and	Sholl	AUC,	although	no	group	was	significantly	different	(p>0.05,	ANOVA	with	Tukey	post-hoc,	
Figure	5.7d).	
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To	test	whether	ChABC	treatment	affected	the	stratification	depth	of	RGC	dendrites	in	the	IPL	when	
combined	with	BDNF	treatment,	the	percentage	stratification	depth	of	ON-stratifying	(0-55%)	and	
OFF-stratifying	(55-100%)	dendrites	was	measured.	There	was	no	difference	(p>0.05,	T-test)	in	
stratification	depth	of	ON	dendrites	between	groups,	but	OFF	dendrites	stratified	10.4%	further	into	
the	IPL	(p<0.05,	T-test)	with	ChABC+BDNF	compared	to	vehicle+BDNF	cells	(Figure	5.7e-f).	
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Figure 5.5 (previous page) Morphometric analysis of RGCs from explants treated with 0.5 U/mL 
ChABC as a topical aliquot from day 0 for 1 d and cultured for 6 d. (a) Culture timeline. (b) 1024x1024 
pixel confocal images (top) and 8-bit tracings (bottom) of diolistically labelled RGCs from each treatment 
group. Arrows indicate axons. Scale bars: 100 µm. (c) Locations of all cells analysed relative to the 
optic nerve (origin) demonstrating no evidence of labelling bias. (d) Sholl profiles. *p<0.05, Kruskal-
Wallis. The number of cells for each group is indicated. Means ±SEM. 
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Figure 5.6 (previous page) Morphometric analysis of RGCs from explants treated with 0.5 U/mL 
ChABC applied as a topical aliquot on day 0 for 1 d, followed by 100 ng/mL BDNF treatment for 3 d 
initiated at day 3 (6 d total). (a) Culture timeline. (b) 1024x1024 pixel confocal images (top) and 8-bit 
tracings (bottom) of diolistically labelled RGCs from each treatment group show no difference in 
morphology between groups. Arrows indicate axons. Scale bars: 100 µm. (c) Locations of all cells 
analysed relative to the optic nerve (origin) demonstrating no evidence of labelling bias. (d) Sholl 
profiles. p>0.05, Kruskal-Wallis. The number of cells for each group is indicated. Means ±SEM. 
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Figure 5.7 (previous page) Morphometric measures of RGCs from explants treated with ±0.5 U/mL 
ChABC ±100 ng/mL BDNF over 6 d. (a) Soma diameters show no difference between groups. p>0.05, 
ANOVA with Tukey post-hoc. Measures of dendritic arbor morphology (b-d) demonstrate a general 
trend of increased dendritic arbor complexity and size with addition of BDNF or ChABC. (b) Dendritic 
field area for each group. *p<0.05, ANOVA with Tukey post-hoc. (c) Area under the Sholl profile. 
*p<0.05, **p<0.005, ANOVA with Tukey post-hoc. (d) Branching index. p>0.05, ANOVA with Tukey 
post-hoc. (e) Representative XY orthogonal views of dendritic arbors stratifying in the OFF lamina for 
cells treated with BDNF (top) or BDNF + ChABC (bottom). In each image lower black arrow indicates 
GCL, upper black arrow indicates INL, open arrow indicates stratification depth. Nuclei stained with TO-
PRO-3 (blue), dendrites stained with DiI (red) or DiO (green). (f) Quantification of stratification depth for 
ON and OFF-stratifying dendrites for cells treated with BDNF or BDNF + ChABC. Blue dotted line 
represents boundary (55%) IPL depth for classification of ON (below line) or OFF (above line). *p<0.05, 
T-test. Means ±SEM.	
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5.5	Following	ChABC	digestion,	BDNF	fails	to	protect	against	RGC	dendrite	loss,	even	
when	an	increased	concentration	of	BDNF	is	used.		
To	 test	 the	 effect	 of	 increased	 concentration	 of	 BDNF	 with	 ChABC	 treatment	 to	 see	 if	 the	
neuroprotective	effect	of	BDNF	could	be	enhanced.	Eleven	explants	(n=6	animals	of	either	sex,	aged	
6	weeks-2	months)	were	treated	with	a	topical	aliquot	of	0.5	U/mL	ChABC,	or	vehicle	as	control,	at	
day	 0,	 followed	 by	 1000	 ng/mL	 BDNF	 treatment	 initiated	 at	 day	 3	 for	 3	 d	 (6	 d	 total).	 RGCs	were	
analysed	as	before.	The	culture	 timeline	 is	 shown	 in	Figure	5.8a.	RGCs	 from	explants	 treated	with	
delayed	1000	ng/mL	BDNF	had	dendritic	arbors	that	were	visibly	larger	and	more	complex	than	control	
cells,	but	there	was	no	visible	difference	following	ChABC	treatment	(Figure	5.8b-c).	This	observation	
was	quantified	by	Sholl	analysis,	 in	which	the	Sholl	profile	peak	for	cells	treated	with	delayed	1000	
ng/mL	BDNF	was	approximately	doubled	between	30-110	µm	(p<0.05,	Kruskal-Wallis)	from	the	soma	
centre	and	was	translated	rightwards	relative	to	the	profile	for	control	cells	(Figure	5.8d).	There	was	
no	significant	difference	(p>0.05,	Kruskal-Wallis)	between	curves	at	any	distance	from	the	soma	centre	
for	cells	from	explants	treated	with	ChABC	(or	vehicle)	and	1000	ng/mL	BDNF	(Figure	5.8e).	
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Figure 5.8 (previous page) Morphometric analysis of RGCs from explants treated with 0.5 U/mL 
ChABC, or vehicle as control, applied as a topical aliquot on day 0 for 1 d, followed by 1000 ng/mL 
BDNF treatment, or vehicle as control, initiated at day 3 for 3 d (6 d total). (a) Culture timeline. (b) 
1024x1024 pixel confocal images of diolistically labelled RGCs from each treatment group show 
dramatically increased dendritic arbor branching and size following BDNF treatment. Arrows indicate 
axons. Scale bars: 100 µm. (c) Locations of all cells analysed relative to the optic nerve (origin) 
demonstrating no evidence of labelling bias. (d) Sholl profiles. *p<0.05, **p<0.005, ***p<0.001, Kruskal-
Wallis. (e) Sholl profiles. p>0.05, Kruskal-Wallis. The number of cells for each group is indicated. Means 
±SEM. 
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5.6	Pre-treatment	with	BDNF	may	benefit	combination	therapy	with	ChABC	
In	order	 to	 test	whether	 reversal	 of	 treatment	order	 could	enhance	 the	neuroprotective	effect	of	
either	BDNF	or	ChABC,	6	explants	 (n=3	animals,	male,	aged	4	months)	were	 first	 treated	with	100	
ng/mL	BDNF,	or	vehicle	as	control,	at	day	0	for	1	d,	followed	by	a	topical	aliquot	of	0.5	U/mL	ChABC	at	
day	1,	and	finally	at	day	3	RGCs	were	labelled	and	analysed	as	before.	The	culture	timeline	is	shown	
in	Figure	5.9a.	RGC	dendritic	arbors	from	explants	treated	with	BDNF	and	ChABC	appeared	larger	than	
those	treated	with	ChABC	only	(Figure	5.9b-c).	The	Sholl	peak	amplitudes	were	unchanged	between	
groups,	but	the	Sholl	profile	for	RGCs	treated	with	BDNF	and	ChABC	was	translated	rightwards	100-
120	µm	and	180	µm	from	the	soma	centre	(p<0.05,	Kruskal-Wallis),	relative	to	the	curve	for	ChABC-
treated	cells	(Figure	5.9d).	There	was	no	difference	in	soma	diameter	between	groups	(p>0.05,	T-test,	
Figure	5.9e).	Although	there	was	no	significant	difference	(p>0.05,	T-test)	between	groups	for	either	
dendritic	 field	 area	 or	 area	 under	 the	 Sholl	 profile,	 these	 results	 followed	 the	 same	 trend	 as	 the	
branching	index,	which	was	33.8%	increased	(p<0.05,	T-test)	in	BDNF+ChABC-treated	cells,	relative	to	
ChABC	only-treated	cells	(Figure	5.9f-h).
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Figure 5.9 (previous page) Morphometric analysis of RGCs from explants cultured for 3 d, treated with 
100 ng/mL BDNF at day 0 for 1d, followed by 0.5 U/mL ChABC treatment at day 1. (a) Culture timeline. 
(b) 1024x1024 pixel confocal images (left) and 8-bit tracings (right) of diolistically labelled RGCs from 
each treatment group. Arrows indicate axons. Scale bars: 100 µm. (c) Locations of all cells analysed 
relative to the optic nerve (origin) demonstrating no evidence of labelling bias. (d) Sholl profiles. 
*P<0.05, Kruskal-Wallis. The number of cells for each group is indicated. (e) Soma diameter. P>0.05, 
T-test. (f) Dendritic field area. P>0.05, T-test. (g) Area under the Sholl profile. P<0.05, T-test. (h) 
Branching index. *p<0.05, T-test. Means ±SEM. 
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5.7	Conclusions	
In	this	chapter	I	explored	the	effect	of	digesting	the	CSPG	components	of	the	PNN	with	respect	to	RGC	
plasticity	 and	 in	 combination	 with	 BDNF	 treatment.	 The	 data	 shown	 here	 suggest	 that	 ChABC	
treatment	could	facilitate	RGC	plasticity	over	longer	time	periods,	but	that	a	combination	of	ChABC	
and	BDNF	does	not	deliver	an	additional	therapeutic	benefit	in	this	model.	
There	was	no	effect	on	RGC	dendritic	morphology	of	ChABC	treatment	after	3	d	treatment,	but	after	
6	d	there	appeared	to	be	an	increase	in	dendritic	regrowth.	Over	both	of	these	time-frames	ChABC	
treatment	either	blocked	or	had	no	positive	effect	on	the	neuroprotective	effect	of	BDNF	treatment,	
even	when	the	concentration	of	BDNF	was	increased	10-fold.	This	is	perhaps	not	surprising,	given	the	
role	of	the	PNN	in	stabilising	synaptic	connections	and	dendritic	morphology.	Specifically,	CSPGs	of	
the	PNN	have	been	shown	to	bind	anchor	proteins,	such	as	neural	cell	adhesion	molecule	(NCAM),	
which	increase	the	efficiency	of	BDNF-TrkB	interaction	(Vutskits	et	al.	2001).	
It	should	be	noted	that	as	in	Chapters	3	and	4,	some	of	the	groups	in	this	chapter	had	small	number	
of	 cells	 (especially	 in	 Figure	 5.9)	 and	 that	 it	 would	 be	 prudent	 to	 undertake	 further	 work	 to	
substantiate	these	observations.	Despite	this,	the	Sholl	profiles	were	similar	for	all	groups	of	the	same	
culture	period,	 therefore	 it	 is	 likely	 that	 there	was	a	 similar	 spread	of	cell	 types	 in	each	group.	All	
groups	seemed	to	show	the	same	trend,	but	these	patterns	should	be	validated	in	the	future	with	the	
use	of	time-series	imaging.	
Structural	 analysis	 of	 RGCs	 provides	 a	 sensitive	 readout	 of	 cell	 stress	 since	 cell	 swelling/dendritic	
beading	can	be	a	marker	of	 stress	or	necrosis	 (Pasantes-Morales	and	Tuz	2006;	Liang	et	al.	2007).	
There	was	no	evidence	of	cell	stress	with	ChABC	treatment,	supporting	the	notion	that	ChABC	is	not	
toxic.	
Reversal	 of	 treatment	 timeline,	 i.e.	 BDNF	 prior	 to	 ChABC,	 may	 have	 been	 protective	 for	 distal	
dendrites.	 BDNF	 was	 only	 applied	 for	 1	 d	 during	 this	 experiment,	 which	may	 reflect	 the	modest	
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neuroprotective	 effect.	 Nevertheless,	 it	 would	 be	 interesting	 to	 further	 examine	 this	 reversed	
treatment	regime	by	applying	BDNF	for	a	longer	period	prior	to	CSPG	digestion.	In	the	future	it	would	
also	be	instructive	to	investigate	the	duration	of	the	neuroprotective	effect	of	BDNF	following	removal	
of	BDNF	from	the	culture	medium,	in	order	to	provide	information	regarding	dosing	frequencies	for	
any	resultant	treatment	regimes.		
	
5.8	Summary	
ChABC	treatment	was	not	toxic	to	RGCs	in	the	retinal	explant,	and	may	even	be	neuroprotective	over	
longer	culture	periods,	however	it	appeared	to	inhibit	the	neuroprotective	effect	of	BDNF	when	BDNF	
was	added	over	3	d.	There	was	no	evidence	of	inhibition	of	the	positive	effect	of	BDNF	with	ChABC	
treatment	over	6	d,	however	there	was	no	additional	neuroprotective	effect	when	the	two	treatments	
were	 combined,	 even	 when	 the	 concentration	 of	 BDNF	was	 increased	 10-fold.	 Finally,	 there	 was	
evidence	that	reversal	of	the	treatment	regime,	i.e.	treatment	with	BDNF	prior	to	ChABC,	may	increase	
neuroprotection	of	terminal	dendrites.
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Chapter	6:	Neural	Stem	Cell	Migration	
6.1	Introduction	
I	 have	 demonstrated	 that	 BDNF	 application	 significantly	 retards	 RGC	 dendritic	 retraction	 in	 the	
degenerating	 retinal	 explant,	 therefore	 has	 potential	 for	 the	 treatment	 of	 neurodegenerative	
disorders.	Injection	of	BDNF	is	not	suitable	therapeutically	because	BDNF	is	pharmacologically	‘sticky’	
and	has	a	short	half-life,	therefore	it	is	difficult	to	control	concentration	and	location	of	injected	BDNF	
(Poduslo	 and	 Curran	 1996;	 Lu	 2003).	 Further,	 BDNF	 application	 is	 undesirable	 due	 to	 the	 risks	
associated	with	repeat	injections	in	the	CNS,	such	as	inflammation	or	infection.	An	alternative	delivery	
route	is	via	secretion	from	donor	stem	cells	that	can	be	engineered	to	translate	and	secrete	peptides	
of	 choice.	 Cell-mediated	 delivery	 enables	 sustained	 dosing	 of	 the	 agent	 and,	 more	 importantly,	
permits	 control	 of	 agent	 release	 through	 transcription	 control	 techniques	 including	 optogenetics	
(Deisseroth	2011)	or	magnetogenetics	(Long	et	al.	2015).	
Cell-mediated	delivery	of	BDNF	is	an	exciting	method	and	stem	cells	will	migrate	into	tissue	without	
external	influences	(Jeon	et	al.	2008;	Li	and	Jiang	2011),	but	in	order	for	therapies	to	be	effective	with	
minimal	adverse	effects,	stem	cell	migration	must	be	controlled.	Endogenous	magnetic	 fields	have	
been	evidenced	 to	play	a	 role	 in	cell	migration	during	wound	healing.	Further,	magnetic	 fields	are	
deeply	penetrating	without	compromising	 safety,	and	permit	dosing	 to	be	controlled	 spatially	and	
temporally	(Kyrtatos	et	al.	2009;	Chen	et	al.	2013).	Magnetic	fields	also	have	the	advantage	of	allowing	
stem	 cells	 to	 be	 sequestered	 for	 termination	 of	 treatment.	 For	 these	 reasons	 the	 use	 of	 external	
magnetic	fields	is	an	attractive	method	to	direct	stem	cell	migration	in	the	CNS.	The	retinal	explant	is	
an	ideal	platform	to	test	whether	this	technique	can	improve	the	efficiency	of	stem	cell	migration	into	
the	IPL	with	a	view	to	providing	cell-mediated	delivery	of	BDNF	to	RGCs.	
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6.2	The	effect	of	permanent	magnetic	fields	on	NSCs	in	suspension	
To	test	the	effect	of	permanent	magnetic	fields	on	the	movement	of	NSCs	in	suspension	in	vitro,	3	mL	
GFP-expressing	 NSCs	 (passage	 39-42)	were	 seeded	 onto	 10	 µg/mL	 laminin-coated	 35	mm	 culture	
dishes	 overnight	 at	 a	 density	 of	 1.2-1.8X105	 cells/cm2.	 Volumes	 of	 1.5	 uL	 or	 3	 uL	 nTMag	 were	
introduced	into	NSCs	using	a	magnefect	at	2	Hz	for	30	min	at	37°C,	5%	CO2.	Control	dished	contained	
NSCs	with	no	nTMag.	Cells	were	disassociated	from	laminin	using	Accutase®	and	immediately	imaged	
for	 tracking	 analysis.	 NSCs	 were	 imaged	 by	 brightfield	 microscopy	 at	 10X	 using	 time-series,	 with	
images	taken	every	2.5	sec	for	a	total	of	125	sec	(6.7	kg-pull	NdFeB	magnet)	or	every	1	min	for	a	total	
of	9	min	(23	kg-pull	and	38	kg-pull	NdFeB	magnets).	The	imaging	set-up	is	shown	in	Figure	6.1.	Images	
were	taken	at	the	edge	of	the	dish	of	cells	in	suspension	(6.7	kg-pull	magnet)	or	of	cells	on	the	bottom	
surface	of	the	dish	(23	kg-pull	and	38	kg-pull	magnets).	Imaging	experiments	were	conducted	in	the	
absence	of	the	magnet	prior	to	imaging	in	the	presence	of	the	magnet,	for	each	dish.	Images	were	
exported	as	TIFFs	and	tracking	was	analysed	using	mTrack	and	Chemotaxis	in	FIJI.	
6.2.1	NSC	movement	with	6.7	kg-pull	NdFeB	magnet	
There	was	no	observable	change	in	directionality	(a	measure	of	how	systematically	the	cells	move	in	
a	 particular	 direction,	 i.e.	 towards	 a	 magnet)	 of	 the	 movement	 paths	 of	 the	 NSCs	 in	 any	 of	 the	
conditions	investigated	(Figure	6.2).	There	was	no	difference	(p>0.05,	ANOVA	with	Tukey	post-hoc)	in	
migration	 distance	 between	 experimental	 conditions	 (Figure	 6.3a-b).	 Although	 no	 group	 was	
significantly	 different	 (p>0.05,	 ANOVA	 with	 Tukey	 post-hoc),	 there	 was	 a	 trend	 of	 an	 increase	 in	
migration	velocity	in	the	presence	of	the	magnet	(Figure	6.3c).	Forward	migration	indices	and	centres	
of	mass	were	not	significant	between	groups	(p>0.05,	ANOVA	with	Tukey	post-hoc),	but	showed	a	
trend	of	an	increase	in	directionality	in	the	presence	of	the	magnet	(Figure	6.3d-e).	
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Figure 6.1 Experimental set-up for magnet-directed movement of magnetic nanoparticle-containing 
NSCs in suspension in vitro. (a) Magnetic field strength of each magnet measured using a gaussmeter 
at the surface of the magnet and at 1 mm increments up to 10 mm from the magnet surface. (b) GFP-
NSCs ±nTMag were placed in a 35 mm dish and the magnet was held directly against the edge of the 
dish (6.7 kg-pull magnet) or 10 mm from the edge of the dish (all other magnets). Cells were imaged by 
brightfield microscopy at the edge of the dish in the absence of the magnet before introduction of the 
magnet. Open arrow: light source. Black arrow: detector. The north (N) and south (S) poles are 
indicated. (c) Example image of NSCs after analysis with mTrack to show relative position of magnet. 
Each dot represents a tracked cell. Scale bar: 50 µm. 
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Figure 6.2 (previous page) Cell tracking analysis of GFP-NSCs with 6.7 kg-pull NdFeB magnet using 
the plugin mTrack. The start (top) and end (middle) frames are shown for each condition. The cell 
movement plots (bottom) show the migration track of each cell relative to its starting position (origin) 
created using the Chemotaxis plugin in FIJI. Magnet: right of each image, as indicated. (a) No magnet, 
no nTMag. (b) Magnet, no nTMag. (c) No magnet, 1.5 µL nTMag. (d) Magnet, 1.5 µL nTMag. (e) No 
magnet, 3 µL nTMag. (f) Magnet, 3 µL nTMag. Scale bars: 50 µm.
Chapter	6:	Neural	Stem	Cell	Migration	
	
190	
 
Figure 6.3 Quantification of NSC tracking in the presence of a 6.7 kg-pull NdFeB magnet with 0 µL, 1.5 
µL or 3 µL nTMag. (a) Mean accumulated distance for each experimental condition. p>0.05, ANOVA 
with Tukey post-hoc. (b) Mean euclidean distance for each experimental condition. p>0.05, ANOVA 
with Tukey post-hoc. (c) Mean velocity for each experimental condition. p>0.05, ANOVA with Tukey 
post-hoc. (d) Mean x and y migration indices for each experimental condition. p>0.05, Mann-Whitney 
with Bonferroni correction (x forward index); p>0.05, ANOVA with Tukey post-hoc (y forward index). (e) 
Mean x and y centres of mass for each experimental condition. p>0.05, ANOVA with Tukey post-hoc. 
Error bars ±SEM. n=3 dishes for each experiment.
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6.2.2	NSC	tracking	with	23	kg-pull	NdFeB	magnet	
In	the	absence	of	the	23	kg-pull	magnet,	movement	paths	were	random,	but	directionality	appeared	
to	improve	in	the	presence	of	magnet	with	both	volumes	of	nTMag	used	(Figure	6.4).	There	was	no	
difference	in	movement	distance	or	velocity	between	groups	(p>0.05,	ANOVA	with	Tukey	post-hoc)		
	(Figure	6.5a-c).	Although	not	significant	(p>0.05,	Mann-Whitney	with	Bonferroni	correction	or	ANOVA	
with	Tukey	post-hoc),	 there	was	a	 trend	of	an	 increase	 in	directionality	 in	 the	x	axis,	measured	as	
forward	migration	indices	and	centres	of	mass,	in	the	presence	of	the	magnet	with	no	nTMag.	The	y	
forward	migration	index	was	significantly	greater	for	NSCs	with	0	µL	nTMag	no	magnet	compared	to	
3	µL	nTMag	with	magnet	(Figure	6.5d-e).	
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Figure 6.4 (previous page) Cell tracking analysis of GFP-NSCs with 23 kg-pull NdFeB magnet using 
the plugin mTrack. The start (left) and end (right) frames are shown for each condition. The cell 
movement plots (bottom) show the migration track of each cell relative to its starting position (origin). 
(a) No magnet, no nTMag. (b) Magnet, no nTMag. (c) No magnet, 3 µL nTMag. (d) Magnet, 3 µL 
nTMag. Scale bars: 50 µm.
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Figure 6.5 (previous page) Quantification of NSC movement tracking in the presence of a 23 kg-pull 
NdFeB magnet with 0 µL or 3 µL nTMag. (a) Mean accumulated distance for each experimental 
condition. p>0.05, ANOVA with Tukey post-hoc. (b) Mean euclidean distance for each experimental 
condition. p>0.05, ANOVA with Tukey post-hoc. (c) Mean velocity for each experimental condition. 
p>0.05, ANOVA with Tukey post-hoc. (d) Mean x and y migration indices for each experimental 
condition. *p<0.05, ANOVA with Tukey post-hoc. *represents 0 µL no magnet vs. 3 µL with magnet y 
forward migration index. (e) Mean x and y centres of mass for each experimental condition. p>0.05, 
ANOVA with Tukey post-hoc. Error bars ±SEM. n=≥2. 
	
	
6.2.3	NSC	tracking	with	38	kg-pull	NdFeB	magnet	
In	the	absence	of	the	38	kg-pull	magnet,	migration	paths	were	random,	but	there	was	more	coherent	
directionality	in	the	presence	of	the	magnet	with	both	volumes	of	nTMag	used	(Figure	6.6).	There	was	
no	difference	in	movement	distance	or	velocity	between	groups	(p>0.05,	ANOVA	with	Tukey	post-hoc)	
(Figure	6.7a-c).	Although	not	significant	(p>0.05,	ANOVA	with	Tukey	post-hoc),	there	was	a	trend	of	
improved	migration	directionality	in	the	presence	of	the	magnet	with	both	volumes	of	nTMag	(Figure	
6.7d-e).		
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Figure 6.6 (previous page). Cell tracking analysis of GFP-NSCs with 38 kg-pull NdFeB magnet using 
the plugin mTrack. The start (left) and end (right) frames are shown for each condition. The cell 
movement plots (bottom) show the movement track of each cell relative to its starting position (origin). 
(a) No magnet, no nTMag. (b) Magnet, no nTMag. (c) No magnet, 3 µL nTMag. (d) Magnet, 3 µL 
nTMag. Scale bars: 50 µm. 
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Figure 6.7 Quantification of NSC tracking in the presence of a 38 kg-pull NdFeB magnet with 0 µL or 3 
µL nTMag. The data show a trend of increased distance, speed and directionality in the presence of 
the magnet. (a) Mean accumulated distance for each experimental condition. p>0.05, ANOVA with 
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Tukey post-hoc. (b) Mean euclidean distance for each experimental condition. p>0.05, ANOVA with 
Tukey post-hoc. (c) Mean velocity for each experimental condition. p>0.05, ANOVA with Tukey post-
hoc. (d) Mean x and y migration indices for each experimental condition. p>0.05, ANOVA with Tukey 
post-hoc. (e) Mean x and y centres of mass for each experimental condition. p>0.05, ANOVA with Tukey 
post-hoc. Error bars ±SEM. n=≥2. 
	
6.3	The	effect	of	electromagnetic	fields	on	NSC	movement	
Since	electromagnets	can	be	designed	to	have	stronger	fields	than	the	same	sized	permanent	magnet,	
the	effect	of	an	electromagnet	on	the	migration	patterns	of	NSCs	was	investigated.	GFP-expressing	
NSCs	(passage	43)	were	seeded	on	laminin	and	disassociated	as	before	and	imaging	experiments	were	
repeated	as	described	in	6.2	with	no	nTMag	only,	with	NSCs	on	the	bottom	surface	of	the	dish	imaged	
for	cell	tracking	experiments.	Images	were	then	taken	with	a	25	kg	pull	electromagnet,	operated	at	
0.2	A,	24	V,	held	10	mm	from	the	edge	of	the	dish.	NSCs	were	tracked	as	before.	
In	the	absence	of	magnet,	NSC	movement	paths	were	relatively	random,	but	in	the	presence	of	the	
25	 kg-pull	 electromagnet	 movement	 directionality	 was	 improved	 (Figure	 6.8a-b).	 There	 was	 no	
difference	(p>0.05,	ANOVA	with	Tukey	post-hoc)	in	migration	distance	or	velocity	with	the	addition	of	
the	electromagnet,	but	NSC	migration	distance	and	velocity	showed	a	trend	of	decrease	compared	to	
the	data	from	experiments	with	the	23	kg-pull	and	38	kg-pull	NdFeB	magnets	(Figure	6.8c-e).	Although	
not	 significant	 (p>0.05),	 directionality	 in	 the	 x	 axis	 tended	 to	 increase	 in	 the	 presence	 of	 the	
electromagnet,	 as	 measured	 by	 forward	 migration	 indices	 and	 centres	 of	 mass.	 The	 y	 forward	
migration	 index	was	 significantly	 greater	 (p<0.05,	ANOVA	with	 Tukey	post-hoc)	 in	NSCs	with	 0	µL 
nTMag + 38 kg-pull magnet compared to every other group	(Figure	6.8f-g).
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Figure 6.8 Cell tracking analysis of GFP-NSCs with a 25 kg-pull electromagnet using the plugin mTrack. 
Cell tracking demonstrates increased directionality in the presence of the magnet. (a) Images of tracked 
cells ± the electromagnet, with the starting and final frame shown for each condition. Scale bars: 50 
µm. (b) Cell movement plots for each condition, showing the movement tracks of every cells relative to 
its starting position (origin). (c) Mean accumulated distance, shown with the values for the tracking 
experiments with the 23 kg and 38 kg-pull NdFeB magnets with no nTMag for comparison. p>0.05, 
ANOVA with Tukey post-hoc. (d) Mean euclidean distance, shown with the values for the tracking 
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experiments with the 23 kg and 38 kg-pull NdFeB magnets with no nTMag for comparison. p>0.05, 
ANOVA with Tukey post-hoc. (e) Mean velocity, shown with the values for the tracking experiments 
with the 23 kg and 38 kg-pull NdFeB magnets with no nTMag for comparison. p>0.05, ANOVA with 
Tukey post-hoc. (f) Mean x and y migration indices, shown with the values for the tracking experiments 
with the 23 kg and 38 kg-pull NdFeB magnets with no nTMag for comparison. *p<0.05, ANOVA with 
Tukey post-hoc. *represents 0 µL with 38 kg-pull magnet vs. all other groups y forward migration index. 
(g) Mean x and y centres of mass, shown with the values for the tracking experiments with the 23 kg 
and 38 kg-pull NdFeB magnets with no nTMag for comparison. p>0.05, ANOVA with Tukey post-hoc. 
Error bars ±SEM. n=3 (electromagnet); n=≥2 (23 kg-pull and 38 kg-pull NdFeB magnets). 
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6.4	Permanent	magnetic	fields	increase	integration	of	NSCs	into	the	retinal	explant	
To	test	the	effect	of	a	permanent	magnetic	field	on	the	movement	of	NSCs	in	a	more	clinically	relevant	
model,	6	explants	(3	mice,	male,	2	months	old)	were	cultured	for	3	h	with	a	2	mL	topical	aliquot	of	
1X105	NSCs/cm2	with	a	38	kg-pull	NdFeB	magnet	placed	directly	underneath	the	culture	dish	(10	mm	
from	explant)	or	no	magnet	as	control	(Figure	6.9a).	At	the	end	of	the	culture	period	the	explants	were	
fixed	and	nuclear	stained	with	TO-PRO-3.	The	entire	GCL-IPL	of	each	explant	were	imaged	by	confocal	
microscopy	in	1	um	steps	(1024x1024	pixels	images)	in	each	quadrant	of	each	explant	(Figure	6.9b).	
The	green	channel	intensity	of	every	GFP+	NSC	was	measured	in	each	slice	from	the	GCL	to	the	INL	
and	the	IPL	depth	at	each	slice	was	quantified	as	%	IPL	depth.	
In	the	presence	of	the	magnet,	more	GFP+	cells	could	be	seen	in	the	GCL	or	IPL,	whilst	GFP+	cells	in	
control	 retinas	seemed	to	be	mostly	 located	above	the	GCL	(Figure	6.9c-d).	This	was	confirmed	by	
quantification,	 in	which	explants	with	the	magnet	had	significantly	 increased	(p<0.05,	ANOVA	with	
Tukey	post-hoc)	green	channel	intensity	at	depths	of	>0%-50%	IPL	(Figure	6.9e).	
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Figure 6.9 (previous page) GFP-NSC migration into the mouse retinal explant with a permanent 38 
kg-pull magnet. (a) Experimental set-up. The magnet was placed directly underneath the culture dish 
and the NSCs were placed directly on top of the explant, as shown. (b) Locations for confocal images 
of explant following migration experiment. One area in each quadrant of the retina was imaged. (c) 
Representative images of the GCL after 3 hours of NSC migration in the absence (left) and presence 
(right) of the magnet. The orthogonal views are presented. Scale bars: 100 µm. (d) Orthogonal XZ view 
of control (top) and magnet (bottom) explants are shown in higher magnification to demonstrate 
increased depth of NSC migration in the IPL in the presence of the magnet. Scale bars: 10 µm. (e) 
Quantification of green channel intensity at different depths of the IPL with and without the magnet. 
*p<0.05, **p<0.005, ***p<0.001, ANOVA with Tukey post-hoc. Error bars: SEM. 
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6.5	Conclusions	
In	this	chapter	I	explored	the	potential	of	guiding	NSCs	using	external	magnetic	fields,	with	a	view	to	
using	NSCs	to	deliver	a	more	sustained	delivery	of	BDNF	to	RGCs	within	the	retinal	explant.	It	should	
be	noted	that	the	in	vitro	NSC	‘migration’	measured	in	this	chapter	was	the	directed	movement	of	
cells	 in	 suspension	using	magnetic	 fields,	 rather	 than	 traditional	 cell	migration	 across	 a	 substrate.	
Without	 measuring	 the	 changes	 in	 activation	 levels	 of	 proteins,	 such	 as	 Rac	 (Ridley	 et	 al.	 1999),	
following	 introduction	of	a	magnetic	 field	the	NSC	movement	 in	the	retinal	explant	also	cannot	be	
confirmed	as	cell	migration.	Nevertheless,	the	results	thus	far	are	promising	for	the	use	of	magnetic	
fields	to	direct	stem	cells	for	the	efficient	delivery	of	neurotrophic	agents.	
My	data	demonstrated	a	trend	for	movement	distance,	speed	and	directionality	 to	 increase	 in	the	
presence	of	a	magnetic	field,	both	with	and	without	addition	of	mnps,	but	no	significant	difference	in	
migration	parameters	was	measured	for	any	group.	This	may	have	been	because	the	 images	were	
taken	at	the	edge	of	the	dish	where	cell	movement	was	limited	by	the	dish	boundary.	In	the	future	it	
would	 be	 interesting	 to	 segment	migration	 analysis	 into	 smaller	 bands	 and	 examine	 the	 effect	 of	
distance	 from	magnet	surface	–	especially	as	magnetic	 field	strength	declines	exponentially	as	 the	
inverse	 square	 of	 the	 distance.	 The	 lack	 of	 significance	 also	 reflects	 large	 variability	 in	movement	
patterns	 of	NSCs	 in	 suspension,	 particularly	 in	 vitro.	 Experiments	 should	 therefore	be	 repeated	 in	
order	to	obtain	data	for	a	much	greater	number	of	cells,	and	over	longer	time	periods.	
Temperature	 is	 likely	 to	 be	 a	 factor	 that	 was	 largely	 overlooked	 in	 the	 current	 study.	 In	 the	
experiments	described	here,	the	NSCs	were	taken	from	a	37°C	incubator	and	imaged	in	a	room	that	
was	 not	 temperature	 controlled.	 These	 will	 likely	 have	 resulted	 in	 the	 formation	 of	 convection	
currents,	which	may	 have	 had	 a	 confounding	 effect	 on	 the	movement	 of	 NSCs.	 Further,	 since	 an	
alteration	in	temperature	of	only	1°C	affects	the	apparent	magnetic	field	strength	(but	not	magnetic	
flux	density)	(Reiser	et	al.	2007),	there	may	have	been	large	variations	depending	on	day,	and	even	
time	of	the	experiment.	For	these	reasons,	it	would	be	instructive	to	repeat	these	experiments	using	
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a	 temperature-controlled	 chamber.	 Heat	 production	 by	 the	 electric	 current	 of	 the	 electromagnet	
should	also	be	considered.	It	was	noted	that	there	was	considerable	heat	production	during	the	use	
of	the	electromagnet,	which	may	have	been	cytotoxic	and	should	be	checked	with	a	viability	assay.	
Although	not	significant,	it	was	observed	that	the	movement	distances	and	velocities	for	NSCs	with	
the	electromagnet,	including	control	cells,	were	generally	lower	than	controls	with	the	other	magnets.	
This	 may	 have	 been	 a	 result	 of	 low	 n	 numbers,	 which	 can	 be	 easily	 tested	 by	 repeating	 all	 the	
experiments	to	check	for	reproducibility.	Alternatively,	the	reduction	in	motility	may	have	reflected	a	
decrease	in	viability	of	the	cells,	which	were	of	higher	passage	number	for	the	experiments	with	the	
electromagnet,	compared	to	the	other	magnets.	It	is	well	known	that	stem	cell	viability	decreases	with	
passage	number	(Martin-Piedra	et	al.	2014)	and	this	could	be	tested	by	Trypan	blue	staining.	Although	
it	 has	 been	 reported	 that	 mnps	 do	 not	 adversely	 affect	 cell	 viability	 or	 migration	 behaviour	
(Ramaswamy	et	al.	2015),	this	should	be	verified	with	viability	assays.		
Although	I	measured	a	significant	increase	in	the	NSC	migration/movement	depth	with	the	magnet,	
migration	was	limited	to	the	upper	50%	of	the	IPL.	In	the	context	of	cell-mediated	delivery	of	BDNF,	
this	 may	 result	 in	 protection	 being	 given	 to	 ON-stratified	 dendrites	 only.	 However,	 since	 it	 was	
reported	in	the	rat	magnetic	field-mediated	retention	of	cardiosphere-derived	cells	in	the	coronary	
artery	took	24	hours	(Cheng	et	al.	2012),	it	is	likely	that	the	experimental	timeline	used	here	was	not	
long	enough	to	identify	the	limit	of	magnetic	field-directed	movement	of	the	cells.	In	line	with	this,	it	
would	be	valuable	to	monitor	the	movement	of	NSCs	in	the	explant	using	time-series	imaging,	so	that	
migration	speed	can	be	assessed.	
6.6	Summary	
There	was	no	 significant	effect	of	external	magnetic	 fields	 (permanent	or	electromagnetic)	on	 the	
movement	of	NSCs	in	suspension	in	vitro,	even	following	inclusion	of	mnps.	In	contrast,	application	of	
a	 permanent	magnetic	 field	 increased	 the	 depth	 of	 NSC	migration	 into	 the	 IPL	 of	 explants	 in	 the	
absence	of	mnps.	
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Chapter	7:	General	discussion	
7.1	The	retinal	explant	as	a	model	to	investigate	neuronal	degeneration	
In	this	thesis	I	have	shown	that	the	morphometric	analysis	of	RGCs	provides	a	readout	of	neuronal	cell	
health	in	a	translatable	model	of	neuronal	degeneration	that	is	rapid	and	robust,	compared	to	similar	
in	vivo	models,	in	which	neuronal	degeneration	is	markedly	slower.	I	have	highlighted	a	discrepancy	
between	cell	loss	and	dendritic	retraction,	thus	outlining	a	window	in	which	to	delineate	degenerative	
events	and	to	investigate	the	effects	of	neuroprotective	agents.	
There	 are	 a	 number	 of	 challenges	with	working	with	 this	model.	One	 problem	 is	 that	 there	 is	 no	
‘perfect’	RGC	marker.	Thy1	is	one	of	the	most	widely	used	RGC	markers,	but	only	labels	70%	of	RGCs	
(Perry	et	al.	1984)	and	 fluctuates	 in	expression	 level	 following	optic	nerve	damage	 (Schlamp	et	al.	
2001;	Astafurov	et	al.	2014).	 It	would	be	 interesting	to	compare	the	 levels	of	Thy1	to	the	 levels	of	
other	neuronal	markers,	such	as	Brn3,	NeuN	and	TUJ1	to	allow	a	more	accurate	assessment	of	the	
number	of	RGCs.	Given	that	there	is	no	perfect	marker	of	RGCs	and	viability	markers	are	not	reliable	
markers	 of	 cell	 death	 in	 this	model,	 nuclear	 staining	 likely	 provides	 the	best	 readout	 of	 RGC	 loss,	
particularly	given	that	amacrine	cells	are	resistant	to	cell	death	(Kunzevitzky	et	al.	2010)	and	so	their	
numbers	may	be	considered	 to	be	constant	 (offset).	This	model	 is	 limited	as	a	generic	CNS	model	
because,	unlike	most	neurons	in	the	brain,	RGCs	do	not	have	dendritic	spines.	Nevertheless,	the	retinal	
explant	offers	a	major	advantage	over	the	hippocampal	brain	slice	by	the	presence	of	intact	neuronal	
networks.	
Cell	sub-type	analysis	revealed	that	OFF-stratifying	RGCs	may	be	more	susceptible	to	dendritic	pruning	
than	 the	other	 sub-types,	as	 reported	 in	 the	mouse	 (El-Danaf	and	Huberman	2015;	 Johnson	et	al.	
2016).	Although	intriguing,	division	of	cells	into	sub-types	results	in	small	sample	numbers,	thereby	
making	it	difficult	to	draw	firm	conclusions.	This	is	a	problem	in	the	mouse,	where	at	least	14	different	
structural	RGC	types	(Coombs	et	al.	2006)	and	30	different	functional	types	(Baden	et	al.	2016)	have	
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been	identified.	Classification	is	further	complicated	in	disease,	where	the	measurements	required	for	
classification	 (distal	 dendrites	 and	 dendritic	 field	 size)	 are	 often	 altered.	 This	 problem	 can	 be	
circumvented	with	 the	 use	 of	 parameters	 that	 are	 resistant	 to	 change,	 such	 as	measurements	 of	
proximal	dendrites	(Tribble	et	al.	2014).	
Pan-caspase	inhibition	was	modestly	protective	against	retraction	of	proximal	dendrites	(Figure	3.8c	
in	Chapter	 3).	 This	was	 surprising,	 given	 the	breadth	of	 evidence	 for	 caspase-dependent	dendritic	
pruning	(Williams	et	al.	2006;	D'Amelio	et	al.	2010)	and	the	reported	role	of	local	caspases	activity	in	
dendritic	atrophy	in	glaucoma	(Kisiswa	et	al.	2010b;	Erturk	et	al.	2014).	One	possibility	is	that	perhaps	
caspases	do	not	play	a	major	role	in	axotomy-induced	RGC	dendropathy.	There	is	good	evidence	that	
axotomy	 activates	 calpains	 (serine-threonine	 proteases)	 in	 a	 calcium-mediated	manner	 via	 sarm1	
(Yang	2015).	Calpains	degrade	cytoskeletal	proteins,	such	as	microtubule-associated	proteins	1	and	2	
(Billger	et	al.	1988),	resulting	in	proximal	axon	retraction,	a	process	known	as	Wallerian	degeneration	
(Waller	1850;	Stoll	et	al.	2002),	and	glutamate-induced	dendritic	retraction	in	hippocampal	neurons	
(Wilson	et	al.	2000).	 It	would	be	 interesting	 to	apply	calpain	 inhibitors	 to	 investigate	whether	 this	
mechanism	exists	in	axotomy-induced	RGC	degeneration	in	the	retinal	explant.		
Absence	of	light	may	contribute	to	neuronal	degeneration	in	the	retinal	explant.	Since	light	inhibits	
the	plasticity	of	synapses	connecting	ON	bipolar	cells	to	ON	RGCs	(Xia	et	al.	2007),	scotopic	conditions	
may	remove	this	inhibition,	as	demonstrated	in	the	mouse	explant	(Xia	et	al.	2006).	In	the	absence	of	
light	retinal	neurotransmission	is	increased	due	to	permanent	photoreceptor	depolarisation	(Xu	et	al.	
2007).	This	increase	in	neuronal	activity	may	result	 in	increased	oxidative	stress	caused	by	reactive	
oxygen	 species,	 or	 glutamate-induced	 excitotoxicity	 caused	 by	 increased	 glutamate	 secretion	 that	
have	 been	 shown	 to	 induce	 dendritic	 atrophy	 in	 CA1	 and	CA3	pyramidal	 neurons	 (Christian	 et	 al.	
2011).	These	mechanisms	may	have	played	a	role	in	the	dendritic	retraction	of	RGCs	measured	here.	
	Dendrite	loss	implies	synapse	loss.	Since	synapses	are	formed	throughout	dendritic	arbors	(Spruston	
2008),	 it	 seems	 logical	 to	 infer	 that	 dendrite	 retraction	 would	 be	 associated	 with	 synapse	 loss.	
Chapter	7:	General	Discussion	
	
209	
However,	this	must	be	verified	by	future	experiments	as	it	has	not	been	explicitly	shown	in	this	study.	
This	could	be	achieved	by	immunohistochemistry	with	the	post-synaptic	marker	PSD-95,	and	the	pre-
synaptic	 markers	 VGlut1	 and	 synaptophysin	 (Johnson	 et	 al.	 2007;	 Ippolito	 and	 Eroglu	 2010).	
Alternatively,	biolistic	labelling	could	be	used	(Lo	et	al.	1994;	Morgan	et	al.	2008).	Biolistic	labelling	
would	be	preferable	since	it	would	permit	quantification	of	the	rate	of	synapse	loss	with	time-series	
imaging.	 Although	widespread	 dendrite	 loss	 is	 likely	 to	 be	 accompanied	 by	 synapse	 loss,	 the	 two	
events	may	not	occur	concurrently,	as	shown	in	a	mouse	model	of	Alzheimer’s	disease	where	dendrite	
loss	precedes	synapse	 loss	 (Williams	et	al.	2013b).	Biolistics	would	allow	the	 relationship	between	
dendrite	 loss	 and	 synapse	 loss	 to	be	delineated	 in	 the	 retinal	 explant,	 as	well	 as	validation	of	 the	
morphometric	changes	reported	here.	Labelling	of	synaptic	 locations	may	also	provide	information	
regarding	neuronal	gain.	The	combination	of	inputs	onto	specific	dendritic	compartments	can	greatly	
alter	the	functional	output	of	the	neuron,	i.e.	firing	rate	or	spike	frequency	(Silver	2010;	Pouille	et	al.	
2013).	It	is	important	to	note	that	biolistics	was	not	suitable	in	the	current	study	because	it	requires	a	
2	d	incubation	period	for	the	expression	of	transfected	DNA	and	since	DiI	and	DiO	are	toxic,	temporal	
‘snapshots’	were	the	best	way	to	quantify	dendritic	changes.	
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7.2	The	retinal	explant	as	a	model	to	investigate	the	effect	of	BDNF	
The	 application	 of	 neurotrophic	 agents	 is	 an	 appealing	 therapeutic	 strategy	 to	 combat	 neuronal	
degeneration.	The	retinal	explant	is	an	ideal	model	to	test	potential	treatment	paradigms	and	their	
effect	on	neuronal	morphology.	Since	BDNF	application	has	been	shown	to	protect	against	cell	loss	
(Chen	and	Weber	2001),	it	is	an	attractive	agent	for	neuroprotection.	However,	it	is	difficult	to	control	
the	concentration	and	location	of	BDNF	in	vivo	because	it	is	a	pharmacologically	‘sticky’	protein	that	
has	a	 short	half-life	and	does	not	 cross	 the	blood-brain	barrier	well	 (Poduslo	and	Curran	1996;	 Lu	
2003).	With	an	ex	vivo	model	BDNF	can	be	applied	directly	to	the	target	site.	Further,	since	Sarm1	
signalling	may	be	implicated	in	axotomy-induced	degeneration,	BDNF	may	target	pathways	implicated	
in	degeneration.	BDNF-TrkB	signalling	activates	Akt,	which	inhibits	MKK4,	thus	blocking	downstream	
activation	 of	 JNK	 signalling	 (Longo	 and	 Massa	 2013).	 Here	 I	 demonstrate	 that	 BDNF	 treatment,	
initiated	immediately	after	axotomy	or	3	d-post	axotomy	significantly	retarded	dendritic	atrophy	of	
RGCs.	
The	neuroprotective	effect	of	BDNF	shown	here	is	perhaps	not	surprising,	given	the	well-evidenced	
role	of	BDNF	in	maintenance	of	dendritic	arbor	morphology	in	development	(McAllister	et	al.	1996;	
Bibel	and	Barde	2000;	Yacoubian	and	Lo	2000)	and	in	the	adult	(Xu	et	al.	2000).	Many	groups	have	
demonstrated	that	BDNF	application	protects	against	cell	death	(Ma	et	al.	1998;	Mocchetti	and	Bachis	
2004).	In	the	cat	optic	nerve	crush	model	BDNF	has	been	shown	to	reduce	RGC	loss	(Chen	and	Weber	
2001)	and	retard	dendritic	retraction	of	RGCs	(Weber	and	Harman	2008))	.	This	work	is	of	interest,	but	
since	exogenous	BDNF	 is	difficult	 to	control	 in	vivo,	 the	ex	vivo	model	 is	a	more	reliable	platform.	
Further,	the	optic	nerve	crush	is	not	a	consistent	injury,	unlike	the	total	axotomy	performed	here.	In	
line	with	the	mechanism	of	BDNF	I	propose	here,	it	has	been	reported	in	the	mouse	retinal	explant	
that	 Thy1-YFP	 labelled	 RGCs	 show	 reduced	 dendrite	 loss	 with	 a	 combination	 of	 BDNF	 and	 CNTF	
(Johnson	et	al.	2016).	However,	the	true	therapeutic	effect	is	not	clear	since,	as	previously	outlined,	
Thy1	 labelling	 underreports	 dendritic	 pruning	 (Williams	 et	 al.	 2013a).	 Furthermore,	 it	 is	 uncertain	
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what	role	BDNF	had	in	the	protective	effect	shown	in	this	study	because	only	a	combination	treatment	
of	BDNF+CNTF	was	used.	
One	of	the	major	limitations	of	work	investigating	neurotrophic	support	in	neuronal	degeneration	is	
the	pathology	vs.	treatment	timescale.	In	general,	agents	are	applied	at	the	time	of,	or	even	before	
the	time	of	injury.	This	is	unlikely	to	be	possible	in	the	clinic	due	to	current	screening	methods	and	the	
ability	of	neuronal	networks	 to	compensate	 for	cell	 loss.	Here,	 I	 show	for	 the	 first	 time	that	BDNF	
treatment	 initiated	3	d-post	axotomy	offers	 significant	protection	against	dendritic	 retraction,	and	
may	 promote	 dendritic	 outgrowth.	 It	 will	 be	 important	 to	 determine	 how	 sustained	 the	
neuroprotective	effects	of	BDNF	are	in	this	model	prior	to	in	vivo	trials.	
The	morphometric	data	 from	retinal	explants	 treated	with	delayed	BDNF	 (Figure	4.3	 in	Chapter	4)	
presented	here	are	suggestive	of	a	neurite	outgrowth	mechanism	of	BDNF,	similar	to	that	reported	in	
the	 adult	 guinea	 pig	 auditory	 nerve	 (Miller	 et	 al.	 2007).	 However,	 it	 should	 be	 noted	 that	 this	
hypothesis	needs	to	be	confirmed	by	time-series	imaging.	Nevertheless,	the	prospect	of	an	agent	that	
can	 be	 applied	 post-injury	 and	 restore	 neurons	 to	 a	 native-like	morphology	 is	 exciting	 because	 it	
suggests	that	it	may	be	possible	to	re-wire	neuronal	networks	and	restore	function.	In	the	future	it	
would	be	interesting	to	investigate	synapse	formation	in	the	IPL	in	parallel	with	dendrite	outgrowth,	
since	the	presence	of	synapses	is	essential	for	dendrite	extension	to	have	a	positive	functional	effect.	
This	 could	 be	 achieved	 by	 biolistic	 labelling,	 for	 example	 using	 PSD-95,	 which	 could	 be	 used	 in	
combination	 with	 biolistic	 labelling	 of	 cytoskeletal	 markers	 in	 order	 to	 validate	 the	 dendritic	
outgrowth	mechanism	of	BDNF.	
BDNF	is	an	attractive	candidate	for	treatment	of	retinal	degeneration	because	it	has	been	reported	
that	 its	 main	 receptor,	 TrkB,	 is	 upregulated	 following	 optic	 nerve	 injury	 (Cui	 et	 al.	 2002).	 The	
neuroprotective	effect	of	cell-mediated	delivery	of	BDNF	is	potentially	 limited	by	the	availability	of	
extracellular	BDNF-processing	enzymes.	High	level	BDNF	secretion	in	the	unprocessed	pro-BDNF	form	
could	saturate	active	sites	of	enzymes	such	as	plasmin,	resulting	in	increased	pro-BDNF	signalling.	The	
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resultant	pro-apoptotic	and	pro-dendritic	 retraction	signalling	could	counterbalance	 the	protective	
effects	of	BDNF.	Fortunately,	p75NTR	is	not	expressed	by	RGCs	in	the	mouse	retinal	explant	(Hu	et	al.	
1999).	Confirmation	 that	p75NTR	 is	not	expressed	by	RGCs	 in	 the	explant	would	 support	 cell-based	
delivery	of	BDNF	because	presumably	any	secreted	pro-BDNF	would	not	have	a	negative	effect	on	
RGCs.	It	would	be	interesting	to	map	the	expression	levels	of	TrkB	and	p75NTR	over	time	in	the	retinal	
explant	 to	 verify	 that	 TrkB	 is	 a	 good	 target.	 The	 phosphorylation	 state	 of	 TrkB	 should	 also	 be	
measured,	since	there	is	evidence	that	TrkB	is	inactivated	(dephosphorylated)	following	glaucomatous	
damage	(Gupta	et	al.	2012).		
	
	
Chapter	7:	General	Discussion	
	
213	
7.3	Chondroitin	sulphate	proteoglycan	remodelling	does	not	augment	
neuroprotection	in	combination	with	BDNF	
The	PNN	is	postulated	to	be	a	barrier	to	neuronal	plasticity	and	stem	cell	integration	(Pizzorusso	et	al.	
2002;	Fawcett	2015).	I	used	morphometric	analysis	to	investigate	the	effect	of	CSPG	digestion	on	RGC	
plasticity	in	the	degenerating	explants,	as	well	as	a	potential	synergistic	effect	of	combined	ChABC	and	
BDNF	 treatment.	 Over	 longer	 culture	 periods	 (6	 d)	 ChABC	 treatment	 promoted	 RGC	 dendritic	
remodelling.	 I	 was,	 however,	 surprised	 to	 find	 that	 ChABC	 treatment	 completely	 blocked	 the	
neuroprotective	effect	of	BDNF,	even	when	the	concentration	of	BDNF	was	increased.	
Successful	CSPG	digestion	by	ChABC	was	evidenced	by	immunohistochemistry.	However,	it	is	worth	
noting	that	there	was	only	evidence	of	CSPG	digestion	around	RGC	somas	and	proximal	dendrites,	
presumably	because	the	PNN	tends	to	be	restricted	to	these	areas	(Lee	et	al.	2012).	Since	the	proximal	
dendrites	are	most	resistant	to	retraction,	this	may	begin	to	explain	the	limited	effect	on	plasticity	of	
ChABC	treatment.	Alternatively,	given	the	limited	immune	response	in	ex	vivo	preparations,	the	PNN	
may	not	be	upregulated	to	the	same	extent	as	in	vivo	models	of	CNS	damage	(Raposo	and	Schwartz	
2014).		
NCAM	has	been	reported	to	 improve	the	efficiency	of	BDNF-TrkB	binding.	NCAM	interacts	with	CS	
GAG	chains	on	CSPGs	and	also	binds	directly	to	TrkB.	NCAM	binds	directly	to	TrkB	and	the	polysialic	
acid	tail	of	NCAM	interacts	with	BDNF	(Vutskits	et	al.	2001),	thereby	increasing	the	likelihood	of	BDNF	
binding	 to	 TrkB	 (Cassens	 2010).	 NCAM	 interacts	 with	 CS	 GAGs	 on	 CSPGs	 (Figure	 1.7),	 thereby	
positioning	NCAM	close	to	neurites	where	BDNF-TrkB	signalling	occurs.	Since	CSPGs	are	upregulated	
in	response	to	CNS	injury,	it	is	possible	that	this	may	facilitate	neurotrophin	signalling	in	an	attempt	
improve	neuronal	survival	 in	the	wake	of	an	immune	response.	Interaction	between	BDNF	and	the	
PNN	may	also	be	explained	by	the	large	number	of	positively	charged	residues	on	the	BDNF	protein,	
which	enable	the	formation	of	electrostatic	bonds	with	the	highly	negatively	charged	components	of	
CSPGs.	Digestion	of	CSPGs	may	therefore	 reduce	the	binding	affinity	of	BDNF	 for	TrkB,	which	may	
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explain	 the	 inhibitory	 effect	 of	 ChABC	 treatment	 on	 BDNF-induced	 neuroprotection,	 even	 when	
ChABC	and	BDNF	were	not	present	at	the	same	time.		
The	possible	effect	of	NCAM	on	BDNF-TrkB	binding	 strengthens	 the	 case	 for	using	TrkB	activating	
agents	in	place	of	BDNF.	TrkB	agonists	improved	RGC	survival	in	models	of	optic	nerve	injury	(Hu	et	
al.	2010)	and	glaucoma	 (Bai	et	al.	2010).	 In	addition,	TrkB	agonists	 can	be	designed	 to	have	more	
favourable	properties	than	BDNF,	including	higher	binding	affinity,	higher	specificity	to	TrkB,	longer	
half-life,	and	better	ability	to	cross	the	blood-brain	barrier	(Qian	et	al.	2006;	Bai	et	al.	2010;	Massa	et	
al.	2010;	Brahimi	et	al.	2014;	Liu	et	al.	2016).	Since	these	agents	would	presumably	not	require	the	
presence	of	 CSPGs	 to	 strengthen	binding	 to	 TrkB,	 they	 could	 be	used	 in	 combination	with	ChABC	
treatment.	Finally,	these	agents	could	be	generated	as	peptides,	meaning	that	DNA	encoding	their	
sequence	could	be	used	in	conjunction	with	cell-mediated	delivery	to	secrete	the	agent	to	the	target	
cells.	
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7.4	Cell-mediated	delivery	of	neurotrophic	agents	may	be	improved	by	manipulation	
of	NSC	migration	using	external	magnetic	fields	
Here	I	present	data	that	support	of	the	use	of	external	magnetic	fields	to	guide	NSCs	in	vitro	and	into	
ex	vivo	tissue,	with	a	view	to	using	NSCs	to	deliver	BDNF	in	a	sustained	manner.	Permanent	magnets	
have	been	used	to	direct	mnp-containing	stem	cells	or	endothelial	cells	in	vitro	(Moysidis	et	al.	2015),	
as	well	as	to	lesion	sites	in	the	spinal	cord	(Vishwakarma	et	al.	2015)	and	to	the	retina	(Yanai	et	al.	
2012),	with	moderate	success.	To	date,	work	with	magnetic	field-driven	migration	in	vivo	has	generally	
only	been	applied	to	target	sites	bordering	the	bloodstream.	In	this	study	I	present	the	first	evidence	
that	this	technology	may	be	used	to	drive	migration	of	stem	cells	into	neuronal	tissue,	offering	promise	
that	it	may	finally	be	possible	to	target	previously	inaccessible	parts	of	the	brain.	
The	data	presented	here	demonstrating	increased	migration	depth	of	NSCs	in	the	absence	of	mnps	
into	a	retinal	explant	towards	the	direction	of	a	permanent	magnet	(Figure	6.9	in	Chapter	6)	supports	
the	postulated	presence	of	a	magnetoreceptor	in	mammals.	Once	a	ridiculed	idea,	the	concept	of	a	
magnetic	 field-sensitive	 receptor	 has	more	 recently	 become	 generally	 accepted	 (Lohmann	 2016).	
There	is	evidence	that	a	magnetoreceptor	may	explain	the	migratory	behaviour	of	several	organisms,	
including	bacteria,	drosophila	and	homing	pigeons	(Mora	et	al.	2004;	Baumgartner	et	al.	2013;	Qin	et	
al.	 2016)	 but	 researchers	 have	 debated	 the	 existence	 of	 such	 a	 receptor	 in	 mammals,	 including	
humans.	The	data	I	present	here	supports	the	existence	of	a	mammalian	magnetoreceptor	and	poses	
the	exciting	possibility	of	using	external	magnetic	fields	to	control	both	the	migration	and	the	selective	
gene	 expression	 of	 stem	 cells	 to	 deliver	 neurotrophic	 support	 to	 degenerating	 neurons.	 Since	
activation	of	the	magnetoreceptor	stimulates	calcium	influx	(Knoepfel	and	Akemann	2010;	Long	et	al.	
2015),	 it	 is	 easy	 to	 envisage	 how	 magnetic	 fields	 could	 be	 used	 to	 control	 BDNF	 expression	 in	
transfected	NSCs.	These	cells	could	then	be	directed	to	the	target	site,	where	the	secretion	of	BDNF	
could	be	remotely	controlled.	
Chapter	7:	General	Discussion	
	
216	
It	has	been	reported	that	CSPG	digestion	improves	integration	efficiency	of	photoreceptor	precursor	
cells	in	the	adult	mouse	retina	(Barber	et	al.	2012).	It	would	be	interesting	to	examine	the	effects	of	
ChABC	treatment	on	NSC	migration	depth	in	the	retinal	explant.	On	the	other	hand,	this	is	unlikely	to	
be	clinically	useful	if	the	NSCs	are	used	to	deliver	neurotrophic	agents,	given	the	inhibitory	effect	of	
ChABC	 treatment	 on	 the	 action	of	 BDNF.	 ChABC-digested	 PNN	 components	 are	 replaced	within	 5	
weeks	in	vivo	(Fawcett	2015).	The	CSPG	replacement	time	should	be	investigated	in	the	explant,	since	
it	may	be	that	ChABC	could	be	used	to	aid	migration	of	BDNF-expressing	NSCs	into	the	IPL,	and	after	
the	PNN	has	been	rebuilt,	BDNF	could	elicit	its	neuroprotective	effects.		
The	specifications	of	the	magnet	need	to	be	optimised	to	enable	clinical	translation.	Small	instruments	
can	 be	 placed	behind	 the	 retina	 during	 surgery,	 therefore	 the	 retina	 is	 an	 ideal	 tissue	 to	 test	 the	
potential	of	magnetic	field-directed	migration	of	stem	cells.	However,	it	should	be	noted	that	the	38	
kg-pull	magnet	used	here	is	too	large	to	fit	behind	the	retina	in	vivo.	I	have	demonstrated	a	proof-of-
principle	that	magnetic	fields	can	be	used	to	direct	migration	of	NSCs	 into	the	retinal	explant.	This	
experiment	should	be	repeated	with	a	smaller	magnet	that	could	be	placed	behind	the	retina.	Indeed,	
the	magnets	used	here	may	not	have	appropriate	magnetic	field	strengths	for	application	in	vivo.	If	
the	field	strength	is	too	low,	there	will	be	no	beneficial	effect,	but	field	strengths	that	are	too	high	
could	cause	neurotoxicity	due	to	an	increase	in	noradrenaline	levels	(Rajendra	et	al.	2004).	Further,	it	
would	be	interesting	to	test	the	migratory	effect	of	more	than	one	magnet,	either	to	shape	magnetic	
fields	outside	the	eye,	or	to	generate	magnetic	field	gradients.	
The	use	of	electromagnets	may	allow	better	control	of	cell	migration	with	the	aid	of	magnetic	field	
gradients.	As	previously	outlined,	the	electromagnet	used	in	this	study	generated	a	large	amount	of	
heat,	which	may	have	been	a	confounding	factor	in	migration	experiments.	In	the	clinic	this	problem	
could	be	alleviated	by	 the	use	of	electromagnets	 in	MRI	 scanners,	which	 contain	 cooling	 systems.	
Large	 electromagnets	 such	 as	 these	 circumvent	 the	 need	 to	 implant	 magnets,	 and	 have	 been	
demonstrated	 to	 be	 capable	 of	 directing	mnp-tagged	macrophages	 in	 vivo	 (Muthana	 et	 al.	 2015).	
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Furthermore,	MRI	scanners	can	be	used	to	track	mnp-containing	MSCs	in	a	rat	model	of	Huntington’s	
disease	(Moraes	et	al.	2012),	thereby	providing	a	visual	aid	for	the	direction	of	cells.		
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7.5	Conclusions	
The	 adult	 mouse	 retinal	 explant	 is	 an	 excellent	 model	 for	 the	 investigation	 of	 axotomy-induced	
neuronal	degeneration,	applicable	to	a	wide	range	of	CNS	disorders.	Morphometric	analysis	permits	
quantification	of	neuronal	cell	health,	as	well	as	inferred	information	regarding	synaptic	connectivity	
and	 functional	 ability.	 I	 have	 demonstrated	 that	 morphometric	 data	 can	 highlight	 a	 therapeutic	
window	in	which	to	probe	mechanisms	implicated	in	neuronal	pathology	and	neuroprotection.		In	this	
model	it	has	been	shown	that	the	activation	of	TrkB	provides	potent	neuroprotection	to	RGC	dendritic	
arbors,	 and	 may	 promote	 dendritic	 remodelling.	 Although	 CSPG	 digestion	 is	 unlikely	 to	 be	
therapeutically	useful	in	combination	with	BDNF	treatment	in	this	model,	my	data	supports	cell-based	
delivery	of	BDNF,	which	may	be	optimised	using	magnetic	fields.	
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Appendix	
Chemotaxis	measurements	equations	
All	Chemotaxis	equations	from	Chemotaxis	and	Migration	Tool	Version	1.01,	Ibidi,	accessed	from	
http://ibidi.com/xtproducts/en/Software-and-Image-Analysis/Manual-Image-Analysis/Chemotaxis-
and-Migration-Tool,	last	accessed	28.02.16. 
	
	
xFMI cell = 	 xOPQaccumulated	distance	
	
xFMI mean = 	1n xFMI(cell)\]\^_ 	
 
Equation S1. X forward migration index 
	
	
yFMI cell = 	 yOPQaccumulated	distance	
	
yFMI mean = 	1n yFMI(cell)\]\^_ 	
	
Equation S2. Y forward migration index 
	
x	centre	of	mass = 	 1n endpoint	x	
Equation S3. X centre of mass 
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y	centre	of	mass = 	 1n endpoint	y	
Equation S4. Y centre of mass 
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